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A b s t r a c t
Over the past twenty years, there has been an accumulation of evidence indicating that certain 
peptides that exert biological effects outside the CNS, may also possess neurotransmitter or 
neuromodulator functions in brain. Thyroliberin (Thyrotropin-Releasing Hormone) was the first 
of these such peptides displaying a dual role as a hormone and as a neurotransmitter. Its 
ubiquitous distribution in the hypothalamus and in the extra-hypothalamic regions, and its 
diverse pharmacological and physiological effects are all features of its dual functions. The 
study of brain peptidases that hydrolyse thyroliberin is of importance in securing an 
understanding of the possible mechanisms for termination of its neurotransmitter or 
neuromodulator actions and the possible enzymic biotransformation of the the original peptide 
to cleavage products that themselves may exhibit biological activity.
The brain peptidases involved in the primary degradation of thyroliberin studied to date are 
three forms of pyroglutamate aminopeptidase (PAP), a cytosolic, particulate and serum form, 
and a cytosolic prolyl endopeptidase (PE) activity.
This work studied the primary degradation of thyroliberin by the enzymes found in the 
particulate fraction of bovine brain. It began by investigating the methods available for the 
quantitation of the particulate PAP activity, and the development of two new assays for its 
detection, the first a coupled enzyme fluorimetric assay, and the second, a spontaneous 
cyclisation assay. Using these assays, PAP activity from the synaptosomal membranes of 
bovine brain was purified and characterised for the first time. This enzyme proved to have many 
of the characteristics of the previously studied particulate PAP activities, with some notable 
differences. The particulate PAP activity was shown to be 230kDa in size, had a narrow 
substrate specificity, cleaving only thyroliberin or very closely related peptides, and displayed a 
high affinity for thyroliberin. It was inhibited by thiol protease inhibitors, had a requirement for 
DTT and was unaffected by EDTA. By combining these features, the particulate PAP from 
bovine brain appears to be a ‘hybrid’ form of the cytosolic and the particulate PAP activities 
previously studied.
Prolyl endopeptidase is widely distributed, has a broad substrate specificty and has been 
previously characterised in the cytosolic fractions of many species. It is involved in the primary 
degradation of thyroliberin, producing the bioactive peptide, acid thyroliberin. Prior to this 
study, PE had only been characterised as a cytosolic activity, and despite references to the 
possibility of there being a particulate activity, it was never identified. PE activity was located on 
the synaptosomal membranes of bovine brain, and following vigorous salt-washing, osmotic 
shock and solubilisation with detergents, has been identified conclusively as a membrane- 
associated activity. It was purified from the synaptosomal membranes, and characterised as 
having a broad substrate specificity and a high affinity for thyroliberin (in fact a higher affinity than 
the particulate PAP). It was inhibited by some of the thiol protease inhibitors and some of the 
metal chelators, suggesting that it may be a thimet protease. It also is inhibited by the specific 
prolyl endopeptidase inhibitor, Z-Pro-prolinal.
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1. Introduction
1. T h y ro tro p in  R e le a s in g  H o rm o n e
The hypothalamic control of the anterior pituitary function through endogenous chemical 
substances was postulated several years ago, but it was only in the mid 1950s that the search 
began for the hypothalamic release-modulating substances (Harris, 1955). Thyrotropin releasing 
hormone (TRH) from porcine hypothalamus was the first hypothalamic hypophysiotropic hormone to 
be purified and characterised in the laboratories of Schally et al. (1969) and Guillemin (1970). 
Working independently, they reported that TRH was a weakly basic tripeptide with the amino acid 
sequence pyroglutamyl-histidyl-proline amide (<Glu-His-Pro-NH 2 ) (Fig 1 .1 ). It has strict 
conformational requirements for biological activity and almost any departure from the structure of 
native thyroliberin results in substantial if not complete loss of biological activity ( Guillemin and 
Burgusp1972).
Fig. 1.1 Structure of thyroliberin
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The availability of TRH in pure form led to the development of specific radioimmunoassays for 
thyroliberin and the realisation that thyroliberin, identical to that found in the hypothalamus, also 
occurs in extrahypothalamic brain regions as well as outside the CNS altogether (Jackson and 
Reichlin, 1979). At this point, it was rapidly realised that in both its amino acid sequence and in its 
biological activity, TRH exhibited no species specificity and that <Glu-His-ProNH2  was readily active
in all mammalian species including humans (Fleischer and Guillemin, 1976). It was also observed 
that while its functions as a hypothalamic regulatory hormone adequately identified this tripeptide as 
a hormone, (stimulating the release of thyrotropin, and perhaps other trophic hormones from the 
anterior pituitary), its widespread extrahypothalamic distribution and its functions which are 
independent of its endocrine activity in the hypothalamus-pituitary-thyroid axis suggested that TRH 
had a much broader functional significance within the body.
In view of the increasing neurological role of thyrotropin releasing hormone within the CNS, as well 
as its neurocrine function, the IUPAC-IUB Commission on Biochemical Nomenclature assigned the 
term ‘Thyroliberin' to thyrotropin releasing hormone to reflect its dual roles.
1.1 P h y s i o l o g i c a l  a c t i o n s  o f  t h y r o l ib e r in  a t  t h e  l e v e l  o f  t h e
a d e n o h y p o p h y s i s
The most obvious effect of thyroliberin, from which it derives its name, is the ability to stimulate the 
release of thyrotropin (TSH) from the anterior pituitary through binding high affinity receptors and 
subsequent activation of adenyl cyclase (Jackson,1982). Thyroliberin receptors in brain are 
ubiquitously distributed, but are found in highest densities in limbic structures, especially the 
amygdala and hypothalamus, and in the lowest densities in brain stem and cerebellum (Parker and 
Capdevila,1984). The receptor is membrane-bound, digestible by trypsin and phospholipase and 
inactivated by various thiol reagents and metal salts (Sharif and Burt, 1984).
The effect of thyroliberin on the thyrotroph (cell types of the anterior pituitary), resulting in TSH  
release, is balanced by the powerful negative feedback control over TSH release exerted by thyroid 
hormones. Besides this feedback, other factors such as noradrenaline, dopamine and somatostatin 
(both of hypothalamic origin) may well be involved in modifying thyroliberin-stimulated TSH release 
(Jackson, 1982, Mannisto,1983). Other neurotransmitters such as serotonin, gamma-aminobutyric 
acid (GABA) and histamine may influence the hypothalamic release of thyroliberin (Mannisto,1983). 
The catecholamines and somatostatin could provide short term inhibitory influences, while the 
thyroid hormones themselves have a much longer-lasting effect. Modulation of the TSH response 
to thyroliberin also may be brought about through changes in the circulating levels of sex steroids, 
cortisol and growth hormone (GH) (Jackson,1982). At the level of the thyroid gland itself, it has 
been shown that thyroliberin can directly stimulate the release of thyroxine (T4 ) from perfused rat
thyroid gland fragments in  vitro  (Attali et al.,1985), adding another complexity to the control of 
thyroid hormone secretion.
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Fig. 1.2 Thyroliberin actions in the adenohypophysis
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In considering the physiological role of thyroliberin in the release of prolactin, it has been shown that 
thyroliberin is at least equipotent in releasing prolactin and thyrotropin from the pituitary and that 
prolactin precedes the release of TSH (Jacobs et al.,1971 ). However it is unlikely that thyroliberin is 
the only peptide prolactin-releasing factor, since vasoactive intestinal peptide (VIP), substance P 
and bombesin can all stimulate prolactin release.
A further effect of thyroliberin on the anterior pituitary may be the release of GH. Although 
thyroliberin does not stimulate GH release normally in man, it does so in several endocrine, 
neuropsychiatrie and metabolic disorders (Jackson, 1982; Scanlon et al.,1983), which may be due 
to a change in balance of other factors regulating GH release.
The effects of thyroliberin on other endocrine tissues include the stimulation of arginine 
vasopressin and oxytocin release from posterior pituitary, enhancement of arginine-induced 
glucagon release from the rat pancreas, inhibition of gastrin-stimulated acid secretion in dog and 
human, and attenuation of pancreatic polypeptide release during insulin-induced hypoglycemia 
(Morley et al.,1977).
Thyroliberin-related changes have been implicated in the pathophysiologies of various disease 
states. These include Huntington's chorea (Spindel et al., 1980), schizophrenia (Nemeroff et al., 
1984), epilepsy (Kubek et al., 1993), Alzheimers disease (Albert et al., 1993), primary thyroid 
diseases, pituitary adenomas, neuropsychiatrie disorders (anorexia nervosa) and other endocrine or 
metabolic disorders such as chronic renal failure and starvation (Duthie et al., 1993).
1.2 D is tr ib u t io n  o f  th yro lib er in
Thyroliberin-like immunoreactivity or biological activity is widely distributed throughout the nervous 
system of vertebrate species including human, rat, guinea-pig, mouse, frog, chicken and salmon 
(Nemeroff, 1978). While hypothalamic thyroliberin, transported to the anterior pituitary via the portal 
vessel circulation, acts on thyrotrophs ( cell types of the anterior pituitary) in a classical fashion to 
cause the release of TSH, there is also much evidence to suggest that the thyroliberin found in 
extra-pituitary locations has a role in neurotransmission (neurocrine function) and in cell-to-cell 
regulation (paracrine function) (Jackson, 1983). Over 70% of the total thyroliberin in the CNS is 
found outside the hypothalamus, although the concentrations are lower than those within the 
hypothalamus or posterior pituitary (Jackson and Reichlin, 1979).
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Table 1.1 The distribution of thyroliberin in tissues and body fluids of various 
species (Prasad, 1987)
S p e cies Tissue/ Body Fluid
Cone
(fmol/mg
P ro te in )
Human Cerebellum 15.0
Hypothalamus 1 . 1
Placenta 54.6
Pineal Gland 71.1
Peripheral Blood 78 pg/ml
Rat Cerebellum 31.5
Hypothalamus 2200.5
Caecum 91.0
Rectum 27.6
Pancreas 93.8
Retina 828.0
Peripheral Blood 77.0
Hypophyseal Portal Plasma 801.0
Frog Brain 6.9
Skin 2 . 6
Blood 227.0
Monkey Cerebellum, anterior 2.3
Hypothalamus, anterior 150.8
Chicken Hypothalamus 938-1352
Snake Hypothalamus 10884-20171
Salmon Hypothalamus 5188-7284
Thyroliberin is distributed throughout the extra-hypothalamic CNS (Winokur and Utiger.1974) and 
spinal cord (Hokfelt et al.,1975), in the retina, (Schaeffer et al. ,1977), in the pancreas and 
gastrointestinal tract (Morley et al.,1977), in the placenta (Shambaugh et al.,1978), in amniotic fluid 
(Morley,1979) and in breast milk (Baram et al.,1977).
Distribution of thyroliberin is uneven throughout the gastrointestinal tract, with the highest 
concentration in the pancreas and caecum, and the lowest concentrations in rectum, jejunum and 
duodenum, (Morley,1979; Leppaluoto et al.,1978). Within the pancreas, thyroliberin has been 
localised in the islets of Langerhans. Ontogenic studies have shown the pancreas to contain much 
higher levels of thyroliberin than the hypothalamus during the early neonatal period (Engler et 
al.,1981), but the concentrations in the pancreas and the gastrointestinal tract subsequently decline 
with age, while hypothalamic and brain levels gradually increase.
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Amniotic fluid thyroliberin appears to be immunologically similar to synthetic thyroliberin, and its 
activity increases with gestational age (Morley et al.,1977). Thyroliberin-like material has been 
shown to be present in both cisternal fluid and in lumbar cerebrospinal fluid (Oliver et al., 1974a) and 
its levels are increased in depressed patients (Oliver et al.,1974b). There are considerable 
difficulties in measuring thyroliberin in the systemic circulation because of rapid degradation by 
proteolytic enzymes and its presence in human peripheral blood is controversial.
Table 1.2 Distribution of thyroliberin in the brain and spinal cord (Leppaluoto et 
a l.,1 9 7 8 )
Tissu e Tissue Wet 
Weight 
(m g )
Thyroliberin
Concentration
(pg/mg)
Thyroliberin 
Total Amount 
(ng)
Hypothalam ic-Pituitary
Complex
Whole Hypothalamus
33.00 410.00 13.53
Posterior Pituitary 
(Neurohypophysis) 0.80 380.00 0.30
Anterior Pituitary 
(Adenohypophysis)
8 . 0 0 18.00 0.14
Extrahypothalamic Brain 
and Spinal Cord
Pons and medulla
275.00 49.00 13.48
Cerebrum
1170.00 2.90 3.39
Cerebellum
300.00 1.30 0.39
Cervical Spinal Cord
67.00 49.00 3.28
Thoracal Spinal Cord
60.00 84.00 5.04
Lumbar Spinal Cord
65.00 115.00 7.48
Within the hypothalamus, a study by Jackson and Reichlin in 1974 showed that in rat, the highest 
concentration of thyroliberin lies in the median eminence (ME) region with levels in excess of 
3.5ng/mg tissue.
Using immunohistochemistry, it was shown that the most dense concentration of thyroliberin is
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found in the external zone of the ME juxtaposed to portal capillaries, consistent with its 
hypophysiotropic role. Thyroliberin is also found in the posterior pituitary of the rat, its concentration 
there being exceeded in the CNS only by that of the hypothalamus .
As can be seen from the Table1.2, the highest total amount of thyroliberin found in the 
extrahypothalamic brain was found to be in the pons and medulla (13.48ng).
The distribution of thyroliberin, its rapid degradation in blood and tissue, its concentration in 
synaptosomes and its demonstrated actions on isolated neurons, have led to the concept that 
thyroliberin is an ubiquitous neurotransmitter that has been co-opted by the pituitary as a releasing 
factor.
1.3  T hyro liber in  a s  a  p o s s i b l e  n e u r o r e g u la to r
Information processing in the brain largely involves chemical communication among neurons 
through substances called neuroregulators. These substances may be subdivided into those that 
convey information between adjacent nerve cells(neurotransmitters) and those that amplify or 
dampen neuronal activity (neuromodulators). The criteria by which a compound is classified as a 
neurotransmitter or neuromodulator have been extensively reviewed and debated. These include:
1. Localisation within presynaptic nerve terminals
2. Release upon nerve stimulation
3. Attachment to specific post-synaptic receptors
4. Induction of biological effects identical to that achieved by direct nerve stimulation (‘synaptic 
mimicry’)
5. Termination of effects by a specific inactivatiing or reuptake mechanism
6 . The capacity of the nerve cell to synthesize the neurotransmitter
In considering the central effects of thyroliberin, it is worth noting that this peptide was originally 
classified as a hormone through its effects on the pituitary, but it also qualifies as a neurotransmitter. 
Its extrahypothalamic distribution in the brain, localisation at the synaptic level, release at synaptic 
terminals, attachment to high affinity receptors which show a remarkable degree of anatomical 
localisation, specific effects on neuronal activity, its stimulation of a wide range of centrally-mediated 
behavioural effects, and the presence of brain peptidases capable of inactivating the tripeptide 
provide a formidable list of criteria consistent with such a neuronal function (Jackson, 1982; Griffiths 
and Bennett, 1983).
Both hypothalamic and extrahypothalamic synaptosomes are richly endowed with immunoreactive 
thyroliberin (Winokur et al., 1977). Immunocytochemically, thyroliberin has been shown to be 
present in nerve endings (Johansson and Hokfelt, 1980). In the hypothalamus, immunoreactive
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thyroliberin is found in two subcellular populations, consisting of large and small particles, with 
sedimentation characteristics similar to those of synaptosomes containing noradrenaline and 
dopamine (Barnea et al.,1976). Following hypo-osmotic shock or exposure to solubilising agents, 
most of the thyroliberin appears near the top of the gradient. The remaining fraction of thyroliberin 
was associated with small particles with a sedimentation coefficient similar to that of synaptic vesicles 
containing acetylcholine. These properties suggest that both thyroliberin-containing particles are of 
synaptosomal origin.
1.3.1 Action of thyroliberin on neurons
Thyroliberin has been shown to inhibit a significant portion of hypothalamic, cerebral cortical and 
cerebellar neurons (Renaud,1978). Winokur and Beckman, (1978) have shown thyroliberin to 
cause a selective reduction in neuronal excitation evoked by L-glutamate but not by acetylcholine in 
rat cerebral cortex. In the cat spinal cord, thyroliberin increases the frequency of spontaneous 
ventral root action potentials and increases the amplitude of the monosynaptic reflex and the 
amplitude and onset of polysynaptic potentials, leading to a general activation of muscle tonus 
(Cooper and Boyer, 1978).
1.3.2 Release and reuptake of thyroliberin at synaptic terminals
The termination of neurotransmitter action at the synapse may be regulated by removal of the 
neurotransmitter from the synaptic cleft. Reuptake of neurotransmitters is one mechanism by which 
neurotransmitters are removed. Such an uptake process may take place either at the pre- or 
postsynaptic neuronal elements or by glial cells that form the synaptic capsule. Studies of the in 
vitro  uptake of exogenous thyroliberin by rat cerebellar slices in the presence of bacitracin (a 
protease inhibitor) suggested that thyroliberin is taken up via a process involving many of the 
properties of a high-affinity transport system including (1 ) saturation kinetics, (2 ) high-affinity kinetic 
constants, (3) temperature dependence, (4) sodium dependence and (5) a high tissue/medium 
ratio. After 1 hour of incubation at 27°C, the tissue-medium ratio was 5:1 and 70% of the total 
radioactivity was discovered as thyroliberin (Pacheco, 1981).
1.3.3. Behavioural effects of thyroliberin
Plotnikoff and his co-workers (1974), were the first to demonstrate the action of thyroliberin in the 
central nervous system. They showed thyroliberin potentiation of the stimulant properties of L- 
dihydroxyphenylalanine in paragyline-treated mice. Furthermore this action of thyroliberin was 
reported to persist in both hypophysectomised and thyroidectomised animals, suggesting a non­
involvement of the pituitary-thyroid axis in its behavioural effects. Since this major discovery, 
thyroliberin has been shown to elicit numerous centrally mediated behavioural effects in man and 
animals (Yarbrough,1979). For example, thyroliberin can reverse narcotic-induced sedation via 
activation of neurons in the septo-hippocampal area (Kalivas and Horita, 1980), this effect may 
involve local changes in the cholinergic system. Thyroliberin can also reverse naturally-induced
sedation, in the form of hibernation, in C ite llus la te ra lis , through a hippocampal site of action 
(Stanton et al.,1980). The tripeptide can stimulate locomotor activity in rats, through the mesolimbic 
dopamine system, an effect which is mediated via the nucleus accumbens (Heal et al.,1983). Its 
effects on thermoregulation are more complex, producing both hyper- and hypothermia induced by 
a variety of pharmacological agents and neuropeptides including (3-endorphin, bombesin and 
neurotensin (Nemeroff et al.,1984).
Thyroliberin can induce shaking behaviour (sometimes described as ‘wet-dog shakes’) seen in 
opiate withdrawal (Griffiths et al.,1982). There can also be induction of forepaw tremor in rodents 
(Nemeroff et a!., 1984). The central administration of thyroliberin has profound effects on the 
cardiovascular and respiratory systems, with an increase in blood pressure induced in rat, rabbit and 
goat (Nemeroff et al., 1984). In relation to the gastrointestinal system, thyroliberin administered 
centrally will induce an increase in gastrointestinal motility via activation of central vagal systems, as 
well as a marked increase in gastric secretion (consisting of increased volume and decreased pH) 
which also appears to be vagally-mediated (Nemeroff et al., 1984). The potential interactions 
between thyroliberin and central cholinergic neurons suggest an involvement in the spinal cord, 
midbrain, cortex and septum/hippocampus (Yarbrough, 1983). Allied to the gastrointestinal effects 
described above, there is evidence that thyroliberin is an anorexic agent, suppressing both food 
and water intake (Nemeroff et al.,1984).
In all these actions, there is an apparent interaction of thyroliberin with a variety of classical 
neurotransmitters and other neuropeptides, from acetylcholine, dopamine and serotonin(5-HT) 
through the opioid peptides and neurotensin. The complexity of these interactions makes the 
definition of the exact physiological significance of thyroliberin in the brain more difficult. However, 
the overall impression of a stimulant action does vindicate the belief that thyroliberin functions as a 
net ‘endogenous ergotropic substance’ in the central nervous system. (Metcalf, 1982).
1.4 T h y r o l ib e r in  r e c e p t o r s
Although thyroliberin is widely distributed in various tissues , the presence of high-affinity 
stereospecific binding of thyroliberin to membranes is limited to relatively few tissues, including 
brain, (Burt and Snyder,1975) pituitary, (Banerji and Prasad,1982) retina, (Burt, 1979) and spinal 
cord (Prasad and Edwards, 1983). Burt and Snyder (1975) were the first to demonstrate the 
stereospecific binding of [3 H]thyroliberin to rat brain membranes and to establish the presence of 
both high- and low-affinity binding sites. Subsequent studies revealed a close similarity between 
the thyroliberin-receptor from the central nervous system (cortex, nucleus accumbens and retina) 
and that in the anterior pituitary gland (Burt and Snyder,1975; Banerji and Edwards, 1982; Burt and 
Taylor, 1980). Banerji and Prasad (1982) demonstrated that following subfractionation of the
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mitochondrial fraction, there was an increase in the specific binding of thyroliberin in the synaptic 
plasma membrane. Although the precise number of thyroliberin receptors could not be determined 
(the detergent used for synaptic junction preparation inactivated the thyroliberin receptor), as many 
as 30% of the synaptic plasma-membrane associated receptors may reside at the synaptic junction. 
The presence of a significant number of thyroliberin receptors in the light synaptic plasma and 
microsomal membranes suggests the existence of extrajunctional receptors (Table 1.3). In the 
human, a single class of high affinity binding sites has been characterised in the hippocampus 
(Eymin et al., 1993).
The many locations of thyroliberin and its receptors in brain and spinal cord and the many diverse 
effects associated with its administration into specific brain sites strongly support the contention that 
it serves as an endogenous regulator of neuronal function. It appears that many of the extrapituitary 
effects of thyroliberin are mediated by other neurotransmitters, notably acetylcholine and the 
monoamines, so that this peptide is delegated the role of a neuromodulator of those systems.
Table 1.3 Subcellular distribution of thyroliberin receptors in rat cerebellum  
(Banerji and Prasad,1982)
F ra c t io n
Thyroliberin 
(fmol bound/mg 
p r o t e in )
Nuclear Fraction 
(P1)
3.57+/- 1.37
Crude Mitochondrial 
(P2)
24.24 +/- 5.51
Synaptic Plasma 
Membrane
44.83 +/- 3.32
Light Synaptic 
Plasma Membrane
29.96 +/- 6.26
Myelin 13.75 +/-4.95
Mitochondria 4.05 +/- 0.32
Microsomal 
Membrane (P3)
20.90 +/- 4.37
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1.4.1 Cloning and functional characterisation of the thyroliberin receptor
Much investigation has recently centred on the cloning and functional characterisation of the 
thyroliberin receptor. Knowledge of the thyroliberin receptor (thyroliberin-R) structure would 
facilitate the study of ligand/receptor interactions, which could lead ultimately to the design of more 
clinically effective analogues.
In 1990 Straub et al. successfully cloned the cDNA encoding the mouse pituitary thyroliberin 
receptor. The 3.8 kilobase mouse thyroliberin-R cDNA was found to encode a protein of 393 amino 
acids which showed similarities to other guanine nucleotide- binding regulatory proteins (G- 
proteins)- coupled receptors (GPCR). The thyroliberin-R cDNA was also isolated from rat pituitary 
and brain (Sellar et al., 1993, Zabavnik et al., 1993). The rat protein sequence closely resembles 
that reported for the mouse (Straub et al., 1990), the main difference being an extra 18 amino acids 
at the carboxyl-terminal end. The nucleotide sequence which encoded for these extra 18 amino 
acids matches a sequence which occurs in the 3’-untranslated region of the published mouse 
sequence, some 230 bases beyond the stop codon which terminates the main open reading frame. 
The differences between the 2 sequences in the two species may result from differential splicing. 
The human thyroliberin-R was shown to encode a 398 amino acid protein, (Duthie et al.,1993), 
compared to 393 for the mouse thyroliberin-R (Straub et al., 1990) and 412 (de la Pena et al., 
1992a), 387 (de la Pena et al., 1992b) and 411 (Sellar et al.,1993) for the rat thyroliberin-R. 
Comparison of the human/ mouse/ rat thyroliberin-R amino acid sequences indicate high homology 
between all isoforms, except for the COOH terminal tail where the major variation occurs. This region 
was shown to be functionally important and has been implicated in receptor desensitisation of the 6 - 
adrenergic receptor (Hausdorff et al., 1991). All forms of the thyroliberin-R isolated so far are 
functional and the reason for the existence of these alternative CO O H tails is not yet known. They 
could possibly play a part in coupling the receptor to different second messenger systems with the 
same cell or be involved in receptor stability. It is also possible that the COOH tail variation could be 
evolutionary neutral rather than functional.
1.4.2 Internalisation of the thyroliberin receptor follows binding
G-protein coupled receptors (GPCRs), like other plasma membrane receptors, are rapidly lost from 
the surface of cells, ie they are internalised, after binding agonist. Internalisation via coated pits and 
recycling to the plasma membrane of receptors has been delineated for low density lipoproteins and 
epidermal growth factor. Specific amino acid motifs in these receptors have been shown to mediate 
this process. Although loss from the cell surface of G PC R s has been studied in several cell 
systems, no general amino acid sequence for internalisation had been identified until recently. The 
ability of thyroliberin to cause both a rise in total inositol phosphate production and [Ca2+]j confirms
that the human thyroliberin-R behaves as a functional GPCR (Duthie et al., 1993). The thyroliberin-R 
complex undergoes rapid transformation in cells, to an acid-resistant form which appears to 
represent internalised agonist-receptor complex. Since residues in the carboxyl terminus of other 
G-protein- coupled receptors appear to be involved in internalisation, Nussenveig et al., (1993)
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studied that region using site-directed mutagenesis and transfection into mammalian cells. A  mutant 
thyroliberin-R, C335Stop, missing the last 59 residues including two cysteine residues, underwent 
minimal transformation to an acid-resistant form even though it bound agonist with equal affinity and 
activated inositol phosphate second messenger formation as effectively as wild type thyroliberin-R. 
Two distinct domains within the carboxyl terminus between residues 335 and 368 were shown to 
affect transformation equally.
Although thyroliberin-promoted transformation of the agonist-thyroliberin-R complex into an 
acid/salt resistant form has not been shown formally to represent the internalisation via coated pits 
and vesicles, this appears to be the most plausible explanation for this phenomenon (Von Zastrow 
and Koblinka, 1992). The functional significance of receptor internalisation is not completely 
understood. It has been considered one component, with receptor G-protein uncoupling and 
receptor down-regulation, of the mechanism whereby G P C R s desensitise. Thus, receptor 
internalisation is seen as a way to redistribute receptors from the plasma membrane to an intracellular 
compartment in which signalling may not occur. This reduces the number of available receptors on 
the cell surface where they could interact with agonist and activate signalling. It is possible that 
thyroliberin signalling is in part desensitised by this process, because thyroliberin signalling in 
pituitary cells appears to occur only at the cell surface and not by internalised receptors (Ramsdell 
and Tashjian, 1986). Recycling of receptors back to the plasma membrane may be a component of 
the process of resensitisation.
1.4.3. Localisation of thyroliberin receptor m RNA
The localisation and distribution of thyroliberin-R mRNA in the rat pituitary gland and brain have been 
studied by means of in-situ  hybridisation (Sellar et al.,1993). In the anterior lobe of the pituitary, the 
hybridisation signal was evenly distributed throughout the tissue, which probably shows the 
presence of thyroliberin-R mRNA on thyrotrophs, lactotrophs and perhaps on somatotrophs (cell 
types in the anterior lobe of the pituitary). No expression was found in the posterior or 
neurointermediate lobes of the pituitary.
Specific hybridisation was also found in discrete areas of the brain. These areas included distinct 
regions of the olfactory system, septal area, amygdaloid complex, cerebral cortex, hippocampus, 
hypothalamus, basal ganglia and the motor nuclei of cranial nerves in the brain stem (Zabavnik et al., 
1993).
The existence of thyroliberin in different regions throughout the brain coupled with receptor binding 
sites in these regions, reinforces the suggestion that thyroliberin has important CN S effects. 
Zabavnik et al., (1993) were able to demonstrate that in virtually every area where there was 
thyroliberin receptor mRNA expression, prohormone or tripeptide thyroliberin immunoreactivity has 
also been described (Lechan and Jackson, 1982). Segerson et al., (1987) , demonstrated the 
presence of thyroliberin prohormone mRNA in regions which Zabavnik et al. had shown to contain
12
thyroliberin receptor mRNA. These regions included the amygdala, the diagonal band of Broca, bed 
nucleus of the stria terminals, periolivary region and the dorsal motor nucleus of the vagus. The 
presence of thyroliberin receptors in the same regions as those which synthesise thyroliberin 
precursor suggests a local action of thyroliberin.
1.4.4. Regulation of thyroliberin receptors
The number of thyroliberin receptors is regulated by thyroid hormones, but the affinity of the 
receptors for thyroliberin is unaltered (Perrone and Hinkle, 1978). But how does thyroliberin 
regulate the level of its own receptors? Thyroliberin causes the level of endogenous thyroliberin-R 
mRNA to decrease in rat pituitary GH3  cells, at least in part, by stimulating the rate of its turnover 
(Fujimoto et al., 1992). This effect of thyroliberin could have been caused by decreasing the 
stability of thyroliberin-R mRNA (or increasing its accessibility to an RNase), or by increasing the 
activity of an RNase that degrades thyroliberin-R mRNA, or both. Nayaranan et al. (1992) used a cell 
free system in which the RNA-degrading enzyme from lysates of thyroliberin-stimulated and 
unstimulated GH3  cells was used to determine whether thyroliberin affected the activity of a RNase 
that degrades thyroliberin-R mRNA. They found that lysates derived from GH3  cells stimulated by 
thyroliberin regulate the activity to degrade transcribed RNAs in vitro. The mechanism of regulation 
by thyroliberin of RNase activity is unknown. It could be caused by regulation of the synthesis of an 
RNase or of post-translational modifications that lead to changes in the activity of a latent RNase. An 
effect to decrease the action of an RNase inhibitor, which could also explain stimulation of RNase 
activity, appears less likely. The observation using the cell-free system that increased RNA 
degrading activity occurs as rapidly as within 10 mins of stimulation by thyroliberin of GH3 cells, may
provide an insight into the mechanism of this effect (Nayaranan et al.,1992). It is likely that this effect 
occurs via a post-translational mechanism affecting the RNase system rather than involving induction 
of RNase synthesis. Because thyroliberin signals via a mechanism that activates protein kinase C 
(Gershengorn, 1986), and it has been shown that protein kinase C mediates enhanced mRNA 
degradation caused by thyroliberin (Fujimoto et al., 1991), it is possible that this effect may be 
mediated by phosphorylation of a regulatory protein in the RNase system. It is also possible that in 
GH3 cells stimulated by thyroliberin, some mRNAs, such as that for prolactin, are protected from
increased degradation during thyroliberin action by effects on other components of the RNA 
degrading system. Thyroliberin stimulation of GH3  cells appears to lead to degradation of
thyroliberin-R mRNA by increasing RNase activity and simultaneously affecting a specific factor that 
allows for degradation (or destabilises) thyroliberin-R mRNA. Further work is necessary to define the 
molecular details of thyroliberin-stimulation of RNase activity and of thyroliberin-induced 
destabilisation of thyroliberin-R mRNA.
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1.5 Thyroliberin Biosynthesis
Many other aspects of the physiology and pharmacology of thyroliberin have been extensively 
studied and although investigations following the structural characterisation of thyroliberin in 1969 
have provided considerable information on the localisation, release, mechanism of action and 
inactivation of the tripeptide, the mechanisms of biosynthesis were amongst the last features of 
thyroliberin to be investigated.
Three possible methods of producing thyroliberin were suggested:
1 . By non-ribosomal enzymatic synthesis,
2 . By ribosomal production of a high-molecular weight thyroliberin precursor and subsequent 
processing to the tripeptide, and
3. By the uptake and reamidation of one of its metabolites, acid thyroliberin (<Glu-His-ProOH). 
There was difficulty in elucidating the precise means of thyroliberin biosynthesis possibly because 
relatively small quantities of thyroliberin (nanogram) are detectable in brain and the actual rate of 
biosynthesis appears to be low (Griffiths and Millar, 1983).
The possibility of non-ribosomal thyroliberin biosynthesis was initially suggested by Mitnik and 
Reichlin, 1972) because of the short tripeptide sequence of this peptide, but the concept was not 
widely accepted (McKelvy, 1983; McKelvy and Epelbaum, 1978). Bauer and Lipmann (1976) did 
not find any biosynthetic activity and observed that the tripeptide amide was rapidly degraded in 
hypothalamic homogenates.
The concept of ribosomal thyroliberin biosynthesis stems from the mechanisms of biosynthesis of 
other polypeptide hormones, notably insulin and somatostatin. Here a high molecular weight 
precursor of the polypeptide is produced and packaged in the endoplasmic reticulum and golgi 
apparatus of the cell, which is then transferred to its site of release (Chretien and Seidah, 1981). 
During these steps, the precursor is modified either by specific proteolytic cleavage, addition of 
groups to the peptide structure eg glycosylation, phosphorylation or both, until the mature, 
biologically active peptide is present in the secretory granules ready for release.
Although the majority of evidence favoured the idea of the synthesis of a prohormonal form of 
thyroliberin and its subsequent activation to <Glu-His-ProNH2 , another interesting possible
mechanism of thyroliberin biosynthesis was suggested by McKelvy (1983). Acid thyroliberin (<Glu- 
His-ProOH), formed by the action of prolyl endopeptidase on thyroliberin, is relatively stable to 
further degradation and could potentially be taken up at nerve terminals for reamidation to 
thyroliberin. There is virtually no evidence of neuropeptide uptake and reamidation because of the 
relatively small contribution of this process to the overall thyroliberin pool. However improbable this 
scheme may seem, the obvious similarity of this uptake/reamidation process to that occurring for 
classical neurotransmitters can only add weight to its possible significance in thyroliberin 
biosynthesis.
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The long standing controversy concerning the mode of thyroliberin biosynthesis was only solved in 
1979 (Rupnow et al., 1979). It was shown that thyroliberin, like other hypothalamic releasing factors 
such as Lutenising Hormone Releasing Hormone (LHRH), arises from the post-translational 
cleavage of a large precursor protein and not by soluble non-ribosomal enzymatic mechanisms. 
Richter et al. (1984), isolated mRNA from the skin of the frog Xenopus laevis (a rich source of 
thyroliberin), and were able to obtain a cDNA clone with an insert of 478 nucleotides coding for a 
portion of the preprohormone precursor of thyroliberin (preprothyroliberin). The deduced 
thyroliberin precursor of 123 amino acids contained three copies of the sequence Lys-Arg-Gln-His- 
Pro-Gly-Lys/Arg-Arg and a fourth incomplete copy. The paired flanking basic amino acids are 
potential cleavage sites in thyroliberin peptide biosynthesis. Thyroliberin would then arise from 
enzymic amidation at the carboxyl terminus with the glycine residue acting as an amide factor while 
glutamine would undergo a cyclisation to form the mature hormone.
Jackson et al. (1985) raised an antiserum against a synthetic peptide hypothesised to represent a 
portion of the mammalian thyroliberin prohormone. Immunocytochemical studies indicated that this 
antiserum recognised the rat thyroliberin prohormone but not the fully processed peptide. From 
this they were able to identify a cDNA that encoded the thyroliberin precursor from a rat 
hypothalamic Iambda-gt1 1  bacteriophage expression library. Because of the small size of the 
thyroliberin sequence and the degeneracy of the codons representing the three amino acids, the 
application of conventional hybridisation techniques to identify a cDNA encoding mammalian 
hypothalamic thyroliberin presents several problems.
1.5.1. Distribution of the thyroliberin prohormone
Lechan et al. (1986a) used immunolocalisation techniques to examine the distribution of the 
thyroliberin prohormone in the CNS of the rat. It was found that immunoreactive prothyroliberin is 
present in several hypothalamic nuclei, the medullary raphe, and regions of the telencephalon, 
including the diagonal band of Broca, medial septum and bed nucleus of the stria terminalis, in a 
distribution identical to that reported for the mature tripeptide (Lechan and Jackson, 1982). 
Confinement of reaction product to the cell soma or dendrites in all of these areas, however, 
contrasts to the widespread distribution of thyroliberin in axons and axon terminals in the CNS  
(Lechan and Jackson, 1982). This suggests that, in general, prothyroliberin is processed within all 
soma in most regions throughout the brain and is rarely transported in axons. The distinct 
compartmentalisation of immunoreactive prothyroliberin in the cell cytoplasm of paraventricular 
neurons, which is suggestive of its association with the Golgi apparatus, as opposed to the more 
diffuse cytoplasmic distribution in lateral hypothalamic neurons and certain other regions of the brain 
however, indicates that the location of thyroliberin prohormone processing may vary in different 
nuclear groups.
In addition to the presence of immunoreactive prohormone in regions of the CNS where thyroliberin
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had been observed (Lechan et al., 1983), the prothyroliberin was located in the perikarya in several 
nuclear groups where no thyroliberin had previously been located by immunocytochemical 
methods. This included particularly prominent groups of neurons in the glomerulus of the olfactory 
lobes, sexually dimorphic nucleus of the pre-optic area, reticular nucleus of the thalamus, 
periaqueductal gray, cerebral cortex and hippocampus.
In addition to ascribing a large and varied role for the products of thyroliberin precursor in the CNS, it 
is intriguing to speculate that in certain regions of the brain, the thyroliberin prohormone may be 
preferentially processed to non-thyroliberin peptides or extended forms of thyroliberin, which may 
be of biological importance. This possibility is supported by the structure of pro-thyroliberin 
deduced from cloned cDNA derived from the rat hypothalamus (Lechan et al., 1986b). In addition to 
thyroliberin, this molecule of approximately 26 kDa molecular weight, includes a 22 amino acid 
sequence at the amino terminal portion of the molecule and a 49 amino acid peptide at the carboxyl 
terminal. Consequently the thyroliberin prohormone may be akin to other peptide precursors that 
contain more than one biologically active peptide, such as the precursors for vasoactive intestinal 
peptide (Itoh et al., 1983), substance P (Nawa et al., 1983) and LHRH (Seeberg et al., 1984) and the 
final biosynthetic products may depend on the type of processing enzymes contained within the 
cell.
1.5.2. Processing of the thyroliberin prohormone
Lechan et al. (1986a) also used an antiserum raised against a synthetic peptide hypothesised to 
represent a portion of the mammalian thyroliberin prohormone, to encode the complete sequence 
of the thyroliberin prohormone. The deduced amino acid sequence reveals that the prohormone is 
approximately 26 kDa molecular weight and contains five copies of the sequence Gln-His-Pro-Gly 
flanked by pairs of basic residues and separated by intervening sequences. Two of the pro- 
thyroliberin-connecting peptides, preprothyroliberin (160-169) and preprothyroliberin (178-199) 
have been detected in rat neural tissues by radioimmunoassay (Bulant et al., 1988). The 
connecting peptides were found in the paraventricular nucleus of the hypothalamus, and a dense 
plexus of immunopositive nerve terminals was observed in the external zone of the median 
eminence, in a distribution similar to that described for thyroliberin. Bulant et al. (1988) suggested 
that both the preprothyroliberin (160-169) and (178-199) were, together with thyroliberin, 
predominant storage forms of the thyroliberin precursor in hypothalamus and spinal cord, as they 
were present in molar ratios corresponding to those expected for a nearly complete processing of 
the prohormone molecule. The presence of pro-thyroliberin-connecting peptides in various brain 
regions, including the median eminence, suggests that these peptides might act as 
neuromodulators in the CNS and/or neuroendocrine signals at the pituitary level. In the olfactory 
lobes, preprothyroliberin is processed differently since a C-terminally extended form of thyroliberin, 
preprothyroliberin (172-199), is found as a major end product along with lower but significant 
amounts of preprothyroliberin (178-199) and preprothyroliberin (161-169). The striking difference
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in pro-thyroliberin processing patterns among the various tissues examined suggests differential 
regulating mechanisms for thyroliberin and/or thyroliberin-related mechanisms.
Fig 1.3 Structure of preprothyroliberin
preproTRH
160-169
(Ser-Phe-Gln-His-Pro-Gly-Bas-Bas)
255
I
Bas-Bas-Gln-His-Pro-Gly-Bas-Bas (ie proTRH) 
Bas = Lys or Arg
More recently Bulant et al. (1990b), continuing their research into the processing of pro­
thyroliberin, found that the preprothyroliberin (160-169) (Ps4), was involved in regulating 
thyroliberin-induced thyrotropin secretion. Using a radiolabelled probe, iodinated Tyr-Ps4, they 
found that the anterior lobe of the pituitary contains a high density of Ps4 binding sites, while the 
posterior lobe is almost devoid of binding sites. The concentration of 1 2 5 l-labeled Tyr-Ps4 binding 
sites in the adenohypophysis was in the same range as that reported for thyroliberin receptors (Burt 
and Snyder, 1975). It was also found that Ps4 does not affect TSH secretion, but potentiates the 
action of thyroliberin on TSH release. This result suggests that the two peptides, derived from a 
single precursor, may act in a synergistic manner on the same target cells to modulate hormone 
release. The differential processing of the thyroliberin precursor may contribute an important 
regulatory point in modulating the biological potency of thyroliberin-connecting sequences (Ladram 
et al., 1992).
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Carr et al (1993) found that Ps4 (thyroliberin-potentiating peptide) not only stimulated TSHG gene 
promoter activity (as reflected by CAT synthesis in GH 3  cells), but also stimulated both the synthesis
and secretion of endogenously produced PRL. The disparate responses of synthesis and 
secretion to Ps4 will probably be an important tool to facilitate determination of the intracellular 
signalling events in thyroliberin regulation of gene expression. Ps4 was found to stimulate TSH  
secretion in GH 3  tumour cells, but did not directly stimulate TSH secretion in the pituitary (Bulant et
al., 1990a), suggesting that different receptor and/or effector systems exist for preprothyroliberin 
(160-169) on lactotrophs, thyrotrophs and tumour cells.
While Ps4 stimulated TSHI3 gene expression as did thyroliberin, it is unlikely that Ps4 acts through 
the same cellular mechanism as thyroliberin. Thyroliberin and Ps4 have distinct binding sites, and a 
demonstration of unique binding sites for Ps4 in the anterior pituitary was shown by Ladram et al. 
(1992) and Carr et al. (1993). Moreover, the effect of Ps4 appears to be additive to that of 
thyroliberin, further emphasising the likelihood of distinct pathways. A final common pathway is 
possible, because the same region of the TSHB-subunit gene required for thyroliberin regulation of 
TSHG gene expression was also essential for Ps4 effects (Carr et al. 1993). These data supports 
the hypothesis that processing of the thyroliberin precursor molecule, pro-thyroliberin, gives rise to 
at least two peptides (ie thyroliberin and preprothyroliberin (169-169)) with biological activity. This 
processing may constitute an important regulatory element in modulating the biological potency of 
thyroliberin and maintaining constant levels of TSH.
1.6 . D eg rad at io n  o f  th yro liber in
Neuropeptides represent a class of extremely potent biological substances acting as 
neurohormones, neuromodulators, neurotransmitters or paracrine effector substances on a variety 
of target cells via binding to specific receptors. In general, the effect a hormone produces varies 
with its concentration at the receptor sites in its target organ or tissue. This can be influenced by a 
variety of factors such as peptide binding to plasma proteins, the rate of diffusion of the hormone 
through capillaries and irreversible biochemical processes initiated by the hormone at its target 
organ or tissue, but the ultimate control over a hormone’s activity is through a balance between its 
biosynthesis (section 1.5) and degradation. As for other biologically potent substances, highly 
efficient degradation and/or elimination mechanisms must also exist for neuropeptides, because at 
inappropriate concentrations, highly active biological substances are also highly toxic. This is 
especially true for neuronal communication factors transmitting chemical signals and it is clear that for 
neuropeptides which are released with high frequency, these mechanisms not only have to be very 
efficient, but they also have to be very rapid.
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There has been much interest in the enzymatic inactivation of hypothalamic hormones and in the 
significance of the peptidase enzymes involved in the physiological control of their action. The 
study of these peptidases both in vivo and in vitro  requires the ability to detect the particular 
hypothalamic hormone and to measure its concentration, and to identify and quantify metabolites 
formed as a result of enzyme action. Bioassays and radioimmunoassays were used initially, but 
these have been replaced more recently by the cheaper, faster and more sensitive 
spectrophotometric and fluorimetric assays. In vitro, rapid degradation by blood and tissue enzymes 
has been demonstrated for all other neuropeptides and the rapid inactivation of thyroliberin had 
already been observed long before its structure had been elucidated (Griffiths, 1976). However, 
thyroliberin was found to be resistant to a variety proteolytic enzymes and even against the action of 
very unspecific enzymes such as pepsin, papain or thermolysin (Burgus and Guillemin, 1970). This 
fact is explained by the structural features of the tripeptide amide. Due to the cyclised aminoterminal 
end and the amidated carboxyterminus, thyroliberin is resistant against the action of exopeptidases 
and due to the internal proline residue, thyroliberin is not even susceptible to degradation by 
general hydrolytic enzymes.
In order to understand the biological function of neuropeptide-degrading enzymes, it is a 
prerequisite to first delineate the pathways of neuropeptide fragmentation and to evaluate the 
biochemical properties of the individual enzymes capable of hydrolysing the neuropeptide.
Fig 1.4 (a and b) summarises the degradation pathways of thyroliberin.
Thyroliberin is unstable in serum and tissues due to the presence of both specific and non-specific 
peptidases. There exists 2 modes of primary inactivation:
1. a pyroglutamyl aminopeptidase (cleaving the <Glu-His bond), and
2 . a proline endopeptidase (cleaving the C-terminal amide group)
These enzymes are of physiological importance in regulating various aspects of the endocrine and 
CN S actions attributed to thyroliberin (Griffiths,1976).
To fulfil such a function the enzymes should conform to certain criteria i.e. they should be located at 
the most appropriate sites in the body to perform their proposed function, they should have the 
correct biochemical characteristics such as substrate specificity, kinetics and products formed and 
finally, it should be possible to demonstrate changes in their activity with changes in physiological 
status(Griffiths and McDermott, 1984; Griffiths et al., 1983).
19
Fig 1.4 Primary degradation of thyroliberin by enzymes
a. Thyroliberin degradation by enzymes in the soluble fraction of brain cells
Thyroliberin 
<Glu-His-ProNH2
B
Acid Thyroliberin 
<Glu-His-Pro + NH3
<Glu + His-ProNH3
Spontaneous 
Cyclisation
His-Pro
Diketopiperazine
His-Pro + NH3 
D
t
His + Pro
A= Pyroglutamate Aminopeptidase Type I 
B= Prolyl Endopeptidase 
C= Dipeptidyl Peptidase II 
D= Proline Dipeptidase
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b. Thyroliberin degradation by enzymes of the particulate fraction of brain cells
Thyroliberin 
<Glu-His-ProNH2
<Glu-His + ProNH2
▼ F
<Glu + His-ProNH2 ------ His-Pro + NH3
His-Pro 
Diketopiperazine
His + ProNH2
E= Pyroglutamate Aminopeptidase Type II 
F= Dipeptidyl Peptidase IV 
G= Imidiopeptidase
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The first of the primary inactivators of thyroliberin is Pyroglutamate Aminopeptidase (PAP) (EC
3.4.19.3.) which generates His-ProNH 2  from brain thyroliberin. The brain contains at least 2
enzymes that exhibit this activity (Emerson and Wu, 1987).
1.6.1 Pyroglutamate Aminopeptidase (EC 3.4.19.3.)
PAP was first described in Pseudomonas fluorescens by Doolittle and Armentrout (1968) and has 
since been reported to be present in several bacterial, plant, animal and human tissues. In each 
case, this enzyme has been shown to exhibit maximal activity and stability in a highly reduced 
environment and to be highly sensitive to inhibition by sulphydryl reagents and heavy metal ions. 
Soluble PAP has been purified from several microbial sources including Pseudomonas fluorescens 
(Armentrout and Doolittle, 1969), Bacillus subtilus (Szewczuk and Mulczuk, 1969), Klebsiella docae 
(Kwiatkowska et al., 1974) and Streptococcus faecium (Sullivan et al., 1977). It has also been 
partially purified from bovine adenohypophysis (Mudge and Fellows, 1973), bovine brain (Hersh 
and McKelvy, 1979), rat adenohypophysis (Bauer and Kleinkauf, 1980), chicken liver (Tsuru et 
al.,1982), human cerebral cortex (Lauffart et al., 1988) and human kidney (Mantle et al., 1990).
The soluble PAP (PAP I) purified from rat adenohypophysis (Bauer and Kleinkauf, 1980) and guinea 
pig brain (Browne and 0 ’Cuinn,1983) was found to be capable of cleaving the N-terminal <Glu 
residue from various pyroglutamyl peptides, such as Neurotensin, LHRH and Bombesin - the 
exceptions being those commencing with the sequence <Glu-Pro. PAP I cleaves the thyroliberin 
tripeptide to yield free glutamic acid and the dipeptide His-ProNH2 . This dipeptide spontaneously 
and non-enzymatically undergoes a cyclisation reaction to form His-Pro diketopiperazine (Cyclo(His- 
Pro) ). Guinea-pig brain PAP I was shown to have a molecular weight of 24 kDa (Browne and 
O'Cuinn, 1983).
This enzyme has also been reported to be inhibited by diazomethyl ketone, an active site-directed 
irreversible inhibitor (Wilk et al., 1985) and by 5-oxoprolinal, an active site-directed reversible 
inhibitor (Ki=26nM) (Friedman and Wilk, 1985).
There appear to be conflicting reports regarding the role of PAP I in the metabolism of thyroliberin 
and LHRH in the brain and CNS. The role of soluble PAP in the metabolism of LHRH and 
thyroliberin in the brain was addressed by Mendez et al. (1990). By exposing hypothalamic cells or 
median eminences in culture to pyroglutamyl diazomethyl ketone (a specific PAP I inhibitor) they 
found that the thyroliberin content or recovery of released thyroliberin did not vary. Even though 
the activity of PAP I is regulated in GH 3  cells by 5-oxoprolinal (Friedman and Wilk, 1986), 3,5,3’-
Triiodo Thyronine(T3 ) (Suen and Wilk,1987b) and sodium butyrate (Suen and Wilk,1989a), 
Mendez et al. concluded that there does not appear to be a direct role for PAP I in thyroliberin or 
LHRH degradation. However a more recent study by Svoboda and Currie (1992) suggests the 
opposite. By chemically synthesising a series of chloromethyl ketone analogues of thyroliberin
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which had previously been shown to possess thyroliberin-like activity (Bhargava et al.,1982) in the 
CNS, and which were also found to be good inhibitors of PAP I, they suggested that thyroliberin-like 
activity could derive indirectly from inhibition of endogenous thyroliberin degradation of PAP I.
1.6.1.1. Inhibitors of the soluble PAP
PAP I is primarily a cytosolic enzyme with a widespread tissue distribution. Within the brain, the 
enzyme is fairly uniformly distributed (Torres et al.,1986). Active site-directed inhibitors of the 
enzyme were synthesised by Fujiwara et al. (1981) and included Z-pGlu-chloromethylketone, Z- 
pGlu-diazomethyl ketone and pGlu-chloromethyl ketone (Wilk, 1989).
Fig 1.5. Structures of inhibitors of the soluble PAP
1. Z-pGlu-chloromethyl ketone 2. pGlu-chloromethyl ketone
3. Z-pGlu-diazomethyl ketone 4. pGlu-diazomethyl ketone
The chloromethyl ketone derivatives were found to be excellent inhibitors but difficult to evaluate, 
because they interacted with thiol-reducing agents which were in the assay mixture to stabilise the 
enzyme. Z-pGlu-diazomethyl ketone was found to be relatively inert toward thiol reagents, but it was 
1 0 -fold less potent an inhibitor than pGlu-chloromethyl ketone. Wilk (1989) synthesised 
pyroglutamyl diazomethyl ketone (PDMK). This compound, lacking the Z-group, had a dramatically
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the particulate PAP.
There are no such doubts about the role of the second pyroglutamyl aminopeptidase activity 
involved in the primary degradation of thyroliberin. Several authors had reported PAP activity to be, 
at least in part, particulate in the brain tissue of several species (Schock,1977; Griffiths et al.,1979, 
1980, 1982; Joseph-Bravo et al.,1979; Krieder et al.,1981). However the relationship between the 
soluble and particulate activities was not clear. Browne et al. (1981) first proposed that there were 
two pyroglutamyl aminopeptidase activities present in guinea-pig brain: one a soluble enzyme 
requiring DTT and EDTA for expression of its activity, and the second a particulate activity that was 
inhibited by EDTA. This finding was confirmed by O’Connor and O ’Cuinn (1984) who located the 
particulate PAP activity to synaptosomal membrane preparations of guinea-pig brain from which it 
could be solubilised by papain treatment, thus confirming an earlier suggestion by Greany et al. 
(1980) that the particulate activity was located on synaptosomal membranes. Similarly, two PAP  
activities, one soluble and one particulate, were demonstrated in rat brain (Charli et al.,1984), and 
further studies involving subcellular preparations (Garat et al.,1985; Torres et al.,1986; Vargas et 
al.,1987). A  particulate PAP was also reported in rat adenohypophysis (Bauer,1987) and it was 
found to be involved in a biologically important control function within feedback-regulatory 
mechanisms.
1.6.2. The particulate PAP
The particulate PAP (EC 3.4.19.- designated as PAP II to differentiate it from the cytoplasmic PAP I 
by McDonald and Barrett,1986) was purified from synaptosomal membranes of guinea-pig brain and 
shown to be more restricted in its substrate specificity than the soluble PAP I . PAPII has been 
shown to only hydrolyse tripeptides containing N-terminal pyroglutamate and with histidine in the 
penultimate position (O’Connor and O ’Cuinn, 1985). In marked contrast to the nonspecific soluble 
activity, the particulate PAP of guinea-pig brain was found to have its active site oriented toward the 
extracellular space where thyroliberin would be expected to be located when involved in 
neurotransmission (Charli et al.,1988). Therefore PAP II should be considered a true ectoenzyme. 
It is primarily located in the synaptosomal region (O’Connor and O ’Cuinn,1984; Garat et al.,1985; 
Torres et al.,1986). Using primary cultures of neuronal, glial and adenohypophyseal cells from rat, 
Bauer et al. (1990) found a heterogeneous distribution of PAP II. Relatively high enzymatic activity 
was found on neuronal cells while glial cells were almost devoid of it. Low, but significant, activities 
were associated with pituitary cells as measured in aggregates consisting of the total pituitary cell 
population. This extremely heterogeneous distribution indicates that the thyroliberin-degrading 
ectoenzyme is not a general constituent of plasma membranes and thus strongly supports the 
hypothesis that it may serve very specialised functions for the inactivation of thyroliberin after its 
release. While peptidases associated with glial cells very likely only carry out general scavenger 
functions, peptidases on neuronal target cells potentially could be involved in turning off 
peptidergic signals, provided they are localised in the vicinity of the receptors or the site of
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neuropeptide release.
PAP II has been found to be a metalloenzyme of molecular weight 230 kDa (Czekay and Bauer, 
1993), with a Km of 40|iM for thyroliberin (O’Connor and 0 ’Cuinn,1985). It has a broad pH optimum 
in the neutral range, is sensitive to chelating agents such as EDTA, 8 -hydroxyquinoline and 1,10- 
phenanthroline, and it shows no sensitivity to sulphydryl reagents (O’Connor and O ’Cuinn, 1984). 
Moreover, pyroglutamyl diazomethyl ketone, an active site-directed inhibitor of PAP I does not 
inhibit synaptosomal PAP II (Friedman and Wilk,1986).
Perhaps the most significant difference between the soluble and the particulate PAP activities was 
the finding that the particulate activity, purified from the synaptosomal membranes of guinea-pig 
brain, cleaved the N-terminal <Glu from only thyroliberin or very closely related peptides (O’Connor 
and O’Cuinn,1985; Elmore et al., 1990). In these studies, various N-terminal pyroglutamyl peptides 
of varying lengths were used, and with the exception of <Glu-His, each peptide competitively 
inhibited the hydrolysis of thyroliberin by PAP II. The inhibition by LHRH (Ki=20jxM) is of specific 
interest, as LHRH, although not hydrolysed by PAP II, showed a  greater affinity for the enzyme than 
thyroliberin (Ki =42|iM) itself (O’Connor and O ’Cuinn, 1985). Substitution of <Glu or His by either 
Phe or N-Val in the thyroliberin sequence abolished the ability of the peptide to be hydrolysed, 
although some tolerance to substitution of the Pro-NH2  residue was observed (Elmore et al.,1990).
These observations and the non hydrolysis of thyroliberin analogues that possessed modified <Glu 
or His residues (Elmore et al.,1990) suggest that PAP II has an absolute requirement for an amino- 
terminal <Glu-His sequence for hydrolysis action, as opening the pyroglutamate ring, substitution of 
the histidyl residue or addition of any amino acid to the amino end of the molecule alter the 
molecules so that the enzyme cannot cleave them (Wilk and Wilk,1989).
The enzyme also appears to have a preference for substrate molecules which have a carboxy- 
terminal NH2  group. This was seen when the peptide amides tested which contained carboxy-
terminal NH 2  groups had lower Ki values (though they may not have been hydrolysed) than the
corresponding molecules without the NH2  group . Studies on the active site of PAP II indicate that
tyrosine, histidine, arginine and possibly lysine residues are necessary for catalytic activity and that 
the Tyr, His and Arg are probably within the enzyme’s active site (O’Connor and O ’Cuinn, 1987). 
Czekay and Bauer (1993) confirmed the presence of tyrosine, histidine and arginine residues as 
catalytically important elements of PAPII and also identified zinc as the catalytically-active metal of 
the enzyme- a feature which confirms the enzyme as a metalloprotease.
In an attempt to establish the inactivation mechanism of pyroglutamate aminopeptidase activity, 
Suen and Wilk (1989b) identified a 48kDa subunit of the PAP and showed that the inactivation 
mechanism was likely due to phosphorylation and not due to internalisation or dissociation. The 
regulation of the PAP activity will be discussed further in section 1 .6.4.
Trypsin-treatment of rat brain cells or rat brain intact synaptosomes has been found to destroy 70-
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80% of PAP II without affecting LDH or PAP I activity. Moreover, pretreatment of intact 
synaptosomes with saponin did not lead to an increase in PAP II activity (Charii et al.,1988). These 
findings suggest that PAP II is an ectoenzyme that is involved in the metabolism of thyroliberin in 
the synaptic cleft.
1.6.2.1. The distribution of PAP II activity
The highest PAP II activity is found in brain tissue (Friedman and Wilk, 1986), with the cortex being 
richest in enzyme activity (Suen and Wilk, 1989b; Bauer, 1988). Significant activity is also found in 
spinal cord, cerebellum and posterior pituitary, with lower levels detected in liver, retina and anterior 
pituitary (Wilk et al., 1988). Vargas et al. (1987) also reported a wide variation in levels of specific 
activity of membrane-bound PAP in different regions of rat brain, but was unable to find a correlation 
between specific activities of the enzyme and thyroliberin levels or density of thyroliberin receptors. 
However, Wilk et al. (1988) observed that membranes of rat retina, a tissue known to contain 
relatively high levels of immunoreactive thyroliberin (Martino et al., 1980) and of thyroliberin 
receptors (Taylor and Burt, 1982) exhibits a specific activity for membrane-bound PAP II that 
exceeds specific activity values for all non-CNS tissues thus far investigated. They suggested a 
functional relationship between PAP II and thyroliberin, which was supported by Bauer (1988), who 
reported rapid degradation of thyroliberin by PAP II of neuronal cells, while noting an absence of this 
activity in astroglial cells. These findings suggest that this enzyme is only associated with neuronal 
cells in brain. Wilk (1986) proposed that the membrane-bound PAP II be considered the first 
characterised neuropeptide-specific peptidase.
Table 1.5 The distribution of PAP II in rabbit and rat brain regions and 
hypophysis (Vargas et al., 1992a)
R egion Rat PAP II
Specific Activity  
(T h y ro lib e r in / m in /  
mg protein)
Rabbit PAP II 
Specific  Activity  
(T h y ro lib e r in / m in /  
mg protein)
Olfactory Bulb 6.58 6.33
Posterior part of Cerebral Cortex 6.50
Hippocampus 4.98 5.05
Cerebellar vermis 4.64
Cerebellar hemisphere 3.78
Nucleus accumbens-lateral septum 2 . 2 0 2.80
Mesencephalon 1.90
Median Eminence 1.53
Hypothalamus (minus ME) 1.25
Pons 1.13
Medulla oblongata 0.90 1 . 1 2
Adenohypophysis 0.50
Hypophysis 0.23
Serum 0 . 0 2 0 . 1 1
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Bauer et al. (1990) studied the cellular localisation of PAP II in primary cultures of neuronal, glial and 
adenohypophyseal cells and found the the thyroliberin-degrading ectoenzyme (PAP II) is 
specifically located on PRL cells. This preferred localisation of PAP II on PRL cells strongly suggests 
that the hormonally regulated thyroliberin-degrading activity plays an important and specific role in 
thyroliberin signalling to this cell type and might provide a rational explanation for the differential 
response of distinct pituitary cell types to the hypothalamic thyroliberin signal. A s known, 
thyroliberin stimulates PRL release in vitro and has been implicated as a physiologically relevant 
secretagogue in  vivo. It is also known that secretion of PRL is strongly modulated by peripheral 
hormones such as thyroid, glucocorticoid, and sex hormones. However, apart from the species- 
dependent luteotrophic action of PRL in rodents (McNeilly ,1987), which may give rise to 
production of oestrogens, these hormones are not produced by PRL-responsive organs and 
consequently, the secretion of PRL is not regulated by peripheral hormones via a classical feedback 
mechanism comparable to the well-known feedback action of thyroid hormones on the release of 
TSH. Obviously other mechanisms acting centrally or peripherally are required for balancing PRL 
secretion. The observed hormonal regulation of the enzyme by T 3  and estradiol may determine the
availability and/or the duration of action in the vicinity of PRL cells and thus may modulate the 
stimulatory effect of thyroliberin on PRL release according to the needs of the body (Bauer et al., 
1990).
1.6.3. Serum PAP
The presence of a potent thyroliberin-degrading activity in serum was first observed by Redding and 
Schally in 1969 and confirmed by Vale et al. (1971). The characterisation of the enzyme ( Taylor and 
Dixon, 1978; Bauer and Nowak, 1979; Bauer and Kleinkauf,1980) showed that the enzyme present 
in serum degrades thyroliberin into <Glu and His-ProNH 2  in a manner similar to the tissue
pyroglutamate aminopeptidase. However, this enzyme of molecular weight 260 kDa, exhibited 
chemical characteristics distinctly different from the previously characterised PAP I. It was inhibited 
by EDTA and DTT (agents which were known to activate PAP I), but not by 2-iodoacetamide and N- 
ethylmaleimide. It was shown to be inhibited by metal chelators such as 1 ,1 0-phenanthroline and 8 - 
hydroxyquinoline and was characterized as a metalloprotease (Bauer et al., 1981). In contrast to the 
broad specificity of PAP I, the serum enzyme caused rapid, stereo-specific cleavage only of the 
<Glu-His bond of thyroliberin and very closely related analogues. <Glu-Ala, <Glu-His and <Glu-G- 
naphthylamide are not effectively degraded by the serum enzyme and inhibit it poorly. 
Pyroglutamyl-containing peptides such as LHRH (<Glu-His-Trp...), neurotensin (<Glu-Leu-Trp...) or 
gastrin (<Glu-Gly-Pro....) and thyroliberin-analogues such as LLD-thyroliberin, <Glu-His-Pro-GlyNH2  
or <Glu-Gly-ProNH2  are not hydrolysed by the serum enzyme (Bauer et al., 1981). It was not until 
the discovery of a particulate PAP in 1984 (O’Connor and 0 ’Cuinn,1984) which resembled the 
serum thyroliberin-degrading activity in its size, chemical characteristics and substrate specificity that 
the serum enzyme (designated a Thyroliberinase' rather than a PAP due to its strict substrate
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specificity, (Bauer,1983)) and the PAP II were suggested to be products of the same gene code 
(Bauer,1988).
1.6.4. PAP regulation
The possibility that the rapid inactivation of thyroliberin by serum, may be related to thyroid status 
was first suggested by Redding and Schally (1969) when they observed that degradation of 
thyroliberin was reduced in hypothyroid rats and the effect could be reversed by the administration 
of thyroid hormones. Similar studies by Vale et al. (1971) however, could not confirm these findings 
and human studies detected no difference in thyroliberin-degrading activity in patients with varying 
thyroid status (Jeffcoate and White, 1975). In 1976 a study by White et al., confirmed the 
relationship between thyroid status and thyroliberin inactivation originally suggested by Redding 
and Schally. They found that thyroliberin degradation is reduced in hypothyroid rat serum and 
increased in hyperthyroid rat serum. They went on to suggest that the mechanism by which this 
regulation was exercised most likely involved enzyme synthesis and degradation. Bauer (1976) 
compared the activity of serum from control rats to that of T 3 - (triiodothyroxine) and PTU-
(propylthiouracil, a mild goitregenic agent) treated cells. The study reported that enzymatic 
degradation contributes to the balance of thyroliberin secretion and its degradation is controlled by 
thyroid hormone-induced negative feedback mechanisms.
1.6.4.1. PAP regulation by thyroid hormones
With the characterisation and localisation of the thyroliberin-degrading enzymes, PAP I and II and the 
serum thyroliberinase in the 1980s, came a further surge of insight into regulation of thyroliberin 
levels by thyroid hormones. The ability to isolate and purify the specific enzyme fractions from brain 
homogenates allowed more exclusive research into the effect of thyroid status on thyroliberin 
degradation via regulation of PAP I and II.
The regulation of PAP I and II and the serum thyroliberinase has been studied both in vivo and in  
vitro. In vivo studies have been performed with T 3  (triiodothyroxine) or T 4  (thyroxine) to induce
hyperthyroidism, or with PTU to induce hypothyroidism (Wolf et al., 1984; Aratan-Spire et al., 1984; 
Bauer, 1987; Scharfmann et al., 1990). The in vitro approach to investigation of the regulation of 
thyroliberin degradation by thyroid hormones has also been widely used (Suen and Wilk, 1987a; 
Bauer et al.,1990).
There is a conflict of reports regarding the effect of thyroid status on PAP I activity. Suen and Wilk 
(1987a) demonstrated that low concentrations of T 3  induce PAP I in the thyroliberin-target G H 3  cell. 
Later they found elevations in the PAP I activity in a number of brain regions and in the pituitary
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following chronic but not acute T 3  treatment (Suen and Wilk, 1989b). Changes in the activity of
PAP I are not necessarily related to thyroliberin, as other pyroglutamyl peptides such as LHRH and 
neurotensin are substrates of PAP I. However they felt it was possible to suggest that the 
increased levels of the enzyme in pituitary and hypothalamus may contribute to the negative 
feedback regulation of thyroid status by T 3  (Suen and Wilk, 1987a). Scharfmann et al. (1990) found 
that there were no changes in soluble rat liver PAP I with thyroid status. This report agreed with 
earlier reports from brain (Emerson and Wu, 1987) and adenohypophysis (Bauer, 1987) that PAP I 
is thyroid-hormone insensitive.
Emerson and Wu (1987) also found that that thyroid status influences only rat serum PAP, but has 
no effect on the cytosolic or membrane-bound PAPs of brain, even at increasing T 4  concentrations.
In the case of serum thyroliberinase, activity significantly increased in the hyperthyroid group and 
correspondingly decreased in the hypothyroid group. This evidence supported Bauer’s findings 
(Bauer, 1976) that thyroid hormones modulate thyroliberin degradation in rat serum.
A study by Bauer (1987) indicated that thyroid hormones exerted a direct effect on the activity of 
the membrane-bound adenohypophyseal enzyme, unlike the serum enzyme whose activity 
increases significantly only when thyroid hormones are injected repeatedly for long periods of time 
(Bauer,1976). This study agreed with Emerson and Wu (1987) that while the activity of the brain 
PAP II is not controlled by thyroid hormones, the adenohypophyseal PAP II is controlled by thyroid 
hormones. This suggests that the enzyme itself could serve as a regulatory control element to 
influence the extent and duration of the endocrine activities of thyroliberin at adenohypophyseal 
target sites. Hence the induction of the enzyme and the rapid decline in its activity within 
physiologically significant time periods indicate a high turnover of the enzyme, and thus it supports 
the concept of specialised functioning of the membrane-bound thyroliberin-degrading enzyme of 
the adenohypophysis.
The detection of increased activity of PAP II in the pituitary in response to acute T 3  treatment (Suen
and Wilk, 1989b) firmly supports the earlier report of a 550% increase on control levels of PAP II 
activity when T 3  was acutely administered (Bauer,1987). This finding indicates that the biological
activity of thyroliberin at the pituitary is terminated by PAP II and that the increased enzymatic activity 
contributes to the negative feedback regulation of thyroid status by T 3 . This increase is no longer 
seen in the chronically treated animals where other mechanisms such as induction of PAP I may 
come into play. The increased activity of PAP in rat serum following chronic T 3  treatment is a well 
documented phenomenon and has already been discussed (White et al., 1976; Bauer,1976). 
Suen and Wilk (1989b) also provided evidence to suggest that PAP II activity in particulate brain 
regions is also modulated by thyroid hormone levels. This possibility had been rejected by previous 
studies (Emerson and Wu, 1987; Bauer, 1987). The fractionation of the brain into particular areas 
allowed the study of hormone effects on PAP in localised regions.
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Effects of hormones on PAP activities were possibly masked in the earlier studies by the use of 
whole brain homogenates. Ponce et al. (1988) found the effect of thyroid hormones to be tissue 
specific- affecting thyroliberin degradation only in serum and at its target site in the axis: PAP II 
activity localised on adenohypophyseal membranes. Their results agreed with the findings of Bauer 
(1987) and indicates that if PAP II is an ectoenzyme in adenohypophysis as in brain, the degradation 
of thyroliberin on adenohypophyseal plasma membranes plays a role in the rapid negative feedback 
control, more than the delayed changes in thyroliberinase (serum PAP), or in PAP I whose contact 
with thyroliberin in adenohypophysis has not been demonstrated (Suen and Wilk, 1987b). The 
picture which emerges from recent studies is that negative feedback by thyroid hormones involves 
multiple level of regulation: thyroliberin metabolism (biosynthesis, release and inactivation), 
thyroliberin receptors and TSH secretion.
1 .6.4.2. Significance of regulation studies in establishing the biochemical role of PAP I . PAP II and 
the serum thyroliberinase
PAP regulation studies have led to increased speculation as to the underlying role of the PAP 
enzymes in thyroliberin degradation and consequently the importance of thyroliberin degradation in 
biochemical and neurological pathways. There is little doubt that PAP II of adenohypophyseal tissue 
is tightly controlled by thyroid hormone levels (Bauer, 1987; Scharfmann et al., 1990b). This finding 
is of major importance as it suggests that this enzyme in particular may serve as a regulatory control 
factor, to determine the extent and duration of the endocrine activity of thyroliberin at pituitary target 
sites. Thus control of the secretion of adenohypophyseal hormones can be effectively exercised.
Bauer (1987) recognised that the rapid induction of pituitary PAP II in response to augmented T3  
levels and its subsequent decline in activity, lies within time periods which are of significance in 
demonstrating a high turnover of the enzyme in the pituitary. Such a high enzyme turnover in this 
specialised location is desirable if PAP II is to play a role in feedback regulation of thyroliberin levels, 
which modulate secretion of hormones from the pituitary. The lag phase of 4 hours reported by 
Bauer (1987), before rapid induction of PAP II activity in adenohypophysis is interesting as it 
indicates a period of protein synthesis which would make large quantities of enzyme available for 
thyroliberin degradation. If increased PAP II activity can be explained by the induction of enzyme 
synthesis, then it is reasonable to suggest that the decline in activity reflects an inhibition of the 
existing enzyme activity and of further enzyme synthesis. Some insight into the mechanism by 
which such inhibition is achieved has come to light in a recently published report by Suen and Wilk 
(1991). The implications of this suggestion will be discussed later. The inability to produce 
substantial evidence that PAP II in brain regions is controlled by thyroid hormones may be significant 
in itself as it suggests that this enzyme in such locations serves a more specialised function in 
neurotransmission.
30
The significance of the finding that PAP I enzyme is also regulated by chronic treatment with thyroid 
hormones, remains unclear. The broad specificity of PAP I means that changes in its activity cannot 
be interpreted with confidence in terms of thyroliberin degradation alone. There appears to be a 
case for the regulation of adenohypophyseal PAP I by thyroid hormones due to T 3  on PAP I of brain
and extrahypothalamic regions. Further studies are necessary.
The thyroliberin-degrading serum pyroglutamyl peptidase enzyme has also been shown to be up- 
regulated in hyperthyroidism and down-regulated in hypothyroidism (Emerson and Wu, 1987). 
However a later report (Yamada et al., 1990) did not find this relationship, so the true significance of 
the finding remains to be seen. Efforts are being made to establish the nature of the enzyme which 
mediates this effect in serum. Much evidence points to PAP II as the two enzymes share similar 
physical and biochemical properties as well as substrate specificity. The role of the serum 
pyroglutamyl peptidase in thyroliberin degradation will be approached again in the next section as 
reports have suggested that it is also affected by steroid hormones.
1.6.4.3. Regulation of Pvroalutamvl Aminopeptidases by steroid hormones 
The case for control of thyroliberin degradation through the regulation of specific thyroliberin- 
degrading enzymes in serum and the adenohypophysis has been established. Such regulation is 
mediated by thyroid hormone effects on thyroliberin-degrading enzymes. Studies on PAP II and 
the serum enzyme have supported the notion that thyroliberin is important in the regulation of 
adenohypophyseal hormone secretion. Equally the inability to confirm that PAP I in pituitary, brain 
and extra-hypothalamic regions and PAP II of brain, are regulated by thyroid hormones, may be 
significant. It implies that pyroglutamate aminopeptidase (especially PAP II) may serve some special 
role in transmission of thyroliberin signals and may represent the peptidergic equivalent of acetyl 
cholinesterase, which would cause the termination of nervous signals at the appropriate time. 
Steroid hormones are thought to effect the degradation of thyroliberin-degrading enzymes (Bauer, 
1988). Through the study of steroid hormone effects on the PAP enzymes it has been possible to 
lend support to the proposal that PAP II, the membrane-bound thyroliberin-degrading enzyme, has 
specialised and independent functions in the pituitary and brain.
A  1988 study by Bauer was carried out to determine the effect of both thyroid hormones and 
oestrogens on the regulation of membrane bound PAP II of rat anterior pituitary. The study reveals 
some interesting results regarding the difference in the response of male and female rats to T 3  at
the level of the membrane bound PAP in brain, pituitary and serum. The study then investigates 
the effect of injection of estradiol and testosterone on the induction of enzyme activity by T 3 .
Significant and appropriate findings resulted for both serum and adenohypophyseal (membrane- 
bound )enzyme. Activities were influenced by the sex of the animal and by estradiol administration 
but brain PAP II enzymes were not affected. For the serum enzyme, euthyroid females showed 
only 85% enzyme activity of males. It has been demonstrated that this enzyme is controlled by 
thyroid hormones and also that its activity alters with developmental changes (Neary et al., 1976).
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With regard to PAP II of rat brain, no alteration in activity in response to thyroid status and moreover, 
no sex difference could be determined. Conversely, the activity of adenohypophyseal PAP II 
enzyme from male rats showed 75% reduction with PTU treatment and this activity was recovered 
following injection of thyroid hormone. A significant sex difference was noted for this enzyme, only 
25% of the enzyme activity was found in female rat pituitary tested. Studies of ovariectomised 
females showed a three-fold increase in pituitary PAP II activity which was reduced with estradiol 
benzoate but injection of testosterone propionate could not counteract the effect of T 3 . Injection of 
T 3  into intact females caused a rapid increase in PAP II adenohypophyseal enzyme (about 10-fold 
on control levels), an increase which could be counteracted by injection of estradiol benzoate.
Thus the experiments have shown that estradiol exerts a negative effect on the feedback regulation 
of PAP II by thyroid hormones. The results confirm a role for oestrogen in the regulation of PAP II 
enzymes by thyroid hormones and weaken the possibility that PAP II from brain sources may be 
affected by sex differences. The activity variations of the serum enzyme, brain PAP II and pituitary 
PAP II can be interpreted to contend with postulated specialisation of these enzymes to a particular 
function. For the membrane-bound thyroliberin-degrading brain enzyme, it could be demonstrated 
that it preferentially associated with synaptosomal membranes and represents a true ectoenzyme 
which is almost exclusively associated with neuronal cells. Therefore, this enzyme may exert a 
biologically important function for the inactivation of synaptically released thyroliberin in order to clear 
the target site for the transmission of the next thyroliberin signal. For such static functions, the 
activity of the thyroliberinase should not be a limiting factor and, therefore, it is not surprising that the 
activity of the brain enzyme was found not to be influenced by the hormonal manipulation of the 
animals (Bauer, 1988).
Adenohypophyseal PAP II has been shown to be dually controlled by steroid and thyroid hormones 
(Bauer, 1988). This finding should also be regarded in terms of the proposed function of pituitary 
PAP II. All evidence appears to point to a regulatory role for the enzyme in the release of 
adenohypophyseal hormones (mediated by hypothalamic thyroliberin). Such an effective 
regulation system would be expected to be finely tuned to respond to the levels of both thyroid and 
steroid hormones at target sites. The dual and inverse control of PAP II in the pituitary by 
oestrogens and thyroid hormones, is desirable if the stimulation and duration of thyroliberin action at 
its target sites is to be maintained in accordance with thyroid and steroid hormone levels.
The serum thyroliberinase has also been found in many studies to be controlled by thyroid 
hormones and to alter with developmental changes. This suggests that the enzyme functions in a 
regulatory system. There has been a suggestion that thyroliberin degradation by hypophyseal 
portal blood may represent a functional control element within the regulatory mechanism. Perhaps 
by limiting thyroliberin levels in serum and thus restricting the hormones availability to the trophic 
cells of the pituitary, the production of hormone by the cells could be limited (Bauer, 1988). This
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possibility however requires further study, particularly of the enzyme’s source and exact relationship 
with PAP II of the pituitary as some identity between the two enzymes is suspected. Bauer’s 
findings (Bauer, 1988), have provided firm evidence to support the proposed roles of the individual 
pyroglutamyl aminopeptidases in brain, adenohypophysis and serum. In vitro  studies carried out 
(Bauer et al., 1990) arrived at very similar results for the dual effect of thyroid hormones and estradiol 
on PAP II of pituitary cells which demonstrate that the observed effect is a result of a direct action of 
T 3  on the cells rather than an indirect effect via other T 3  -responsive systems.
1 .6.4.4. Possible mechanisms of PAP enzyme regulation
The study of regulation of thyroliberin-degrading PAP enzymes has uncovered a vast quantity of 
information which allows the pathways of thyroliberin degradation to be examined, with a view to 
ascertaining the tuning of the endocrine system to hormone levels. Such studies have established 
that thyroid hormones control the activities of some of the thyroliberin-degrading enzymes, in an 
effort to regulate hormone levels in accordance with bodily needs. There has however been little 
insight into establishing the mechanism which allows enzyme activity to be turned on and off.
In 1991 Suen and Wilk suggested that PAP II is subject to short term regulation and that the protein 
kinase C (PKC)- mediated phosphorylation is the most likely mechanism for this effect (Suen and 
Wilk, 1991). Earlier studies had shown that phosphorylation of hormone-responsive peptides was
mediated in vitro by a Ca2+-dependent phospholipid-activated protein kinase C  (Drust and Martin, 
1984). Furthermore PKC has been shown to be stimulated by diacylglycerol and phorbol ester in  
vitro (Drust and Martin, 1985). Thus it is reasonable to suggest that thyroliberin rapidly initiates both
Ca2+ and lipid-dependent pathways of protein phosphorylation.
Suen and Wilk’s studies are based on the inhibition of PAP II in Y-79 retinoblastoma cells by phorbol 
ester 12-o-tetradecanyl-phorbol-13 acetate (TPA). This tumour-promoting phorbol ester dually 
inactivates Ca2+ and phospholipid-dependent PKC, which in turn causes a variety of biological 
effects in a fashion very similar to hormonal treatment. In their 1990 study, Suen and Wilk observed 
that the time course of TPA-mediated effects paralleled the time course of translocation and 
activation of protein kinase C in this cell line. They demonstrated a decrease of PAP II activity to 1 0 % 
of control levels within 15 mins, followed by a return to 70% of control levels within 1  hour. They 
reasoned that the initial decrease in activity resulted from enzyme phosphorylation via a TPA- 
activated protein kinase C. In a 1991 report, Suen and Wilk further investigated the TPA treatment 
of Y-79 retinoblastoma cells and reported a second phase of inactivation which occurs following a 
long exposure to TPA. After 1  hour enzymatic activity slowly declined and by 7 hours 15% of the 
control levels remained. It was Suen and Wilk's aim to explain this biphasic inactivation of PAP II in 
terms of enzyme phosphorylation mediated by PKC. Proof of a protein kinase C involvement in the 
decreased enzyme activity, observed on thyroliberin treatment, came from the pre-treatment of the 
Y-79 cells with a PKC inhibitor, H-7 or sphingosine. This was seen to prevent the inactivation of PAP
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II. Using immunoblotting techniques they showed that the amount of PAP II was not changed 
following TPA treatment. Neither was the decreased activity due to dissociation or internalisation of 
PAP II (Suen and Wilk, 1991). By incubating Y-79 cells for varying times with TPA, they showed that 
TPA treatment causes the phosphorylation of a 48 kDa subunit of PAP II thereby causing the 
inhibition of PAP II activity.
How is the second phase of PAP II inactivation accomplished? A  possible insight into the 
mechanism has come from Suen and Willi’s 1991 study, where the amount of PAP II enzyme in the 
Y-79 cell membranes was determined by immunoblotting. Following incubations with TPA, the 
membrane proteins were immunoblotted with a PAP II polyclonal antibody. The amount of the 48 
kDa subunit of PAP II was seen to decrease with increasing time of exposure to TPA.
PKC was thus shown to be targeted by phorbol esters in vitro and in  vivo. The activation of PKC  
stimulates dual signals which can stimulate or inhibit biological responses (Suen and Wilk, 1991). 
Recovery of PAP II activity in the current case, following the initial decrease in activity is no doubt 
due to a reversal of phosphorylation, restoring the enzyme to its active state. The second 
inactivation, from the above experiment by Suen and Wilk, also appears to involve PKC. The 
mechanism for this second phase of inactivation was seen not to be due to dissociation from the 
membrane or internalisation of PAP II, as no activity could be detected in the cytosol or in the 
medium.
The 1990 and 1991 experiments have elucidated the mechanism by which thyroliberin regulates 
PAP enzymes. It has been established that thyroliberin somehow activates protein kinase C. The 
mechanism by which protein kinase C  activates the PAP II enzyme, to degrade thyroliberin, when 
thyroid hormone levels are in excess of requirements, is so far speculative but it most likely involves 
protein phosphorylation or dephosphorylation.
1.6.5. Prolyl endopeptidase activity
The unique cyclic aliphatic structure of proline represents a characteristic target for specific 
endopeptidases and exopeptidases (Kato et al., 1980). Proline differs from the other amino acids in 
the basic set of twenty in that it contains a secondary rather than a primary amino group. Strictly 
speaking proline is an imino acid rather than an amino acid. The side chain of proline is bound to 
both the amino group and the a-carbon which results in a cyclic structure as shown in Fig 1.6 . 
Enzymes hydrolysing peptide bonds involving proline are of particular interest because of the 
significance of this amino acid in determining the conformation of peptide chains. Enzymatic 
hydrolysis of peptide bonds in which either the carboxyl group or the imido group of proline are 
involved have been known for years.
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Fig 1.6 The unique cyclic aliphatic structure of proline (Kato et al., 1980)
C O O “
r
O H  
^ 2
C
/
m
O L ----------- CH 2
1. Iminopeptidase (Proline dipeptidase EC 3.4.13.9.)> hydrolyses dipeptides containing a free imino 
group of proline or hydroxyproline
2. Prolinase (Prolyl dipeptidase EC 3.4.13.8.), hydrolyses dipeptides containing a substituted imino 
nitrogen of proline
3. Dipeptidyl Aminopeptidases (DAP II EC 3.4.14.2. and DAP IV EC 3.4.14.5.), can both act as post 
proline cleaving enzymes on a number of tripeptides which have proline in the central position
4. Aminopeptidase P (EC 3.4.11.9.), is an exopeptidase which cleaves the N-terminal residues 
linked to proline in oligopeptides of low and high molecular weight (Holtzman et al., 1987)
5. Proline carboxypeptidase (EC 3.4.16.2.), is a COOH terminal exopeptidase which cleaves at the 
carboxyl side of proline provided that the imino group is protected and the carboxyl group of the 
terminal is free.
6 . Post Proline Cleaving Enzyme (EC 3.4.21.26), is capable of cleaving the peptides on the 
carboxyl side of proline residues located internally in the peptide (Walter and Yoshimoto, 1978)
In 1971, Walter et al. reported on the partial purification of an enzyme from uterine homogenates 
which cleaved the prolyl-leucyl bond of oxytocin:
Cys-Ty r-1 le-G In-Asn-Cys- Pro-Leu-G ly-N H2 
This enzyme was purified to apparent homogeneity from lamb kidney by Koida and Walter (1976) 
and termed ‘post-proline cleaving enzyme’ based on its specificity for peptide bonds in which the 
carbonyl group was provided by proline residue. Oxytocin, angiotensin II and bradykinin were all 
cleaved at the appropriate ‘post-proline’ sites, although the Pro-Pro bond of bradykinin was not 
cleaved. The enzyme was reported to have a dimeric structure and a molecular weight of 115 kDa. 
Subsequent studies established PPC E  as a serine protease (Yoshimoto et al., 1977). In 1976 
Oliviera et al., studying the degradation of bradykinin, partially purified an enzyme from the 
supernatant fraction of rabbit brain homogenates which they named kinase B. This thiol-activated 
enzyme cleaved bradykinin at the Pro7 -Phe8  bond and was reported to have a molecular weight of
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In 1978 Oriowski et al. purified a brain enzyme which cleaved peptides on the carboxy side of proline 
residues. This enzyme had a molecular weight of 6 6  kDa and showed a substrate specificity similar 
to that of PPCE (Oriowski et al., 1979) in that it hydrolysed peptidyl prolyl-peptides and peptidyl 
prolyl amino acid bonds. However, because it was inactive on substrates with an unsubstituted 
imino group of proline, the name of prolyl endopeptidase was proposed.
The degradation of thyroliberin at the prolyl-amide group uncovered another enzyme with a similar 
specificity to lamb kidney PPCE (Hersh and McKelvy, 1979; Knisatschek and Bauer, 1979; Rupnow 
et al., 1979). This enzyme was isolated from bovine anterior pituitary and had a molecular weight of 
76 kDa. It was inhibited by diisopropylfluorophosphate (DFP) and sulphydryl blocking agents. 
Despite the discrepancy by Koida and Walter (MW of 115 kDa, dimeric structure) for PPCE from lamb 
kidney, the other enzymic activities detected in different species and in a variety of tissues, that 
cleave peptide bonds at the carboxyl side of proline residues within a peptide chain share many 
common features (Table 1.6).
Table 1.6 A comparison between Prolyl Endopeptidase and other proline- 
cleaving peptidases _____________  ______
68 kDa.
Peptidase Source Molecular
Weight
(kDa)
Inhibitors Substrate Specificity
Prolyl Rabbit brain 69 Thiol reactive Thyroliberin,
Endopeptidase Cow brain 76 reagents LHRH Pro9-Giy10
Lamb brain 
Human serum
74
100
Z-Pro-prolinal NT Pro7-Arg8 
NT Pro10-Tyr11 
BK Pro3-Gly4, Pro7-Phe8
Angiotensin Rat brain 165 EDTA (metallo- Ang I Phe8-His9
Converting Pig kidney 180 protease) BK Phe5-Ser6, Pro7-Phe8
Enzyme (ACE) Human liver 
Human serum
150
140
Captoprii NT Tyr11-lle12 
LHRH Trp3-Ser4 
Tyr5-Gly6, Leu7-Arg8
EC 3.4.24.11 Rabbit kidney 93 EDTA Ang I Arg2-Val3,
Human kidney 90 Thiols Tyr4-lle5, Pro7-Phe8
Human lung 90 Phosphoramidon BK Gly4-Phe5, Pro7-Phe8 
NT Pro10-Tyr11,
Tyr11 -11 e 12
EC 3.4.24.16 Rat brain 
Pig brain
EDTA NT Pro10-Tyr11 
Ang I Pro7-Phe8 
LHRH Tyr5-Gly6, 
Gly6-Leu7 
BK Phe5-Ser6
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NT = Neurotensin 
BK = Bradykinin 
Ang I = Angiotensin I
LHRH = Lutenising Hormone Releasing Hormone
The true identity of proline-specific endopeptidase activities was elucidated by Hersh in 1981 using 
immunochemical techniques. These revealed that a single enzyme was responsible for prolyl 
endopeptidase activities. An antibody to the bovine brain enzyme cross-reacted with the brain 
enzyme of various species and with prolyl endopeptidase-like activity from rat liver, lung and kidney 
(Hersh,1981). The rat brain and kidney enzymes had similar molecular weights, substrate 
specificities and sensitivity to thiol blocking agents. Antibodies to the rat brain precipitated the lamb 
kidney enzyme, and also cross-reacted with the enzyme from a number of other tissues (Andrews et 
al., 1982).
In view of the identity of enzymes from various tissues and different species, a unified nomenclature 
was proposed. The name prolyl endopeptidase was chosen, rather than post-proline cleaving 
enzyme, since not all post-proline bonds are cleaved (eg. Pro-Pro). The names thyroliberin- 
deamidase and kinase B implied restrictive specificity and were therefore misleading. The name 
prolyl endopeptidase (EC 3.4.21.26) was therefore adopted (Barrett, 1980).
Since its discovery in 1971 by Walter et al. in human uterus, prolyl endopeptidase has been found 
to be widely distributed. It has been purified from a variety of mammalian sources such as rat brain 
(Rupnow et al., 1979), rabbit brain (Orlowski et al., 1979), bovine brain (Yoshimoto et al., 1983), lamb 
brain (Yoshimoto et al., 1981),pig brain (Schonlein et al., 1990) and human tissues (Kato et al., 
1980; Daly et al., 1985; Zolfaghari et al., 1986). The distribution of prolyl endopeptidase in a 
number of species, including rat (Fuse et al., 1990), rabbit (Orlowski et al., 1979), bovine (Tate,
1981) and human (Kato et al., 1980) has been studied.
Prolyl endopeptidase has been predominately described as a soluble, cytosolic enzyme. However, 
it has become increasingly clear that prolyl endopeptidase is found in both soluble and insoluble 
fractions of tissue homogenates. Very few studies have described the exact distribution of enzyme 
activity between soluble and insoluble fractions from tissue to tissue. Dresdner et al. (1982) 
localised the prolyl endopeptidase of rabbit brain in the cytoplasm. They noticed a sizable 
percentage of prolyl endopeptidase activity to be associated with the particulate fraction, but took 
that activity to be due to entrapped cytoplasm as they had not washed the membrane fraction.
Camargo et al. (1984) found that 10% of prolyl endopeptidase activity in rabbit brain remained 
attached to the membrane fraction during extensive salt washing, but it could be solubilised with 
detergents such as Triton X-1 0 0 . They suggested that the enzyme was only loosely associated with
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the membrane. They confirmed this report by immunoprécipitation of the cytosol and solubilised 
membrane enzyme with the anti-prolyl endopeptidase immunoglobulin, as both fractions contained 
an antigen immunoprecipitated by the immunoglobulin.
Dalmaz et al. (1986) also found prolyl endopeptidase activity in the membrane fractions of rat 
hypothalamus and localised it in the synaptosomal fraction. However, they found that within the 
synaptosomal fraction, the highest prolyl endopeptidase specific activity 40 times higher than the 
synaptic vesicle or membrane fractions. Particulate forms of the prolyl endopeptidase have been 
reported in the brush border of kidney (Sudo and Tanabe, 1985), in the neuroblastoma x glioma 
hybrid cell lines NG 108-15 (Chappell et al., 1990) and in the N1E-115 neuroblastoma cells (Checler 
et al., 1986).
In brain homogenates, the amount of membrane-bound activity amounts to 10% of the total activity 
(Dresdner et al., 1982). In the brush border of the kidney, a 10-fold greater amount of prolyl 
endopeptidase specific activity is membrane bound as opposed to being soluble (Sudo and 
Tanabe, 1985). Prolyl endopeptidase activity is also found in membrane preparations of circular, but 
not longitudinal muscle from canine ileum (Checler et a l„ 1987).
It is not known whether expression of different gene products account for insoluble and soluble 
forms of prolyl endopeptidase. Presently, there is no information on the prolyl endopeptidase 
genes and the cDNA sequence is consistent with a cytosolic or soluble enzyme (Rennex et al., 
1991). It is possible that the difference between soluble and particulate forms results from a post- 
translational modification.
1.6.5.1 Tissue distribution of Prolyl Endopeptidase
Prolyl endopeptidase is widely distributed in various tissues (Table 1 .7). The brain is one of the 
richest sources of the enzyme. Within the brain, prolyl endopeptidase activity is found in all regions. 
In rabbit brain, the highest activity is found in some cortical regions, hippocampus and striatum, and 
lowest activity in the pons and medulla (Orlowski et al., 1979). A difference of 2 to 3 -fold separates 
regions of highest and lowest activity. In human, the frontal cortex shows the highest prolyl 
endopeptidase activity, and activity is also found in the nucleus caudatus, the thalamus and 
hypothalamus (Kato et al., 1980). Yoshimoto et al. (1983) showed a similar regional distribution for 
prolyl endopeptidase activity in bovine brain.
Table 1.7 Tissue Distribution of Prolyl Endopeptidase (Welches et al., 1993)
Species Kidney Lung Testis Heart Serum Brain
Man 1.00 0.30 1.40 0.20 0.00 .
Rabbit 1.00 2.20 . . . _
Mouse 1.00 2.40 . 1.00 - 1.00
Rat 1.00 0.60 - 0.60 - 0.80
Rat 1.00 0.20 - 0.70 . 1.60
Rat 1.00 1.80 3.30 1.60 0.00 2.10
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Levels of PE activity are expressed relative to the value found in kidney. A dash indicates that the 
activity was not determined.
1 .6.5.2. Characterisation of Prolyl Endopeptidase
Prolyl endopeptidase is a serine peptidase with no metal ion requirement. Its molecular weight is 
approximately 70 kDa. However there are two reports of a human serum prolyl endopeptidase that 
appears to be a dimer of 70 kDa molecular weight subunits (Kato et al., 1984; Soeda et a l 1984). It 
has a pH optimum of 7-8.5 depending on the source of the enzyme and the substrate used 
(Yoshimoto et al., 1983; Knisatschek and Bauer, 1979).
Prolyl endopeptidase has an essential thiol residue, and its levels of activity are increased by 
including a thiol reagent such as 13-mercaptoethanol or dithiothreitol (DTT). The typical increase in 
activity by thiols is from 1.3 to 1.6-fold using synthetic substrates (Orlowski et al.,1979; Kato et 
al.,1980; Kalwant and Porter, 1991). However, one report shows a 30-fold activation of prolyl 
endopeptidase by thiols using the natural peptide substrate angiotensin II (Greene et al., 1982). 
This result suggests that there may be differences in prolyl endopeptidase activity observed when 
using synthetic and natural substrates.
Rennex et al. (1991) used prolyl endopeptidase from porcine brain to isolate a cDNA clone. This 
clone contained the complete coding sequence of prolyl endopeptidase and encoded a 
polypeptide of molecular weight 80,751 Da. The deduced amino acid sequence of prolyl 
endopeptidase showed no sequence homology with the other known serine proteases. Tritiated 
DFP was used to identify the active-site serine of prolyl endopeptidase. One labelled peptide was 
isolated and sequenced. The sequence surrounding the active-site serine was Asn-Gly-Gly-Ser- 
Asn-Gly-Gly. This sequence is different from the active site sequences of other known serine 
proteases. This difference and the lack of overall homology with the known families of serine 
proteases suggested that prolyl endopeptidase represents a new type of serine protease.
1.6.5.3. Substrate Specificity of Prolvl Endopeptidase
Prolyl endopeptidase was originally discovered as an enzyme which could degrade oxytocin (Walter 
et al., 1971). This enzyme can also hydrolyse many oxytocin and vasopressin analogues by 
cleaving the peptides on the carboxyl side of proline (Walter, 1976), with the exception of Pro-Pro 
bonds. However it will cleave at the alanine residues in oligoalanine peptides at low efficiency 
(Yoshimoto et al, 1978). A report from Rosen et al. (1991) showed prolyl endopeptidase cleaving at 
the Ala-Ser bond in which the serine is phosphorylated in an undecapeptide mimicking a 
phosphorylation site in proteins. What is most interesting was the failure of prolyl endopeptidase to 
cleave at this site of the unphosphorylated peptide because it suggests that prolyl endopeptidase’s 
specificity and protein peptide phosphorylation could function as a method for peptide processing.
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Prolyl endopeptidase is an oligopeptidase and shows no activity toward proteins as opposed to 
peptides (Camargo et al., 1979).
There exist significant differences in the rates of cleavage depending on the nature of the amino 
acid occupying the Pro-X bond. The rate of cleavage is faster when X is a lipophilic residue, slower in 
the case of a basic residue and slowest when an acidic residue is present in the vicinal residue 
(Koida and Walter, 1976). Prolyl endopeptidase from human erythrocytes have been shown to 
have a preference for phosphorylation in the X position (Rosen et al., 1991). Tate (1981) isolated 
prolyl endopeptidase from bovine brain and claimed that it had a requirement for a basic amino acid 
prior to the proline moiety which set it apart from prolyl endopeptidase from other sources. Andrews 
et al. (1982) showed that prolyl endopeptidase is the only enzyme capable of cleaving the Pro- 
Naphthylamide (NA) bond of the thyroliberin analogue <Glu-His-ProNA. This compound would 
satisfy the requirements of a limited specificity described by Tate as it has the basic amino acid 
residue preceding the proline residue eg thyroliberin, LHRH, a-Melanocyte stimulating hormone, 
substance P, neurotensin, angiotensin II and dynorphin 1-13. It is also of interest to note that the 
majority of the synthetic substrates used in vitro to quantify the prolyl endopeptidase activity do not 
have a basic amino acid preceding the Pro and are all readily cleaved by prolyl endopeptidase eg Z- 
ala-Pro-4-methoxy-2-NA (Taylor and Dixon, 1980), Z-Gly-Pro-SM (Friedman et al., 1984) and Z-Gly- 
ProMCA (Yoshimoto et al., 1979).
Prolyl endopeptidase clearly prefers small peptide substrates over large polypeptides. Taylor and 
Dixon (1980) could not demonstrate hydrolysis of albumin or myoglobin. Denatured proteins with 
molecular weights of approximately 16 kDa were not cleaved. Camargo et al. (1979) prepared (Gly)3 -
Arg-bradykinin and attached this peptide to succinyl polylysine polymers (MW 3-180kDa) and to Affi- 
Gel 10. Trypsin released bradykinin from the 3 bound forms and from free (Gly)3 -Arg-bradykinin. On
the other hand, prolyl endopeptidase hydrolysed only the free bradykinin analogue. On the basis of 
their experiments, Camargo et al. described the enzyme as an endo-oligopeptidase with a specificity 
towards small peptides.
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Table 1.8 Naturally occurring peptide substrates for prolyl endopeptidase 
(Welches et al., 1993)
Cleavage points are indicated by ^
Peptide Sequence
Anqiotensin I Asp-Arg-Val-Tyr-lle-His-Pro ^Phe-His-Leu
Angiotensin II Asp-Arg-Val-Tyr-lle-His-Pro ^Phe
Bradykinin Arq-Pro-Pro/Gly-Phe-Ser-Pro ^  Phe-Arg
Substance P Arg-Pro-Lys-Pro ^  Gln-Gln-Phe-Phe-Glv-Leu-Met-n
Neurotensin pGlu-Leu-Tvr-Glu-Asn-Lys-Pro ^  Arg-Arg-Pro ^  Tyr-lle-Leu
Vasopressin Cys-Tyr-lle-Gln-Asn-Cys-Pro ^  Arg-Gly
Oxytocin Cys-Tyr-lle-Gln-Asn-Cys-Pro ^  Leu-Gly
LHRH pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro ^  Gly-n
Thyroliberin pGlu-His-Pro^-n
Cleavage of a number of naturally occurring neuropeptides by prolyl endopeptides was mentioned 
previously. These include thyroliberin, LHRH, bradykinin, neurotensin, substance P, angiotensin I 
and II and oxytocin. The peptides with the consistently lowest Kms for prolyl endopeptides are 
angiotensin I and bradykinin. Table 1.9 shows that neurotensin, substance P, vasopressin, 
oxytocin and LHRH have moderately low Kms. One report of prolyl endopeptidases Km for 
substance P is extremely high at 1000p.M (Kato et al., 1980). Thyroliberin and LHRH have a variable 
range of Kms as low as 10(iM or less (in the case of LHRH) increasing to a range of 10 0 ’s or 1000’s 
of |xM. The variation in Km values seen for prolyl endopeptidase is presently unexplained and may 
reflect species differences or perhaps procedural differences.
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Table 1.9 Prolyl endopeptidase affinity (Km) for natural peptides (Welches et 
al., 1993)
Neuropeptide Peptidase
Affinity
(}iM Km)
Source Reference
Thyroliberin 540.00 Bovine Brain Hersh and McKelvey(1979)
18.90 Bovine Brain Hersh (1981)
690.00 Bovine Brain Yoshimoto et al. (1983)
17.10 Human Lung Hersh (1981)
4100.00 Rat Brain Andrews et al. (1980)
LHRH 150.00 Bovine Brain Hersh and McKelvey(1979)
4.00 Bovine Brain Tate (1981)
Neurotensin 1.80 Bovine Brain Tate (1981)
Substance P 1.10 Bovine Brain Blumberq et al. (1980)
1000.00 Rat Brain Kato et al. (1980)
5.40 Rabbit Brain Camargo et al. (1984)
Anqiotensln I 3.20 Human Lunq Zolghari et al. (1986)
Angiotensin II 63.00 Rabbit Brain Greene et al. (1982)
1.20 Bovine Brain Tate (1981)
Bradykinin 2.30 Rabbit Brain Camarqo et al. (1984)
7.00 Bovine Brain Tate (1981)
1  -6.5.4. Prolyl endopeptidase inhibitors
As prolyl endopeptidase is distributed ubiquitously, a naturally occurring prolyl endopeptidase 
inhibitor is also widely distributed in various tissues. Knisatschek and Bauer (1979) found that 
pancreatic trypsin inhibitor was effective in inhibiting 90% of the prolyl endopeptidase activity. 
However, they later showed this inhibition to be due to the presence of impurities in the inhibitor 
preparation. Yoshimoto et al. (1982) purified a specific prolyl endopeptidase inhibitor from porcine 
pancreas. This inhibitor showed no inhibitory activity for trypsin, and was highly specific for proline 
endopeptidases, prolyl endopeptidase from mammalian organs and proline specific endopeptidase 
from F.meningosepticum. It had no effect on dipeptidyl aminopeptidase IV from lamb kidney, 
prolidase from bovine intestine and proline aminopeptidase form B.megaterium, although these 
enzymes have substrate specificity for proline residue. The presence of another naturally occurring 
prolyl endopeptidase inhibitor was investigated by Yamakawa et al. (1990). They purified a peptide 
inhibitor (MW=7000Da) from rat liver cytosol and found that its inhibitory activities for prolyl 
endopeptidase largely depends on peptide compounds having phosphate ester in its molecule. 
They found also that coenzyme A (CoA), its related compounds and acylcarnitine non- 
compepetitively inhibited the activity of prolyl endopeptidase in rat liver cytosol.
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Even though there existed a naturally occurring prolyl endopeptidase inhibitor, much investigation 
leads to the development of specific site-directed synthetic inhibitors. Biochemical studies 
indicated that prolyl endopeptidase is a serine protease (Yoshimoto et al., 1977; Andrews et al., 
1980), but prolyl endopeptidase is also sensitive to cysteine protease inhibitors. The first 
moderately potent inhibitors of this enzyme were proline-containing chloromethyl ketone 
derivatives (Yoshimoto et al., 1977). The most potent member of this series, Z-Gly-Gly-Pro-CH2 C I,
did not inhibit trypsin and only negligibly inhibited chymotrypsin. Such inhibitors are irreversible, 
and it is assumed that they alkylate a histidine residue at the active site.
Fig.1.7 Z-Gly-Gly-Pro-CH2 CI Structure
Serine and cysteine proteases are potently inhibited by peptide aldehyde analogues of good 
substrates. This inhibition proceeds by the formation of a transition state analogue intermediate. N- 
Benzyloxycarbonyl-prolyl-prolinal (Z-pro-prolinal) was the first of the transition state analogues of 
prolyl endopeptidase to be synthesised (Wilk and Orlowski, 1983). This compound inhibits prolyl 
endopeptidase non-competitively with a Ki of 14nM. This value is three orders of magnitude lower 
than the Ki of the acid Z-Pro-Pro or the alcohol Z-Pro-Prolinol, consistent with its designation as a 
transition state analogue inhibitor. At a concentration 150-fold greater than its Ki for prolyl 
endopeptidase, Z-pro-prolinal does not inhibit trypsin, chymotrypsin, papain, DAP IV, 
endopeptidase 24.11 or the multicatalytic protease complex. Bakker et al. (1990) showed that Z- 
Pro-prolinal was a slow tight-binding inhibitor of both mouse brain and human brain prolyl 
endopeptidase activity with a Ki of 0.35nM.
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Fig. 1.8 Z-Pro-prolinal Structure
Z-Pro-prolinal is also an effective inhibitor in vivo. This lipophilic compound readily crosses the blood 
brain barrier, where it produces a long-lasting inhibition of brain prolyl endopeptidase (Friedman et 
al., 1984). Friedman et al. showed that a dose of 0.5mg/kg, intraperitoneally administered, inhibited 
the brain prolyl endopeptidase more than 50%, and 5mg/kg significantly inhibited the brain enzyme 
for as long as 6.5 hours. It is clear that Z-pro-prolinal is an excellent tool for exploring the biological 
significance of prolyl endopeptidase.
As seen previously, prolyl endopeptidase is also sensitive to cysteine protease inhibitors. Green 
and Shaw (1983), treating prolyl endopeptidase as a cysteine protease, synthesised a series of 
diazomethyl ketone inhibitors. Z-Ala-Ala-Pro-CHN2  rapidly inactivated prolyl endopeptidase from
mouse peritoneal macrophages at a concentration of 4x10'7 M. It is also able to cross the blood- 
brain barrier and appears specific for prolyl endopeptidase, because other cysteine proteases were 
inhibited only at concentrations many orders of magnitude greater.
Fig 1.9 Z-Ala-Ala-Pro-CHN2 Structure
A similar approach was taken by Knisatschek and Bauer (1986) who synthesised Z-Gly-ProCHN2 - 
Exposure of the bovine brain enzyme to 2.8 x 10"7M inhibitor for 5 minutes resulted in total
44
inactivation. This compound was assessed by demonstrating that at a concentration of 6  x 10'7 M, Z- 
Gly-Pro-CHN2  did not inhibit trypsin, PAP I or dipeptidyl peptidase IV.
Fig. 1.10 Z-Gly-Pro-CHN2 Structure
However in cell culture studies such specificity was no longer apparent (Faivre-Bauman et al., 
1986). In these studies inclusion of the inhibitor not only caused a decrease in prolyl 
endopeptidase activity, but also a corresponding decrease in PAP I activity. 50% inhibition of both
enzymes was found at an inhibitor concentration of 1 0 ' 8 M. Apparently in purified preparations of 
PAP I, DTT added to the assay mixture served to protect the enzyme from inactivation. When the 
DTT concentration was decreased from 2  to 0 . 0 2  mM, Z-Gly-Pro-CHN2  at a concentration of 6 |i.M  
inhibited PAP I by 88.7%.
Tsuru et al. (1988) discovered that the inhibitory effect of Z-pro-prolinal can be increased by the 
introduction of a sulphur atom into the pyrolidine. By the replacement of pyrrolidine with thiazolidine 
or thiazolidine aldehyde (thioprolinal) and the conversion of an L-proline to an L-thioproline residue, 
an increase in the inhibitory activity resulted. They showed that Z-Thiopro-thiazolidine and Z-L- 
Thiopro-L-thioprolinal showed Ki values of 0.36 and 0.01 nM respectively, for prolyl endopeptidase 
from bovine brain, both values being significantly lower than that of Z-Pro-prolinal (Ki=3.7nM). 
Yoshimoto et al. (1991) continued to examine the potential of Z-Pro-Pyrrolidine derivatives as 
potent prolyl endopeptidase inhibitors. They found that replacement of L-proline by the D-isomer in 
the inhibitor almost completely abolished the inhibitory activity. This is consistent with the 
stereospecificity found in these enzyme-substrate interactions, confirming that the inhibitor binds to 
the substrate binding region of the enzyme.
Bakker et al. (1990) studied the inhibitory characteristics of two novel Z-pro-prolinal derivatives, Z- 
Cyclohexyl-Prolinal and Z-lndolinyl-Prolinal, in vitro and in vivo. These compounds were shown to 
be slow-tight binding inhibitors of prolyl endopeptidase (like the naturally occurring inhibitor 
discovered by Yoshimoto et al.1982) and were shown to cross the blood-brain barrier in vivo. The 
half time for the recovery of enzyme activity in vivo was found to be 3 to 4 hours as opposed to a half
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time of in excess of 5 hours for Z-pro-prolinal. This feature is important in the determination of drug 
efficiency, as compounds with excellent in vitro potency may often be poor inhibitors in vivo.
The inhibitors were also used to elucidate the kinetics of inactivation and the sites of modification. 
Using active site-directed choromethanes, Stone et al. (1991), showed that Ac-Ala-Ala-Pro-CH2 CI
was a competitive inhibitor of prolyl endopeptidase. The kinetic mechanism was shown to involve 
the formation of an initial complex between the enzyme and the chloromethane, followed by an 
inactivation step. The substrate was shown to compete for the formation of the initial complex, 
indicating that binding at the active site was a prerequisite for inactivation. After reaction of the 
enzyme with a radiolabelled Ac-Ala-Ala-Pro-CH2 CI, it was possible to isolate 5 labelled peptides.
Four of these peptides contained a cysteine residue as the site of modification, whereas the fifth 
peptide contained no cysteine and a histidine residue was identified as the site of modification. This 
residue (His-680) may be the active site of prolyl endopeptidase.
A non-peptide prolyl endopeptidase inhibitor was synthesised in the laboratories of Nakajima et al.
(1992). This compound, Y-29794, was found to be a highly specific prolyl endopeptidase inhibitor, 
ie the compound was completely inactive to common serine and thiol proteases, (DAP IV, trypsin, a- 
chymotrypsin, elastase, leucine aminopeptidase, papain and cathepsin B) at concentrations up to 
1 0 0 |xM. The inhibitory potency of Y-29794 to regional prolyl endopeptidase activity was unchanged 
in all brain regions, suggesting broad distribution of the compound in the brain. But several 
synthetic and naturally occurring inhibitors of prolyl endopeptidase have been described - why the 
need to find another? Some of the inhibitors were not as potent as Y-29794 (Nakajima et al., 1983; 
Yoshimoto et al., 1987) and others irreversibly interact with the enzyme (Wilk and Orlowski, 1983). 
Prolyl endopeptidase recently moved into the focus of interest when it was reported that the 
enzyme has some important role in memory process, based on the findings that nootropic 
aniracetam and several related pyrrolidine derivatives with anti-amnesic properties inhibit prolyl 
endopeptidase in vitro (Nakajima et al., 1983). Although known inhibitors of prolyl endopeptidase 
showed anti-amnesic properties in animal models (Yoshimoto et al., 1987), their bioavailability and 
duration of action would be limited by their peptido-mimetric structures. In contrast, the non-peptide 
inhibitor,Y-29794 can pass through the blood-brain barrier to exhibit long duration of action. 
Therefore Y-29794 is advantageous over some of the known inhibitors in potency, reversibility, oral 
bioavailability, brain penetrability and duration of action.
In brains of patients with Alzheimer’s disease, it is well known that the cerebral ACh content 
decreases and the cerebral function suffers severe damage. The stimulatory effect of Y-29794 on 
thyroliberin-induced ACh release suggests that this compound has some positive effect on the 
metabolism of reduced ACh functions in the CNS. Ishiura et al. (1990) claimed that prolyl 
endopeptidase is a possible candidate engaged in the generation of brain (3-amyloid. The 
protective activity of substance P involved in the neurodegenerative effect of G-amyloid was 
demonstrated in vivo (Kowall et al., 1991). Since substance P is known to be susceptible to prolyl
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endopeptidase (Blumberg et al., 1980; Kato et al.P 1980), it is expected that Y-29794 might have 
neuroprotective activity by inhibiting substance P degradation to elevate cerebral substance P 
content. If these theories are correct, use of Y-29794 alone or in combination with neuropeptides 
would be an effective therapy that might halt or slow the progression of the disease.
Fig. 1.11 Y-29794 Structure (Y-29794 = 2-(8-dimethylaminooctylthio-6-isopropyl-
3-pyridyl 2-thienyl ketone citrate)
iCHpOOH
HOCCOOH
CH,pOOH
1 .6 .5.5. Prolvl endopeptidase actions on neuropeptides
Studies oh the physiological role of prolyl endopeptidase have lagged behind studies on its 
biochemical properties. Considerable attention has been paid to its role in thyroliberin degradation 
(Taylor and Dixon, 1976; Orlowski et al., 1979; Tate, 1981; Knisatschek and Bauer, 1979). In fact, 
Busby et al. (1982) calculated that the total catalytic activity of prolyl endopeptidase in brain exceeds 
that of pyroglutamate aminopeptidase but they also found that the Km for thyroliberin of prolyl 
endopeptidase exceeds that of PAP for thyroliberin.
Prolyl endopeptidase removes a glycinamide moiety from LHRH (Wilk et al., 1979; McDermott et al., 
1983a). However Advis et al. (1982) studied changes in prolyl endopeptidase activity in rat 
hypothalamus during the prepubertal period and during the first estrous cycle at puberty in an 
attempt to find changes correlating to LHRH content and degradation. They found that enzyme 
activity was essentially unaltered indicating that prolyl endopeptidase may not play a physiologically
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relevant role in LHRH inactivation. McDermott et al. (1983b) showed that following the inactivation of 
LHRH with intact synaptosomes the major degradation product was LHRH(1-5) caused by the action 
of neutral endopeptidase (EC 3.4.24.11). LHRH(1-9) formed by the action of prolyl endopeptidase 
is the second most prominent product.
Neurotensin is cleaved at the Pro1 0 -Tyr1 1  bond by prolyl endopeptidase (Taylor and Dixon, 1980), 
producing biologically inactive fragments. Prolyl endopeptidase is by no means the most prominent 
neurotensin-degrading enzyme- neurotensin endopeptidase (EC 3.4.24.16) cleaves Prol°-Tyr11 
and has been purified from rat brain synaptic membranes and reported to be a metallopeptidase 
(Checler et al., 1986; Dauch et al., 1991; Millican et al., 1991). Hydrolysis of both the Pro10-jyrl 1 
and the Tyr11 -lie 1 2  bonds of neurotensin is catalysed by endopeptidase 24.11 (Coquerel et al.,
1986) and hydrolysis at the Arg8 -Arg9  bond has been attributed to endopeptidase 24.15 (EC 
3.4.24.15) (Checler et al., 1985). Hernandez et al. (1984) found that the neurotensin fragment 1 - 1 0  
formed by the action of prolyl endopeptidase on neurotensin exerts significant cryoprotective 
activity as measured by the ability to significantly prevent the development of cold-restraint 
stress(CRS)-induced gastric ulcers in rats after intra-cistemal injection.
The traditional pathway for the processing of angiotensin I involves angiotensin converting- enzyme 
which converts Ang I to Ang II . Ang II was long considered the physiologically active end point of 
this pathway. Recently prolyl endopeptidase has been found to be involved in the generation of 
Ang (1-7) from Ang I (Welches et al., 1991; Santos et al., 1988). The N-terminal heptapeptide, Ang 
(1-7) possess biological activity including activation of vasopressin secretion (Schiavone, 1988), 
stimulation of neuronal excitability within the vagal-solitary complex (Barnes et al., 1990), modulation 
of the baroreflex (Campagnole-Santos et al., 1989) and release of prostaglandins (Trachte et al., 
1990). Because the formation of Ang (1-7) is from a pathway not dependent on ACE, prolyl 
endopeptidase and neutral endopeptidase 24.11 should all be defined as Ang I processing 
enzymes, ie those enzymes that act on Ang I to form biologically active end products.
Substance P interacts with prolyl endopeptidase with a high affinity and is specifically cleaved at the 
Pro4-Gln5  bond to yield the C-terminal heptapeptide and the N-terminal tetrapeptide (Blumberg et 
al., 1980; Endo et al., 1988). Observations have been made which suggest that additional 
properties of substance P may be encoded in the N-terminal part of the substance P molecule. For 
example, it has been reported that substance P can increase intracellular cyclic AMP levels and 
neurite extension in neuroblastoma cells (Narumi and Maki, 1978), and in cultured dorsal root 
ganglion cells (Narumi et al., 1979) and that this property may be due to the N-terminal tetrapeptide. 
An additional activity of the N-terminal tetrapeptide which could be related to a possible role of 
substance P in neurogenic inflammation is the enhancement of the phagocytic activity of 
macrophages. Furthermore, studies of the inactivation of substance P and partial sequences of 
substance P by homogenates and membrane fractions of rat brain suggest a stabilisation toward
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inactivation mechanisms of the substance P molecule by its N-terminal tetrapeptide sequence. 
These observations raise the possibility that prolyl endopeptidase plays a role in the action of 
substance P in the nervous system.
It has been reported that vasopressin may facilitate learning and memory. Since prolyl 
endopeptidase cleaves vasopressin in vitro it is possible that inhibition of this enzyme in vivo could 
lead to a beneficial increase of CNS vasopressin levels (Bakker et al., 1990). In passive learning 
avoidance tests using rats, pretreatment with Z-pro-prolinal prevented the induction of amnesia by 
scopolamine at a dose of 1 (imol/animal. The anti-amnesic effect of this compound was found to be 
approximately parallel to the in vitro inhibitory activities of prolyl endopeptidase (Yoshimoto et al.,
1987), suggesting that the anti-amnesic effects can be produced by the inhibition of prolyl 
endopeptidase.
The significance of prolyl endopeptidase measurements for clinical medicine is unclear. Kar and 
Pearson (1981) reported that the activity of the enzyme is elevated in muscle biopsies of patients 
with muscular dystrophies. The activities of other proteases are also elevated in muscular 
dystrophies. Prolyl endopeptidase activity was also measured in bronchopulmonary lavage of 
patients with pulmonary disease (Orlowski et al., 1981).
Pittaway et al. (1984) has suggested that a linkexists between abnormally low prolyl endopeptidase 
activity (22% of control) found in the caudate nucleus and Huntington’s disease. A significant 
decrease in prolyl endopeptidase activity was also detected in the lateral globus pallidus and medial 
globus pallidus (37% and 40% of control respectively). Prolyl endopeptidase levels were found to 
be higher in knee joint synovial fluid membranes from patients with rheumatoid arthritis than in that 
from patients with osteoarthritis (Kamori et al., 1991). This activity increased in parallel with the 
increase in joint fluid volume. Thus prolyl endopeptidase may be related to immunological or 
inflammatory disturbance in the joint in rheumatoid arthritis. A significant factor in this case is that 
proline is one of the main amino acids in collagen.
1.6.5.6. Regulation of Prolyl Endopeptidase Activity
Little is known on the control of prolyl endopeptidase activity. Ohta et al. (1992) found that prolyl 
endopeptidase activity was higher in the extract of ovary than extracts from liver or brain in rat, pig 
and mouse. They found that prolyl endopeptidase activity was high at estrous and low at diestrus. 
In addition, treatment with oestrogen or progesterone resulted in an increase in the uterine prolyl 
endopeptidase activity in the ovariectomised mice compared with the oil-treated mice. Therefore 
they suggested that the levels of prolyl endopeptidase activity in the uterus and ovary are closely 
related to the circulating levels of ovarian steroids, oestrogen and progesterone. Since prolyl 
endopeptidase is known to cleave the physiologically active peptides which are related to the 
uterine myometrial contraction (oxytocin and bradykinin), PE may contribute to this primary function 
of the uterus, especially during pregnancy and parturition.
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Further information on the physiological role of PE will likely derive from studies on the localisation of 
PE using immunocytochemical techniques and from studies on the effect in vivo of administration of 
the potent and selective inhibitor Z-pro-prolinal.
1.7. Further Degradation of the Primary Metabolites of Thyroliberin
The action of the soluble PAP on thyroliberin produces His-ProNH 2  . and this metabolite
spontaneously and non-enzymatically cyclises to produce His-Pro diketopiperazine at neutral and 
alkaline pH. His-Pro diketopiperazine, which does not appear to be further degraded by any 
enzymatic mechanism, is itself reported to possess endocrine activity (Prasad et al.,1982). The 
conversion of thyroliberin to His-Pro diketopiperazine represents an instance of biotransformation of 
a peptide (Griffiths and McDermott, 1984) (see Fig 1.4).
Any enzyme that converts His-Pro-NH2 to a metabolite other than His-Pro diketopiperazine must be
considered as a regulator of His-Pro diketopiperazine formation by competing with the 
biotransformation process. A post proline dipeptidyl aminopeptidase (EC 3.4.14.2) was described 
in the soluble fraction of rat adenohypophysis (Bauer and Kleinkauf, 1980) and of guinea pig brain 
(Browne and O’Cuinn.1983) that was capable of converting His-ProNH2 to His-Pro. This activity was 
found to be sensitive to puromycin (Ki = 42|xM), and this suggests that it should be properly classed 
as dipeptidyl peptidase II (McDonald and Barrett, 1986), an activity normally located in lysosomes. Its 
location in cytoplasm studies may reflect its release from lysosomes in the presence of hypotonic 
buffers.
As in the case of soluble pyroglutamate aminopeptidase , the products of action of pyroglutamate 
aminopeptidase II on thyroliberin are pyroglutamate and His-ProNH2 - In the absence of further
enzymatic activity, His-ProNH2  cyclises to form His-Pro diketopiperazine. A post proline dipeptidyl 
aminopeptidase has been demonstrated in brain membrane preparations (Garat et al., 1985), and 
this enzyme has been shown to be located in synaptosomal membrane preparations of rat (Torres et 
al., 1986) and guinea-pig brain (O’Connor and O’Cuinn, 1986). This enzyme could be inhibited by 
bacitracin (Garat et al., 1985) but not by puromycin and was shown to be capable of releasing 
aminoacylproline from a range of tripeptides containing a central proline residue ( O’Connor and 
O’Cuinn, 1986). The bacitracin sensitivity of the synaptosomal enzyme differentiates it from the 
puromycin-sensitive post proline dipeptidyl aminopeptidase (dipeptidyl peptidase II). The 
synaptosomal membrane-bound post proline dipeptidyl aminopeptidase is probably correctly 
considered as a dipeptidyl peptidase IV activity (EC 3.4.14.5) and its synaptosomal membrane
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location affords it the possibility of competing with the non-enzymatic cyclisation of His-ProNH2 .
Torres et al. (1986) showed the production of ProNH2  by rat brain membrane preparations
incubated with thyroliberin. They also demonstrated that production of this metabolite was 
dependent on the expression of pyroglutamate aminopeptidase II activity. ProNH2  production was
likely, therefore, to arise from His-ProNH2  by the action of an imidopeptidase, as originally reported 
by Matsui et al. (1979). However, Torres et al. (1986) reported that levels of ProNH2  production 
were very low and did not permit the definitive location of the imidopeptidase activity to a particular 
subcellular fraction.
1.8 Biotransformations
In recent years, an ever increasing number of polypeptides with both endocrine and neuronal 
activity have been identified in the CNS. It is likely that an important component in the mechanisms 
of action of these neuropeptides is the process by which they are inactivated and their effects 
limited. This has led to the identification of peptidases in the CNS and at other sites in the body 
capable of fulfilling this function (Griffiths et al., 1983). However, a further function of neuropeptide- 
metabolising enzymes may be to produce peptide metabolites with inherent biological activities 
distinct from those of the parent peptide, a process termed biotransformation (de Wied and Jolles,
1982). The biological activity of the product may either be related to the effects of the parent 
neuropeptide or it may be entirely independent. Although peptide degradation is the main route of 
biotransformation, other modifications to the parent peptide such as sulphonation and acetylation 
may serve a similar function. Rather than just considering the activity of an individual neuropeptide 
in its defined structure, it is now necessary to examine the mechanisms of inactivation and identify 
the metabolites formed with their actions when appraising the biological effects of the parent 
peptide.
The number of defined neuropeptides whose metabolites also have effects within the body is 
increasing rapidly. At present these include, adrenocorticotrophin (ACTH) and melanocyte- 
stimulating hormone (MSH), opioid peptides such as enkephalins, endorphins and dynorphin, 
oxytocin and vasopressin, the hypothalamic regulatory hormones (thyroliberin, somatostatin and 
LHRH), substance P, neurotensin and cholecystokinin(CCK).
Two main metabolites, acid thyroliberin (<Glu-His-ProOH) and the histidylproline diketopiperazine 
(cyclo(His-Pro)) are formed from thyroliberin by the actions of its two primary degrading enzymes PE 
and PAP (Griffiths et al., 1983).
Acid thyroliberin has been detected by radioimmunoassay in rat brain (Emerson et al., 1980) and 
human urine (Bhanandaru and Emerson, 1980), and induces 'wet-dog shaking’ in rats in a similar 
way to thyroliberin after intracerebroventricular injection (Boschi et al., 1980) and direct application to
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the periaqueductal grey region (Webster et al., 1983). 'Wet-dog shaking (WDS)’ is described as a 
‘paradoxic shudder of the head, neck and trunk reminiscent of the purposeful movement seen in 
dogs’ (Boschi et al., 1980). This property may reflect the relative stability of acid thyroliberin in brain 
tissue, since it is only slowly degraded to its constituent amino acids (Griffiths et al., 1983), and 
perhaps its ability to be reamidated to thyroliberin itself (Webster et al., 1983).
His-Pro diketopiperazine or Cyclo(His-Pro) has been shown to have many effects on the brain 
where it is present in much higher concentrations than thyroliberin and has several properties, both 
related and unrelated to thyroliberin (Peterkofsky et al., 1982; Prasad et al., 1982). The cyclical 
dipeptide has the ability to stimulate the activity of the cortical neurons directly (Stone et al., 1983), 
and has also been detected in blood (Mori et al., 1982a), the gastrointestinal tract (Mori et al 1982 b) 
and urine (Perry et al., 1965).
Table 1.10 Regional distribution of thyroliberin, PAP activity and cyclo(His-Pro) 
in Rat Brain (Prasad et al., 1982)
Region Thyroliberin 
(fmols Peptide/ 
mg protein)
PAP Activity 
(fmols/min/mg 
protein)
Cyclo(H is-Pro) 
(fmols Peptide/ 
mg protein)
Hypothalamus 2208.50 641.00 832.60
Cortex 78.10 431.00 601.60
Hippocampus 50.50 449.00 571.70
Striatum 126.00 432.00 500.50
Mid Brain 351.20 500.00 478.30
Cerebellum 31.50 650.00 414.90
Pons-M edulla 269.10 530.00 397.90
Table 1.10 shows the distribution of cyclo(His-Pro) in rat brain. Thyroliberin is enriched in the 
synaptosomal fraction. In contrast, cyclo(His-Pro) is not concentrated in this fraction. One of the 
criteria for neurotransmitter function is enrichment of an agent in synaptosomes. On the basis of the 
above data, cyclo(His-Pro) does not meet this standard, while thyroliberin does. Rat brain contains 
3.2 times as much cyclo(His-Pro) as thyroliberin. There is considerable variation in the relative 
concentrations of thyroliberin and cyclo(His-Pro) in different brain regions. The highest 
concentrations are found in the pituitary and hypothalamus. This suggests that various parts of the 
brain differ in their capability to metabolise thyroliberin to acid thyroliberin, to form cyclo(His-Pro) from 
thyroliberin or to store the peptides.
A summary of the effects of thyroliberin and cyclo(His-Pro) on various biological activities is shown in
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Table 1.11. The detailed mechanism by which cyclo(His-Pro) produces these activities remains 
unknown. Although bioactive effects of thyroliberin occur through its specific receptor binding sites 
in target tissue, there is no report concerning the specific binding sites of cyclo(His-Pro) in any 
tissues except for the adrenal gland, in which a binding affinity and capacity of cyclo(His-Pro) were 
observed to be low and high respectively (Battaini et al., 1983; Prasad and Edwards, 1984b). Mori 
et al. (1986) showed specific binding of cyclo(His-Pro) in the rat liver plasma membranes with high 
affinity (Kd=59nM). The specific binding of cyclo(His-Pro) in liver membranes was significantly 
reduced in vivo by injection of the dipeptide, but not thyroliberin. A  number of receptor bindings of 
bioactive peptides and hormones have been shown to have either down-regulation or up-regulation 
of themselves (Roth, 1979). The results from Mori et al. (1986) showing the down-regulation of 
cyclo(His-Pro) binding sites indicated the existence of a receptor-like characteristic of cyclo(His-Pro) 
binding in the rat liver plasma membranes.
Table 1.11 Biological activities ascribed to thyroliberin and cyclo(His-Pro)
I. Thyroliberin-related activities of Cyclo(His-Pro)
1. Thyroliberin-like activities
a. Antagonism of ethanol narcosis
b. Elevation of brain cGMP levels
c. Inhibition of food intake
d. Inhibition of cholesterol synthesis
e. Inhibition of abstinence syndrome in opiate dependent mice
f. Attenuation of ketamine-induced anaesthesia
2 . Thyroliberin-opposite activities
a. Hypothermia in rats
b. Inhibition of in vitro prolactin secretion
II. Thyroliberin-unrelated activity of Cyclo(His-Pro)
a. Inhibition of dopamine synthesis
III. Cyclo(His-Pro)-unrelated activities of thyroliberin
a. Stimulation of thyrotropin secretion
b. Interaction with thyroliberin-receptor
c. Behavioural effects, including piloerection, body tremor, and tail lifting
d. Inhibition of pentabarb'ital-induced sleep
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It has been clear for several years, that there is an ubiquitous distribution of thyroliberin, cyclo(His- 
Pro) and PAP in a variety of tissues and body fluids from rodents, primates, amphibians and man 
(Parker Jr et al, 1983; Mori et al.p 1982a; Prasad et al., 1986). If all the cyclo(His-Pro) were derived 
from thyroliberin by the action of the PAP enzyme, one would expect a strong correlation between 
the levels of cyclo(His-Pro) and thyroliberin or PAP activity. However Prasad et al. (1987) found this 
not to be the case. They found no obvious correlation between the normal adult levels of 
endogenous cyclo(His-Pro) and thyroliberin or PAP in most cases (human and CSF, rat and monkey 
brain). However, there are two exceptions: rat gut and the maturation of rat brain and human CSF, 
where endogenous levels of cyclo(Hls-Pro) correlate positively with either thyroliberin or PAP (Mori 
et al., 1982a, Prasad et al., 1983).
Based upon the ubiquitous distribution of thyroliberin, cyclo(His-Pro) and PAP, Prasad et al. (1987) 
proposed a precursor/product relationship between thyroliberin and cyclo(His-Pro) (Prasad, 1984; 
Prasad and Edwards, 1982). The known primary sequence of the prohormone of thyroliberin has 
already been discussed (Section 1.5). However, depending on the extent and the site of 
processing, prepro thyroliberin can lead to the formation of not only thyroliberin, but also extended 
and reduced forms of thyroliberin. From these data , it was proposed that cyclo(His-Pro) is 
synthesised via multiple biochemical pathways (See Fig 1.12).
A precursor common to all three pathways (A,B and C) is His-ProNH2 , which then cyclises to 
cyclo(His-Pro). His-ProNH2  could be derived from:
1. thyroliberin by the action of PAP,
2 . Gln-His-ProNH2  after cleavage of Gin by an aminopeptidase type enzyme, or
3. by the de novo synthesis from amino acid histidine, proline and glycine.
They concluded that the three pathways may not contribute equally toward the formation of 
cyclo(His-Pro), but may also be regulated differentially in various tissues, or during different 
physiologic/pharmacologic changes (Prasad , 1988).
The lack of correlation between the levels of cyclo(His-Pro) and thyroliberin or PAP was also 
addressed by Salers et al. (1991). In the RINm 5F cell line, they actually found thyroliberin content to 
be very low, barely detectable. The low thyroliberin content observed was likely to be related to a 
very low expression of the thyroliberin gene as was suggested by the undetectable 
preprothyroliberin mRNA levels in this cell line (Sevarino et al., 1988). They found that thyroliberin 
content did not increase following incubation with the inhibitor, Z-Gly-ProCHN 2 , under conditions 
which inhibit PE and PAP I activities. In cultured rat hypothalamus cells, the addition of Z-Gly- 
ProCHN 2  induces a significant increase in thyroliberin content of these secreting cells (Faivre- 
Bauman et al., 1986).
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The cyclo(His-Pro) and acid thyroliberin contents of RINm 5F cells are approximately 10 and 13 times 
higher than those of thyroliberin, respectively. These data and the lack of change in thyroliberin, 
cyclo(His-Pro) and acid thyroliberin after the addition of the PE (and PAP I) inhibitor, suggest that 
thyroliberin can be hydrolysed by other unknown peptidases, or thyroliberin may not be the sole 
precursor for these peptides- as suggested by Prasad et al. (1987).
Griffiths et al. (1989) suggested that the most likely peptide sequence to form cyclo(His-Pro) is -His- 
Pro-Gly-. Such a sequence is found in more than one copy on several proteins. The tripeptide may 
be released and cleaved enzymatically, then spontaneously cyclised in order to give cyclo(His-Pro). 
Miyashita et al. (1993) also provided evidence that cyclo(His-Pro) can emanate from a thyroliberin 
precursor thyroliberin-Gly. by the action of pyroglutamate aminopeptidase, and bypass the formation 
of thyroliberin.
So far there is no chemical evidence to suggest that acid thyroliberin may occur through the 
degradation of thyroliberin-unrelated peptides. There is no indication that the -Gln-His-Pro- 
sequence is contained in proteins other than thyroliberin and its precursor.
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Fig 1.12 Three possible pathways of cyclo(Hls-Pro) biosynthesis
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56
255
1.9 Thyroliberin analogues
In the experimental evaluation of thyroliberin and its therapeutic potential for certain clinical 
conditions, one major problem has been the tripeptide’s relatively short half-life, partly resulting from 
rapid enzymatic degradation. Attempts have been made to synthesise thyroliberin analogues with 
greater stability to the major degrading enzymes, pyroglutamate aminopeptidase and prolyl 
endopeptidase, and hence with a more prolonged duration of action, to capitalise on the 
neurotransmitter/ neuromodulator effects of thyroliberin.
Fig. 1.13 Structure of thyroliberin
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The thyroliberin analogue [3MeHis]thyroliberin is the most potent analogue in stimulating the 
release of TSH from the pituitary. However, although [3MeHis]thyroliberin has a high very affinity for 
central thyroliberin receptors (Ward et al., 1987), it is experimentally less active in the brain than 
thyroliberin. By contrast, several analogues that have a much lower affinity for thyroliberin receptors, 
but that are much more stable to degradation by brain peptidases show enhanced central action 
over thyroliberin. RX77368, the most enzymatically stable analogue, is excreted 60% unchanged 
and would be expected to have the greatest activity by virtue of this fact. In some tests though, 
RX77368 is more active than thyroliberin within the latter’s half-life of inactivation; RX77368 
generally varies in potency between 2 and 220 times that of thyroliberin (Metcalf, 1982).
57
Fig. 1.14 Structure of [3MeHís]thyroliberin
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Fig. 1.15 Structure of RX77368
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[3MeHis]thyroliberin bound to receptors in rodent, rabbit and dog brain and spinal cord, and in 
sheep, rat, bovine and dog anterior pituitary (PIT) glands, with high affinity (Sharif et al., 1991). 
Bungaard and Moss (1990) suggested that the problems in using thyroliberin as a potentially 
effective drug were two fold - firstly its rapid degradation and secondly the low lipophilicity of 
thyroliberin may also be a reason for the limited ability of the peptide to penetrate the blood-brain 
barrier. They suggested that a solution to the delivery problems was derivitization of the peptide to 
produce prodrugs or transport forms (Bungaard, 1986), that are markedly more lipophilic than the 
parent peptide and resistant toward the thyroliberin-degrading serum enzyme, but remain cleavable 
by chemical or nonspecific enzyme-catalysed hydrolysis to release the parent thyroliberin in vivo.
By forming N-alkoxycarbonyl derivatives at the imidazole moiety of thyroliberin, the great 
susceptibility of the pyroglutamyl peptide bond in thyroliberin to cleavage by pyroglutamate 
aminopeptidase is abolished. The modification is readily bioreversible, as the parent thyroliberin is 
formed quantitatively from the derivatives by spontaneous hydrolysis or by enzymatic hydrolysis 
effected by plasma enzymes not attacking the pyroglutamyl peptide bond. The increased 
lipophilicity of the derivatives relative to the thyroliberin may render it feasible to deliver thyroliberin 
to the brain in the form of the prodrugs. Further, the N-alkoxycarbonyl moieties are hydrolysed to 
innocuous products (carbon dioxide and alcohols).
1.10 Age dependent changes in thyroliberin-degrading activity
The role of thyroliberin regulation of thyroid status remains a major area of investigation and because 
in most mammals thyroid function matures rapidly in the early days of life, it is of interest to study the 
thyroliberin-degrading activity during this period. Unique differences in thyroliberin-physiology 
occur during the perinatal period in the developing animal. At birth the rat pancreas contains higher 
concentrations of thyroliberin than neonatal or adult hypothalamus; pancreatic levels fall throughout 
the first weeks of life as hypothalamic concentrations increase (Aratan-Spire et al., 1983; Salers et 
al., 1992). Extra-hypothalamic brain thyroliberin is lower than levels in gut tissues during the first 
week of life, and brain levels gradually increase to adult values by the end of the fourth postnatal 
week. The developmental patterns of the specific activity of the two soluble enzymes involved in 
the primary degradation of thyroliberin in vitro, PAP I and prolyl endopeptidase, in mouse 
hypothalamus and cerebral hemispheres of rat brain (Prasad et al., 1983), show that in whole brain 
PE activity increased throughout the first two weeks of life, with levels decreasing after this time, 
while values for PAP I were highest on the first day of life in rats, and decreased over the next two 
weeks to adult levels (Fuse et al., 1990). This developmental pattern is clearly different from the 
development of thyroliberin and most markers of differentiation and synaptogenesis. The low 
specificity and wide localisation of these enzymes, their low proportion in synaptosomes and their
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inability to degrade thyroliberin or LHRH in intact cells (Mendez et al., 1990), suggests a general role 
in cellular metabolism (Vargas et al., 1992b).
In contrast PAP II activity shows a different pattern, increasing from birth to postnatal days 8-22 
depending on the brain region. It appears before or during axon terminals and synapses formation 
in the brain. In the hypothalamus, PAP II increased from day 16 prenatal to 8  postnatal. The 
ontogeny of adenohypophyseal PAP II activity correlates well with that of thyrotropin (peak serum 
and pituitary TSH levels between postnatal days 8  and 28) and thyroid hormones (peak serum 
values between postnatal days 12 and 28) (Vargas et al., 1992b). The parallelism between PAP II 
and T 3  or T 4  ontogenesis suggests that these hormones are involved in the development of PAP II
activity in this region because of their known stimulatory action on enzyme activity in adult rats 
(Ponce et al., 1988).
Bauer et al. (1990) reported that PAP II is preferentially, if not exclusively, localised on prolactin 
(PRL) cells. Vargas et al. (1992) found that not only did PAP II activity and PRL cells appear at 
approximately the same time, but their developmental patterns coincide in agreement with PAP II 
being synthesised in lactotrophs (Bauer et al., 1990). Furthermore, the ontogenetic pattern of PAP 
II activity follows that of thyroliberin receptors, which peak between postnatal days 5 and 21, and that 
of PRL cell physiology. The appearance of PAP II activity and the PRL response to thyroliberin 
show a good correlation with both neurogenesis of the median eminence and the ontogeny of the 
hypothalamo-adenohypophyseal portal system, which does not develop until the post-natal days 4- 
5 (Vargas et al., 1992). Thyroliberin-like immunoreactive nerve fibres and terminals in median 
eminence are first detected on 0.5th day after birth; from the second day onwards, the stage where 
thyroliberin-like immunoreactive nerve fibres appear localised around the basal lamina of portal 
vessels in the external layer of the median eminence, the number and intensity of terminals and 
positive granules increase at least up to 2 0  days (Bauer et al., 1990). All these observations 
suggest that PAP II develops together with the hypothalamic-adenohypophyseal axis (Vargas et a l ., 
992).
PAP II and the serum thyroliberin-degrading PAP activity (thyroliberinase) both follow the same 
developmental pattern in the adenohypophysis (Scharfmann and Aratan-Spire, 1991). 
Thyroliberinase is absent from the plasma at birth and during neonatal periods of both rats and 
humans (Aratan-Spire and Czernichow, 1980; Neary et al., 1978).
It has been shown that the development of PAP II activity in the brain is anticipating or associated 
with synaptogenesis (Vargas et al., 1992). Early appearance of PAP II coincides with rapid 
expression of PAP II in foetal brain cells in culture (Cruz et al., 1991). This suggests that regional 
distribution of PAP II attained in adult animals is a consequence of events occurring during postnatal
6 0
development. In the adenohypophysis, PAP II activity is closely related to the development of 
hypophysiotropic thyroliberin neurons as well as that of its target cells (Vargas et al., 1992). These 
data further contribute to the hypothesis that PAP II is a specific peptidase responsible for 
thyroliberin extracellular inactivation in the brain and adenohypophysis.
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2. Materials and Methods
2.1 Materials
Sigma Chemical Company 
Poole, Dorset, England.
N-Acetylimidazole, Acid TRH (TRH-OH), Ammonium Sulphate, Ammonium Persulphate, 
Angiotensin II, 7-Amino-4-MethylCoumarin (MCA), Blue Dextran, Bombesin, Bradykinin, 
Bromophenol Blue, BSA, Benzamidine, Bacitracin, Coomassie Brilliant Blue, Cyclo(His- 
Pro), Dithiothreitol, Dimethylformamide, EDTA, N-Ethylmaleimide, Glycine, <Glu-His-Gly, 
Gly-ProMCA, <Glu-MCA, 8 -Hydroxyquinoline, DL-Histidine, p-Hydroxymercuribenzoic Acid 
(PCMB), HEPES, lodoacetamide, lodoacetate, p-lodonitrotetrazolium Violet (INT), Lauryl 
Sulphate, Lithium Chloride,Luteinising Hormone-Releasing Hormone (LHRH), Molecular 
Weight Markers (Gel Filtration), Molecular Weight Markers (SDS-PolyAcrylamide Gel 
Electrophoresis), M ES, N.N’-Methylene-Bis-Acrylamide, Neurotensin, Ninhydrin, ß- 
Nicotinamide Adenine Dinucleotide (ß-NADH), Potassium Phosphate (monobasic), 
Potassium Phosphate (dibasic), DL-Pyroglutamic Acid, DL-Proline, 1,10-o-Phenanthroline, 
Phenylmethylsulfonyl Fluoride (PMSF), Puromycin, Pyruvic Acid, Papain, Sodium Chloride, 
Sucrose, Sodium Acetate, Sulphanilic Acid, Substance P, Triton X-100, Triton X-114, 
Trizma Base (Tris), TEMED, Thyrotropin Releasing Hormone (TRH), Trypsin
BDH Chemicals Ltd.
Poole, Dorset, England
Acrylamide, Ammonia, Acetic Acid, Acetone, Biuret Reagent, Butan-1 -ol, Cadmium 
Acetate, Cobalt(ll) Chloride 6 -Hydrate, Chloroform, Citric Acid, Calcium Chloride, 
Dimethylsulphoxide(DMSO), Glycerol, Glycine, Hydrochloric Acid, lron(lll)Chloride 6 - 
Hydrate, Magnesium Chloride, Methanol, Sodium Hydrogen Carbonate, Sodium 
Hydroxide, Sulphuric Acid, Sodium Succinate, Sodium Tartrate, Trichloroacetic Acid, Zinc 
Chloride, Zinc Sulphate
Bachem Feinchemikalein AG.
Bubendorf, Switzerland
<Glu-His-ProMCA, <Glu-(Me)His-ProNH2 , Z-Gly-ProMCA,
Merck Chemical Co.
Frankfurt, Germany
Iron(ii) Sulphate (Heptahydrate), Manganese Sulphate, Polyethyleneglycol 6000,Sodium 
Carbonate (Anhydrous), di-Sodiumhydrogen Phosphate, TLC Plates (Silica Gel 60)
Riedal-de-Haen AG.
Germany
Ammonium Molybdate, Ferrous Sulphate, Potassium Chloride, Silver Nitrate
6 2
Aldrich Chemical Co.
Poole, Dorset, England
Ammonium Sulfamate, Sodium Nitrite, Trifluoracetic Acid (HPLC grade).
Pierce Chemical Company
Illinois, USA 
BCA reagent
Romil Chemicals Ltd.
Loughborough, Leicestershire, England.
Acetonitrile (HPLC grade), Ethyl Acetate
Calbiochem-Novabiochem (UK) Ltd.
Nottingham, England 
<Glu-ProNH2
Penninsula Laboratories
Belmont, Ca., USA  
<Glu-His
New England Nuclear
Dreiechenhain, Germany 
[Pro-2,3,4,5,-3 H]thyroliberin
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2.2. Determination of enzyme activities
2.2.1. Thyroliberin specific Pyrogiutamate Aminopeptidase activity
The thyroliberinase activity of the pyrogiutamate aminopeptidase (PAP) was determined by a 
modification of the method of Bauer and Kleinkauf (1980). [Pro-3 H] thyroliberin was diluted with 
unlabelled thyroliberin (0.42mM) to give a specific radioactivity of 0.125 Ci/mmol. 1 0 (iL aliquots 
of each sample to be assayed were added to 10jiL of diluted [Pro-3 H] thyroliberin 
(0.5^Ci/4mmol) and 1 OjaL of 1 0OmM potassium phosphate buffer pH7.4. Following incubation 
at 37’C  for 30 min the reaction was terminated by the addition of 1 0 )iL methanol. 10p.L aliquots 
were spotted onto prewashed cellulose phosphate paper which was then developed in 1 .0 M 
acetic acid. Under these conditions the weakly basic thyroliberin moves up the paper while the 
highly basic His-ProNH2  remains at the start segment. The start segment was then cut out and
placed in scintillation vials to which were added 1mL of 2M ammonia and 10 min later, 10mL of 
toluene-based scintillation fluor containing: 66.7%(v/v) Toluene, 33.3%(v/v) TritonX-100, 
0.05%(w/v) PPO and 0.01%(w/v) POPOP.
The scintillation vials were counted in a Packard Tri Carb Liquid Scintillation Spectrometer 
(model 3330) using the tritium [3 H] channel. Having calibrated the instrument and determined 
its percentage efficiency with the above scintillation cocktail (Table 2 .1 ) the conversion of <Glu- 
His-[3 H]-Pro-NH2  to His-[3 H]-ProNH2  by the action of the pyrogiutamate aminopeptidase could 
be monitored quantitatively.
Table 2.1 Calculation of the % efficiency of Packard Tri Carb liquid scintillation spectrometer 
(model 3330) using the scintillation cocktail given in section 2.2.1.
iPro-2.3.4.5-3 H(N)1 Thyroliberin (Stock)
Specific Activity 1 0 0  Ci/nmol (100nCi/nmol)
Concentration 10uM (10 nmol/mL)
Volume 0.25uL
Amount 2.5nmol (250jiCi)
Method
Take 50|iL Stock (50|iCi) and dilute 1 in 20 with 0.42mM unlabelled thyroliberin * 
50|iCi/400nmol/1 OOO L^ (stock solution) .
Take 10piL (0.5ji.Ci/4nmol) of that solution .
Read in Packard Tri Carb Liquid Scintillation spectrometer (model 3330)
0.5(jCi 1,110,000 D.P.M.
Reading 444,000 C.P.M.
% Efficiency 40%
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2.2.2.1. A fluorimetric coupled enzyme assay for synaptosomal PAP
Synaptosomal PAP activity was detected using a coupled enzyme assay developed in our 
laboratory based on a modification of the spectrophotometric assay of Friedman and Wilk (1986)
(see Fig 2.1). 10 OjaL of sample was incubated with 20|xL of 10 ' 5  M Z-Pro-prolinal, a specific 
prolyl endopeptidase inhibitor, for 10 min at 37°C  before the addition of 400|iL of 0.1 mM <Glu- 
His-ProMCA in 100mM potassium phosphate buffer, pH 7.4. The assay mixture was incubated 
at 37"C for 60 min, after which time 40p.L of DAP IV and 50nL of 1 0 mM 1,10-phenanthroline was 
added. The 1 ,1 0 -phenanthroline was added to terminate the synaptosomal PAP activity and 
the DAP IV cleaves the His-ProMCA to give Cyclo(His-Pro). The free 7-amino-4-methyl- 
coumarin (MCA) was then measured fluorimetrically in a Perkin Elmer fluorescence 
spectrophotometer (model LS-50) using excitation and emission wavelengths of 370 and 
440nm respectively and slit widths of 10 and 5nm respectively. Blanks were prepared by 
substituting 1 0 0 |iL of buffer for sample. The fluorescence was converted into nanomoles of 7- 
amino-4-methyl coumarin by using a standard curve prepared with 7-amino-4-methyl coumarin 
under corresponding control conditions.
Fig 2.1 Coupled Enzyme Assay for Synaptosomal PAP Activity
2.2.2. Development of two new assays for particulate Pyroglutamate
Aminopeptidase activities
Sample + 20|iL 10*5 M Z-Pro-prolinal
1 0  min 
37°C
+ 400|iL 0.1 mM <Glu-His-ProMCA
60 min 
37°C
+ 40nL DAP IV
+ 50j L^ 10mM 1,10-Phenanthroline
60min 
37°C
+ 1 mL 1.5M Acetic Acid 
Fluorescence read at 370 and 440nm
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Synaptosomal Pyroglutamate Aminopeptidase activity was also determined by a modification of 
the coupled enzyme assay described in section 2 .2 .2 . 1  (see Fig 2 .2 ). 1 0 0 ^L of test solution 
were preincubated with 2 0 (iL of 10' 5  M Z-Pro-prolinal for 10 minutes at 37‘ C. This solution was 
then incubated with 400ni of 0.1 mM <Glu-His-ProMCA ( in 100mM potassium phosphate 
buffer, pH7.4) at 37* C for 60 minutes. The reaction was terminated by the addition of 1 mL of 
1 .5 M acetic acid. The mixture was then heated to 80°C for 2 0  min to encourage the cyclisation 
of the His-ProMCA to Cyclo(His-Pro) and the release of free MCA. The MCA was quantitated as 
described in section 2 .2 .2 .1 .
Fig 2.2 Spontaneous Cyclisation Assay for Synaptosomal PAP Activity
2.2.2.2. Spontaneous cyclisation assay for particulate Pyroglutamate
Aminopeptidase activity
Sample + 20|iL 10‘ 5  M Z-Pro-prolinal 
1 0 min 
37"C
+ 400liL 0 . 1  mM <Glu-His-ProMCA
60min
37°C
+ 1 mL 1.5M Acetic Acid
Spontaneous
Cyclisation
2 0 min
80°C
Free MCA 
Fluorescence read at 370 and 440nm
2.2.3. Prolyl Endopeptidase (PE) activity
The presence of prolyl endopeptidase was detected using a specific prolyl endopeptidase 
substrate, Z-Gly-ProMCA. The substrate was prepared by dissolution in 2% (v/v) DMSO and 
making up to a final concentration of 0.1 mM in 100mM potassium phosphate, pH 7.4 which was 
warmed to 37° C. 100|i.L of sample was incubated with 400pL of Z-Gly-ProMCA at 37’ C for 60
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minutes. The reaction was terminated by the addition of 1mL of 1.5 M acetic acid. The 
enzymatic release of MCA was measured fluorimetrically by reference to a standard curve 
(excitation and emission wavelengths at 370nm, 440nm respectively). Suitable blanks were 
prepared in which the buffer was added to the substrate instead of enzyme.
2.2.4. Soluble Pyroglutamate Aminopeptidase activity
<Glu-MCA was used as a substrate for the detection of soluble pyroglutamate aminopeptidase 
(PAP I) as described by Fujiwara and Tsuru(1978) as modified by Browne and O ’Cuinn (1983). 
0.1 mM <Glu-MCA was prepared in 1 0 0 mM potassium phosphate buffer, pH7.4 with 1% (v/v) 
DMSO. 10 OjiL of sample was added to 400jiL of substrate and incubated at 37° C  for 60 
minutes. The reaction was terminated by the addition of 1 mL of 1.5M acetic acid and the 
resulting fluorescence was measured at excitation and emission wavelengths of 370 and 
440nm respectively. The enzymatic release of MCA was measured with reference to a standard 
curve (0-5 O^M) range. Suitable blanks were prepared where the enzyme sample was replaced 
by buffer.
Soluble pyroglutamate aminopeptidase activity could also be detected using <Glu-His-ProMCA 
as a substrate as described in section 2 .2 .2 .1 .
2.2.5. Assessment of the subcellular fractions from bovine brain
To localise the thyroliberin-degrading activities in bovine brain, various enzymes were assayed 
as markers for specific subcellular components.
2.2.5.1 . Assay for Succinate Dehydrogenase Activity
Succinate Dehydrogenase was used as a marker enzyme for mitochondria. Succinate 
dehydrogenase activity was measured according to the method of Pennington (1961) as 
modified by Porteous and Clark (1965), in which iodonitrotetrazolium was used as an artificial 
electron acceptor.
The assay mixture consisted o f:
0.5mL of 50mm potassium phosphate buffer, pH7.4,
50mM sodium succinate,
2mM EDTA,
2mM sucrose, and
0 . 1  %(v/v) iodonitrotetrazolium
0.5mL of assay mixture were pre-equilibrated at 37°C for 10 min. 0.5mL of sample was then 
added and the mixture was incubated for a further 1 0 min at 37°C. The reaction was terminated 
by the addition of 1  mL of 1 0 %(w/v) TCA. 4mL of ethyl acetate was added and the mixture was 
well shaken. The sample was centrifuged for 10min at 2,000rpm in a Hereaus Christ bench-top
centrifuge to separate the two phases. The formazan-containing layer was removed and its 
absorbance was read at 490nm.
2 .2.5.2 . Assay for 5’-Ribonucleotidase activity
5'-Ribonucleotidase activity was used as a marker assay for synaptosomes and was assayed 
according to the method of Michell and Hawthorne (1965), and the released phosphate was 
determined by the method of King (1932).
Incubation mixture:
100mMKCI 
10mM MgCl2
50mM Tris/HCI, pH7.4 
5mM AMP
10mM Sodium Tartrate
Phosphate Colour Reagent:
1 g of ammonium molybdate in 50mL of 2.3N H2 SO 4  
25mL of d.H2 0  
4g Ferrous sulphate
The total volume was brought up to 100mL with d.H2 0
1 mL of each sample was incubated with 1 mL of incubation mixture for 30 min at 37°C. 1 mL of 
phosphate colour reagent was added and the incubation was allowed to proceed at 37°C for a 
further 30min. The tubes were then spun in a bench-top centrifuge at 2000rpm for 5 min. The 
absorbance of each sample was read at 660nm. A standard curve of phosphate in the range of 
0.2-1 nmoles Pi/mL (mM KH2 PO 4 ) was prepared each time the assay was performed.
2 .2.5.3. Assay for Lactate Dehydrogenase Activity
Lactate dehydrogenase activity was used as an enzyme marker for cytoplasm and was measured 
according to the method of Bergmeyer and Brent (1974).
Incubation Mixture:
100mL of 50mM potassium phosphate, pH 7.5 
0.63mM sodium pyruvate
Reduced NADH:
14mg of NADH-Na2  (working concentration = 1 1 ,3mM RNADH)
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15mg NaHC 0 3  
1.5mL d.H20
100(iL of sample was added to 3mL of incubation mixture and incubated for 10min at 37“C. 
50^L of NADH solution was added. The solution was mixed quickly and the change in 
absorbance was read every 10 seconds for 3 min at 340nm.
2.3. Protein determination
Two methods were employed to determine the protein concentrations as no single method was 
suitable for all the samples, some of which contained interfering substances such as detergents 
and sulphydryl reagents.
2.3.1. Biuret Protein Assay
The Biuret assay was used for the protein determination of the crude homogenate, the 
supernatant fraction (S-| ), the particulate fraction (P 2 ) and the Triton X - 1 0 0  solubilised sample 
(Sj). 50nL of sample was incubated with 2 0 0 |iL of Biuret reagent at room temperature for 30
minutes, and then the O.D. was read at 560nm. A  standard curve using BSA (0-10mg/mL) was 
constructed each time the assay was performed. The Biuret assay is most accurate in the range 
0-10mg/mL of protein.
Sulphydryl agents such as DTT cause interference with the Biuret assay and so the BCA assay 
was used if DTT was present in the sample.
2.3.2. BCA Protein Assay
A modification of the method for protein determination using Bicinchoninic Acid (B C A ), (Smith 
et al., 1985), which may be used in the presence of thiol reagents (Hill and Straka, 1988) was 
used to determine protein concentration in the post-gel filtration samples. This assay is 
particularly useful for low protein concentration samples as is it most sensitive in the 0-2mg/mL 
range. 10|xL of each sample was added to the appropriate microtitre-plate wells. 2 0 0 jjL of the 
BCA working reagent was added to each well and the plate was shaken well on a microtitre plate 
shaker for 10 seconds. The plate was then incubated at 37'C for 30 minutes. The plates were 
allowed to cool to room temperature before measuring the absorbance of each well at 560 nm. 
A standard curve using BSA (0-2mg/ml_) was constructed each time the assay was performed.
2.4. Isolation of soluble rat liver PAP and Prolyl Endopeptidase 
activities
Rat liver was used as a source of soluble PAP and prolyl endopeptidase which were in turn used
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as positive controls in the development of the assay systems, as there were no reliable 
pyroglutamate aminopeptidase or prolyl endopeptidase enzyme activities commercially
available.
2.4.1. Preparation of a Sephadex G-100 column
4g dry weight of Pharmacia Sephadex G-100 was added to 60 mLs of 100mM potassium 
phosphate buffer, pH 7.4 and was allowed to swell at 90* C for 3 hours. It was then left at room 
temperature overnight. By swelling the gel at such high temperatures the gel was degassed. 
The swollen gel was stored at 4“C prior to pouring into the 1.5cm x 20cm Bio-Rad column 
(volume=35.5mL). The gel was poured in one step using a glass rod to ensure even 
sedimentation. The gel was allowed to settle under gravity before applying buffer to the column 
at a flowrate of 0.5mL/min (a higher flowrate than at which the column was to be run). The 
column was equilibrated with 3 column volumes of 1 0 0  mM potassium phosphate buffer, pH 7.4 
with 0.15M KCI, 1mM EDTA and 1mM DTT. 1 mL of a 2 mg/mL solution of Blue Dextran was 
applied to the top of the column to calculate the void volume. Buffer was applied at a flowrate of 
0.16mL/min and 0.5mL fractions were collected. The absorbance of each fraction was 
measured at 620nm and the void volume was calculated.
2.4.2. Preparation of the rat liver
7g of rat liver were homogenised on ice in 20 mL of 0.32M sucrose in 100mM potassium 
phosphate buffer, pH7.4 with 1mM DTT and 1 mM EDTA for 15 seconds using a Sorvall Omni- 
Mixer. The homogenate was centrifuged for 60min at 15,000 rpm and the supernatant was 
decanted and stored in 1 mL aliquots at -20*C.
2.4.3. Partial purification of the soluble PAP and Prolyl Endopeptidase 
activities from rat liver
A 1  mL aliquot of rat liver supernatant was applied to the drained bed of the Sephadex G-100 
column and was allowed to drain into the column before applying buffer to the top of the of the 
column. The running buffer was 100mM potassium phosphate buffer, pH 7.4 with 0.15M KCI, 
1mM DTT and 1mM EDTA which was degassed and vacuum-filtered before applying to the 
column. The column was run at a flowrate of 0.16mL/min at 4*C and 0.5mL fractions were 
collected. Each fraction was assayed for enzymatic activity using the PAP I substrate <Glu-MCA 
and the specific prolyl endopeptidase substrate Z-Gly-ProMCA. The soluble rat liver PAP and 
prolyl endopeptidase activities were used as positive controls in the development of the 
spontaneous cyclisation assay for the measurement of particulate pyroglutamate 
aminopeptidase activity (section 2.2 .22.).
70
2.5. Thyroliberin-degrading enzymes in different locations of 
bovine brain
2.5.1 Demonstration of two PAP activities in different subcellular fractions of 
bovine brain.
25g of freshly isolated bovine brain were homogenised in 100mL of ice cold 0.32M sucrose in 
100mM potassium phosphate, pH 7.4 using a Sorvall Omni-Mixer. The tissue was disrupted by 
two 5-second pulses, and the crude homogenate (CH) was centrifuged at 15,000rpm for 60min 
at 4°C in a Sorvall SS-34 rotor. The resulting supernatant was stored at 4°C while the pellet was 
resuspended in 50 mL of ice-cold 100mM potassium phosphate buffer,pH7.4. Both the 
supernatant (S-|) and the resuspended pellet (P-j) were assayed for synaptosomal PAP activity,
(section 2.2.2.1.) both in the presence and the absence of DTT and EDTA.
2.5.2. Demonstration of two prolyl endopeptidase activities in different 
subcellular fractions of bovine brain
The brain was treated exactly as above and the fractions, S-| and P-| were assayed for prolyl 
endopeptidase activity in the presence and absence of DTT and EDTA (section 2.2.3.).
2.6 Osmotic shock of the particulate fraction
The membrane fraction was subjected to a 0.5M salt wash to remove any loosely and non- 
specifically bound soluble enzyme activity from the fraction. The fraction was then 
resuspended in distilled water with a gentle hand rehomogenisation step. This was in order to 
lyse any entrapped vesicles formed by membranes following the initial homogenisation step. 
Following resuspension, the membrane fraction was then centrifuged at 15,000 rpm for 60min 
at 4°C. Both the supernatant and the particulate fractions were assayed for particulate PAP and 
PE activities (section 2.2.2.1. and 2.2.3.).
2.7. Salt washing of the particulate fraction
The osmotically-shocked particulate fraction, prepared as in section 2.6., was subjected to a 
range of salt washing steps to remove any loosely bound proteins from the membranes and to 
ensure that the enzyme activities were associated with the membrane fraction.
The pellet was resuspended in a range of salt concentrations (0-4M NaCI in 100mM potassium 
phosphate buffer, pH 7.4 at 4‘C) and the mixture was gently inverted for 10 minutes. Following 
this washing step, the preparation was centrifuged at 15,000 r.p.m. for 60 minutes at 4°C. Half 
the samples were subjected to a second salt washing step of either 2 or 4M NaCI, and following 
centrifugation were resuspended in 100mM potassium phosphate buffer, pH 7.4, at 4'C. Each
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sample was assayed for pyroglutamate aminopeptidase and prolyl endopeptidase activity as 
described in sections 2.2.2.1. and 2.2.3. respectively.
2.8. Subcellular localisation of the particulate PAP and prolyl 
endopeptidase activities
25g of freshly isolated bovine brain were homogenised and washed as described above. The 
subcellular fractionation procedures were based on the methods of Marchbanks (1967) and of 
Whittaker and Barker (1972). Aliquots of each fraction generated were removed and stored at - 
20°C. The crude homogenate was centrifuged at 15,000 rpm at 4'C for 60 min in a Sorvall SS- 
34 rotor. The resuiting supernatant (S-|) was removed and the pellet was salt-washed, and
centrifuged again. The pellet was then resuspended in 23 mL of 0.32M sucrose in 100mM 
potassium phosphate, pH 7.4 (P2 ). 3mL aliquots of P 2  were placed on discontinuous sucrose
gradients consisting of 9mL of 1.6m sucrose, 1 0 mL of 1.2M sucrose and 9mL of 0.8M sucrose. 
Following ultracentrifugation at 25,000rpm for 90min, 3 bands of material were observed in the 
gradient- one on top of the 0.8M sucrose, one in the 1.2M sucrose and one in the 1,6 M 
sucrose. Each fraction was diluted up to 60 mL with 100mM potassium phosphate, pH 7.4 
buffer , centrifuged at 25,000rpm for 90min and resuspended in 0.32M sucrose in 100mM 
potassium phosphate, pH7.4 to give fractions A, B, and C  respectively. Each fraction was 
stored for enzyme marker studies as described in section 2.2.7.
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2.9. Phase-partitioning study on the synaptosomal membrane 
bound PAP and Prolyl Endopeptidase activities
Using the method of Bordier (1981), it was possible to determine the location of the membrane- 
bound enzymes - whether they were integral or peripheral membrane proteins.
2%(v/v) of Triton X-114 was added to 2.5mg/mL of membrane protein in 10mM potassium 
phosphate buffer, pH7.4, with 150mM NaCI,1 mM EDTA and 1mM DTT. The mixture was 
shaken gently for 1 hour on ice. The sample was centrifuged at 25,000rpm for 60min at 4‘C  
(100,000g) in a Beckman UltraCentrifuge, using an SW28 rotor. The resulting supernatant was 
decanted and was layered over a 6 %(w/v) sucrose solution (prepared in 10mM potassium 
phosphate buffer, pH7.4 with 1mM DTT and 1mM EDTA). The samples were incubated at 30‘C  
for 15min and were then centrifuged at 1000rpm at 25'C for a further 10 min in a Sorvall 
centrifuge using an SS-34 rotor. Both the aqueous and the oily hydrophobic layers were 
assayed for both synaptosomal PAP and prolyl endopeptidase activity using <Glu-His-ProMCA 
and Z-Gly-ProMCA as substrates respectively (sections 2.2.2.1. and 2.2.3.). An intramembrane 
enzyme activity is found in the oily hydrophobic layer at the bottom, while a peripheral 
membrane enzyme activity is found predominately in the upper aqueous layer.
2.10 Release of the particulate thvroliberin-dearadina enzvmes 
from the synaptosomal membranes
2.10.1. Release of the thyroliberin-degrading enzymes from the synaptosomal 
membranes
The synaptosomal membranes were prepared as described above except the pellet was 
washed once in a 4M salt solution to remove any loosely bound proteins from the membranes. 
The fraction was centrifuged at 15,000 rpm for 60min and the resulting pellet was resuspended 
in 100mM potassium phosphate, pH 7.4.
2.10.2. Solubilisation of the particulate PAP and Prolyl Endopeptidase 
activities from the synaptosomal membranes
2.10.2.1. Triton X-100 Solubilisation
A Triton X-100 solubilisation step was used to remove the particulate PAP and prolyl 
endopeptidase from the Synaptosomal Membranes.
Aliquots of the resuspended salt-washed synaptosomal membrane fraction were treated with a 
range of concentrations of Triton X-100 (0-1% v/v) in 100mM potassium phosphate, pH7.4, to 
find the optimum Triton X-100 concentration. Each sample was incubated for 60 minutes on a 
shaking ice bath.
74
2.10.2.2. Trypsin-Treatment of the Synaptosomal Membranes
A salt-washed synaptosomal membrane fraction was incubated with a Trypsin solution (prepared 
in 1 mM CaCl2  in 0 . 1  mM potassium phosphate, pH 7.4) to give a final concentration of 1040 
units of trypsin activity/10 mg membrane protein. The mixture was then incubated at 30’C  for 60 
minutes in a shaking water bath.
2.10.2.3. Papain-Treatment of the Synaptosomal Membranes.
A synaptosomal membrane preparation was treated with a Papain solution (prepared in 100mM 
potassium phosphate buffer, pH7.4.) to give a final concentration of 1.57units of Papain 
activity/10 mg membrane protein. The mixture was then incubated at 37"C for 60 minutes in a 
shaking water bath.
Equal volumes of 100mM potassium phosphate, pH 7.4 were added to synaptosomal 
membrane fractions and incubated both at 4° and 30°C for 60 minutes to act as controls.
2.10.2.3. Sonication of the Synaptosomal Membranes
5mLs of a synaptosomal preparation were sonicated on ice for 1 0  seconds. Sonication was 
found not to be a suitable method of releasing the enzyme activities from the membranes as it 
was too harsh and very little enzyme activity survived the sonication procedure.
After treatment all samples were centrifuged at 15,000 r.p.m. for 60 minutes. Supernatants and 
resuspended pellets were assayed for synaptosomal PAP activity using <Glu-His-ProMCA 
(section 2.2.2.1.) and for prolyl endopeptidase activity using Z-Gly-ProMCA (section 2.2.4).
The most active synaptosomal PAP samples were pooled and stored in 5mL fractions at room 
temperature. The most active prolyl endopeptidase samples were pooled and stored in 5mL 
aliquots at -20°C.
2.11. Further purification of the Triton X-100 solubilised 
synaptosomal PAP by column chromatography
2.11.1. Purification of the particulate PAP by gel filtration
3ml_ of 0.4% (v/v) Triton X-100 solubilised particulate PAP was applied to a 2.5cm x 50cm 
(Vol=245mL) column of Sephacryl HR S - 2 0 0  which was equilibrated with 100mM potassium 
phosphate buffer, pH7.4, 0.15M KCI, 1mM DTT 1mM EDTA and 0.3% (v/v) Triton X-100 at room 
temperature. Flow was set at 0.75 mLs/min using a Gilsen pump and 3 mL fractions were 
collected using a Bio-Rad fraction collector. Fractions were assayed for particulate 
synaptosomal PAP activity (section 2.2.2) and the fractions with the highest activity were pooled 
and stored at -2 0 °C. The protein concentration was monitored by assaying the fractions using
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the Biuret Assay (section 2. 3.1 )
2.11.2 Ion exchange chromatography
A 25ml_ DEAE-Sepharose ion exchange column was equilibrated with 3 column volumes of 
50mM potassium phosphate, pH7.4, with 1mM DTT, 1mM EDTA and 0.3%(v/v) Triton X-100. A 
4mL TritonX-100-solubilised sample (Sj) was applied to the column. The column was washed
for 3 column volumes with the equilibration buffer at a flow rate of 1 mL/min. A  linear gradient of 
0.2 to 0.5M NaCI in 50mM potassium phosphate , with 1 mM DTT, 1 mM EDTA and 0.3%(v/v) 
Triton X-100 was applied. 3mL fractions were collected and were assayed for synaptosomal 
PAP activity (section 2.2.2). The fractions with the highest activities were pooled and stored at 
4"C.
2.11.3. Concentration of the post-ion exchange synaptosomal PAP activity
Following ion exchange, the synaptosomal PAP activity was concentrated by reverse osmosis. 
Dialysis tubing was boiled in 30mM EDTA for 15 min. 5mL of post-ion exchange synaptosomal 
PAP was placed in the dialysis tubing and sealed at both ends. The dialysis tubing was placed 
on a bed of polyethylene glycol 6000 (PEG) for 30 min or until it was reduced in volume to 2ml_. 
The sample was then stored at 4°C until the next purification stage.
2.11.4. Hydrophobic interaction chromatography
A 2 mL Phenyl-Sepharose column was equilibrated with 2 M(NH4 )2 S 0 4  in 100mM potassium 
phosphate, pH 7.4, with 1mM DTT, 1mM EDTA and 0.3%(v/v) Triton X-100 for 10 column 
volumes. A  2 ml_ concentrated post-ion exchange fraction was applied to the phenyl-sepharose 
column and was washed with 10 column volumes of equilibration buffer. The flow rate was set at 
1 mL/min and 2 mL fractions were collected. A linear gradient of 0 to 25% glycerol (25mLs of 
each ) in 1 0 0 mM potassium phosphate with 1mM DTT, 1mM EDTA and 0.3% (v/v) TritonX- 1 0 0  
was applied. Each fraction was assayed for synaptosomal PAP activity (section 2.2.2.1.) and 
the most active fractions were pooled and stored at 4‘C.
2.12. Further purification of the particulate Prolvl Endopeptidase 
from the synaptosomal membranes bv column chromatography
2.12.1. Preparation of a Sephacryl S-200HR column using the Pharmacia 
FPLC Biopilot System
600mL of Sephacryl S-200 HR were allowed to settle before the fines and supernatant were 
decanted. The gel was resuspended in 10OmM potassium phosphate buffer, pH 7.4. to give a
final concentration of 75% gel. The column (Pharmacia XK100/26, 2.6. x 100cm) was cleaned 
with distilled water and ethanol and allowed to dry before pouring the gel. The gel was degassed 
for 1 hour before pouring . The gel was poured into the column with the aid of a reservoir and a 
flow of buffer was applied immediately at a flowrate of 3ml_/min for 3 hours, followed by 5mL/min 
for 1  hour, The reservoir was removed and the adaptor was placed onto the column and packing 
was continued for a further 30 min. 5mL of a 2 mg/mL solution of Blue Dextran was applied to 
the column at a flowrate of 2 mL/min. The absorbance of the Blue Dextran at 620nm was 
monitored to calculate the void volume. The entire procedure was carried out at 4°C.
2.12.2. Partial purification of the Triton X-100 solubilised synaptosomal Prolyl 
Endopeptidase by gel filtration on Sephacryl S-200 HR.
Synaptosomal membranes were treated with 0.4% (v/v) Triton X-100 as described in section
2 .1 0 .2 .1 . and the solubilised enzyme was separated from the particulate matter by 
centrifugation at 15,000 r.p.m. for 60 minutes at 4“C. 5mL of this supernatant (Sy) was then 
applied to a Sephacryl S-200 HR column (100cm x 2.6cm) which had previously been 
equilibrated with 3 column volumes of 100mM potassium phosphate buffer, pH 7.4 containing
0.15M KCI, 1mM DTT, 1 mM EDTA and 0.3%v/v Triton X-100. This running buffer was 
degassed and vacuum filtered at 4°C using a Gelman Sciences filtration apparatus and Millipore 
Prefilters (pore size 0.45|im). The column was attached to a Pharmacia FPLC  system. The 
buffer was applied at a flowrate of 2mL/min. 3mL fractions were collected using a Pharmacia 
Frac-3000 Remote fraction collector and assayed for prolyl endopeptidase activity (Section
2.2.3.). Protein concentration was automatically monitored at 280nm by the system.
2.12.3. Calcium phosphate chromatography (Hydroxylapatite column)
10mL of a post-Sephacryl S-200 sample were dialysed against 1L of 2 0 mM potassium 
phosphate buffer, pH7.4 at 4°C for 3 hours prior to application to a 25mL Bio-Rad 
Hydroxylapatite column which was equilibrated with 3 column volumes of 2 0 mM potassium 
phosphate buffer, pH7.4 with 1 mM DTT and 1 mM EDTA. The enzyme was eluted with a linear 
gradient of 20mM to 500mM potassium phosphate buffer, pH7.4 with 1mM DTT and 1mM 
EDTA, at a flowrate of 1 mL/min. 2mL fractions were collected. Each fraction was assayed for 
prolyl endopeptidase activity. The fractions with the highest activity were pooled and stored at - 
20”C.
2.12.4. Phenyl-Sepharose hydrophobic interaction chromatography
2 mL of a post-Hydroxylapatite peak was applied to a 1 0  mL Phenyl-Sepharose column which 
had been equilibrated with 2 M (NH4 )2 S 0 4  in 1 0 0 mM potassium phosphate buffer, pH7.4, 1 mM
DTT, 0.3% (v/v) Triton X-100 and 1mM EDTA at 4”C. After the sample was applied, the column 
was washed for 3 column volumes with the equilibration buffer, before a linear gradient of 0-50%
glycerol in 100mM potassium phosphate buffer, pH 7.4 , 1mM DTT, 1mM EDTA and 0.3% (v/v) 
Triton X-100 was applied at a flowrate of 1 mL/min. 2mL fractions were collected and each was 
assayed for prolyl endopeptidase activity. The fractions with the highest activity were pooled 
and stored at -2 0 ‘C.
2.13. Lvophllisatlon
1 0 mL aliquots of sample from each stage in the purification were dialysed against 2L of distilled 
H2 O at 4“C overnight to remove any salts. Each sample was lyophilised on a Hetosicc Freeze-
Dryer for 12 hours and then resuspended in 500p.L of 100mM potassium phosphate buffer, 
pH7.4. The freeze-dried samples were stored at -20‘C  and were used for PolyAcrylamide Gel 
Electrophoresis .
2.14. Electrophoresis
In order to monitor the purification scheme and to estimate the molecular weight of prolyl 
endopeptidase and synaptosomal PAP SDS-PAGE was carried out on all the fractions, from 
crude homogenate to purified enzyme. The SDS-PAGE was carried out on 7.5% and 10% 
polyacrylamide gels as described by Laemmli (1970) to determine the molecular weight of the 
purified enzymes.
2.14.1. 7.5% SDS-PAGE
Stock solutions of 0.1 M Tris-HCI pH 8 .8 ,1 ,0M Tris-HCI pH 6 .8 , 30% (w/v) acrylamide containing
0 .8 % (w/v) bisacrylamide (Acryl/bisacryl), and 1 0 % (w/v) Ammonium Persulaphate (AP) were 
used to prepare both the stacking and resolving gels. A 7.5% resolving gel was used for the 
high molecular weight PAP enzyme, while a 10% resolving gel was used for the PE. The 
volumes required for a 7.5% resolving gel and a 3% stacking gel were as follows:
Table 2.2 Quantities required for a 7.5% SDS-PAGE
Resolving Gel (7.5%) Stacking Gel (3%)
S olution Vol (mL) Vol (mL)
Water
11.5 7.8
Acryl/Bisacryl
7.5 1
Tris-HCI, pH8 . 8
1 1 . 2
Tris-HCI, pH6 . 8
1.25
Ammonium Persulphate 
( 1  0 %w/v) 150nL 75|iL
TEMED
50nL 50nL
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Table 2.3 Molecular Weight Markers for a 7.5% Gel
Molecular Weight Marker Molecular Weight (kDa)
Thvroglobulin 669
Ferritin 440
Catatase 232
LDH 140
BSA 67
2.14.2. 10% SDS-PAGE
A 10% resolving gel was used to visualise the purification scheme of the PE. The following 
quantities were used to prepare a 10% resolving and a 3% stacking gel:
Table 2.4 Quantities Required for a 10% SDS-PAGE
Resolving Gel (7.5%) Stacking Gel (3%)
Solution Vol (mL) Vol (mL)
Water 14.1 9.3
Acryl/Bisacryl 10.5 1.25
Tris-HCI, pH 8 . 8 1 1 . 2
Tris-HCI, pH 6 . 8 . 1.25
Ammonium Persulphate
( 1 0  %w/v) 0.15 50nL
SDS (1 0 % w/v) 0.15 50jiL
TEMED 30nL 50nL
Table 2.5. Molecular Weight Markers for a 10% Gel
Molecular Weight Marker Molecular Weight (kDa)
Myosin 205
ß-Galactosidase 116
Phosphorylase B 97.4
BSA 6 6
Ovalbumin 45
Carbonic Anhydrase 29
Samples were dissolved in solubilisation buffer (0 .8 M Tris-HCI, pH6 . 8  ; 1 0 % glycerol ; 2%(w/v) 
SDS; 0.2% (w/v) Brilliant Coomassie Blue ).
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30^L of sample (containing 1 mg/mL of protein ) were loaded on to the gel. The gel was 
electrophoresed in electrode buffer, pH8.3 (0.025M Tris, 0.1% (w/v) SDS, and 0.192M Glycine) 
at 2 0 mA using an Atto Vertical Electrophoresis apparatus.
Gels were stained for 30 minutes in 0.5% (w/v) Brilliant Coomassie Blue in an acetic acid: 
methanol: water (1 :8 :1 0 ) mixture and then allowed to destain overnight in the same solvent 
system.
2.15. Characterization studies of the synaptosomal membrane- 
bound PAP and Prolyl Endopeptidase activities
2.15.1. Molecular weight determinations
2.15.1.1. Molecular weight determination of the synaptosomal membrane-bound 
Pyroglutamate Aminopeptidase
Known molecular weight markers (Sigma Gel Filtration Molecular Weight Markers, shown in Table
2.6) were applied to the Sephacryl S-200 BioPilot Column at a flowrate of 2mL/min using 
100mM potassium phosphate buffer, pH7.4 as the running buffer. The elution profiles were 
monitored at 280nm and a plot of elution volumes versus the log of the molecular weight was 
plotted. From this graph the molecular weight of the prolyl endopeptidase was estimated. It was 
further confirmed by SDS-PAGE.
Table 2.6 Molecular weight markers for gel filtration column
M olecular Weight Marker M olecular W eight (kDa)
Cytochrome C 12.4
Carbonic Anhydrase 29
Albumin 6 6
Alcohol Dehvdrogenase 150
ß-Amylase 2 0 0
Blue Dextran 2 0 0 0
2.15.1.2. Molecular weight determination of the synaptosomal membrane-bound Prolyl 
Endopeptidase
Sigma Gel Filtration Molecular Weight Markers (Fig.2.4) were also used to estimate the molecular 
weight of the particulate PE. The markers were applied to the 2.5x50cm column and eluted with 
100mM potassium phosphate,pH7.4. The elution profiles were monitored at 280nm and a plot 
of elution volumes versus the log of the molecular weights was plotted. From this the molecular 
weight of the particulate PE could be estimated. This was confirmed by SDS-PAGE.
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2.15.2. pH profiles
2.15.2.1. pH profile of the synaptosomal membrane-bound Pyroglutamate Aminopeptidase 
activity
5mL aliquots of post phenyl sepharose synaptosomal PAP were dialysed against 2L of distilled 
water for 8  hours at room temperature. These dialysed samples were then used for the pH 
optimum studies. 50jxL of sample were pre-incubated with equal volumes of buffer at different 
pH units at 37’C  for 1 0  min. The buffers used were 1 0 0 mM M ES (pH5.5-6.7), 100mM 
potassium phosphate (pH 6.2-7.8) and 100mM Tris-HCI (pH 7.0-8.6). The samples were 
assayed for synaptosomal PAP activity ( section 2.2.2.1.).
2.15.2.2. pH profile of the synaptosomal membrane-bound prolyl ednopeptidase activity
5mL aliquots of post-phenyl sepharose prolyl endopeptidase were dialysed against 2L of 
distilled water for 8  hours at 4”C. These dialysed samples were then used for the pH optimum 
studies as described above. The samples was assayed for prolyl endopeptidase activity using 
Z-Gly-ProMCA (Section 2.2.4)
2.15.3. Enzyme activity in different buffers
5mL aliquots of P2  were resuspended in range of buffers and the Triton X - 1 0 0  solubilisation 
step was preformed as described in 2.8.4.1. The buffers were :
1 0 0 mM potassium phosphate, pH 7.4 
100mM HEPES, pH 7.4 
100mM Imidazole, pH 7.4 
1 0 0 mM Tris-HCI, pH 7.4
Following incubation for 60 min in a shaking water bath, the samples were centrifuged at 
15,000rpm for 60min at 4°C. The supernatants were collected and each supernatant was 
assayed for both synaptosomal PAP (see section 2.2.2.1 .) and PE activity (see section 2.2.3.).
2.15.4 Storage of PAP and PE activities under different conditions
2.15.4.1 PAP activity under different storage conditions
Post phenyl sepharose synaptosomal PAP was aliquoted into 1 mL aliquots and was stored for 
1 week under different conditions as it was found to be quite unstable.
The following conditions were employed to stabilise the synaptosomal PAP activity:
1. Temperature (-20'C, 4’C and room temperature)
2. Glycerol (10, 20 and 30% v/v)
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3. BSA (1 and 2 % w/v, and 1 % w/v with 1 0 % v/v glycerol)
4. Sulphydiyl Reagent (DTT)
5. Different Buffers (Potassium phosphate, Imidazole, H EPES  and MES)
The enzyme activity was monitored by measuring PAPII activity according to section 2.2.2.1 .
2.15.4.2. PE activity under different conditions
Post phenyl sepharose PE activity was quite stable and so only a minimum number of storage 
conditions were used to assess their effects on the PE activity. These included:
1. Temperature (-20°C, 4°C and room temperature)
2. Different Buffers (Potassium phosphate, Imidazole, H EPES  and MES)
3. Glycerol (10, 20 and 30% v/v)
The enzyme activity was monitored for 1 week by measuring the PE activity according to section
2.2.3.
2.16. Preliminary kinetic studies
2.16.1. Kinetic studies on the synaptosomal pyroglutamate aminopeptidase
Kinetic analysis of the synaptosomal pyroglutamate aminopeptidase was carried out using <Glu- 
His-ProMCA as a substrate (Section 2.2.2). The effect of a range of pyroglutamyl peptides on 
the activity of the enzyme was also investigated. A stock concentration of <Glu-His-ProMCA 
(0.5mM) was further diluted with 10OmM potassium phosphate buffer, pH7.4 to give a range of 
concentrations of substrate. 400|i,L of each dilution of <Glu-His-ProMCA was added to 50(iL of 
peptide inhibitor in 100mM potassium phosphate buffer pH7.4. The reaction was initiated by 
the addition of 50p.L of post phenyl sepharose pyroglutamate aminopeptidase. Separate 
blanks were used for each concentration of <Glu-His-ProMCA. The reaction was allowed to 
proceed for 60 min and was then stopped by the addition of 1mL of 1.5M acetic acid. The 
samples were read at 370 and 440 nm, excitation and emission wavelengths respectively. 
Lineweaver Burk plots (Lineweaver and Burk, 1934) were constructed and the kinetic constants 
(Km, Vmax and Ki’s) determined.
2.16.2 Kinetic studies on the synaptosomal prolyl endopeptidase
Kinetic analysis of the synaptosomal prolyl endopeptidase was carried out as described above 
(Section 2.14.1) except that Z-Gly-ProMCA was used as a substrate in the range 0.01mM to
0.3mM concentration. A number of proline-containing neuropeptides were used as peptide 
inhibitors.
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2.17. Substrate specificities
2.17. 1. Investigation of the substrate specificity of the synaptosomal PAP by 
HPLC
The specificity of the post-Ion-exchange and post-Phenyl Sepharose synaptosomal PAP was 
determined using a number of naturally occurring and synthetic pyroglutamyl and histidine 
containing peptides according to the method of Martini et al (1985) as modified by Griffiths,
(1993).
200|xL of the potential substrate (1 mM in 10OmM potassium phosphate buffer, pH 7.4) were 
incubated for 24 hours at 37°C with an equal volume of enzyme. The enzymic reaction was 
terminated by the addition of 1 0 0 jaL of 0 .2 % TriFluoroacetic Acid (TFA), pH 2.0.
The H PLC system consisted of 2 Waters Model 6000a pumps, a model 660 gradient 
programmer, a U6 k injector, a Model 450 variable wavelength detector and a Novapak C-18 
column (3.9 x 150mm).
The column was equilibrated with 0.2% TFA (freshly prepared and degassed). Each sample 
was filtered through a Gelman Sciences Suporfilter (0.2|im pore size) before injection of a 25|jL 
sample onto the column. A 20 minute gradient from 0-70% of a 70% acetonitrile solution in
0 .2 % TFA (i.e. 0-49% acetronitrile) at a flowrate of 1 mL/min was enough to resolve the peaks. 
The absorbance of each peak was read at 220nm and at a sensitivity of 0.01-0.05 AUFS. 
Whenever possible commercially available standards (prepared in the mobile phase of 0.2% 
TFA) were run to compare the retention times of the peaks with those of the known possible 
metabolites resulting from the cleavage of the peptides by PAP.
2.17.2. Investigation of the substrate specificity of the synaptosomal prolyl 
endopeptidase
2.17.2.1. Substrate specificity of the synaptosomal PE by thin layer chromatography
TLC was the first of the two methods employed to investigate the substrate specificity of the 
synaptosomal membrane-bound prolyl endopeptidase.
Equal volumes of membrane-bound, Triton X-100 solubilised, post-gel filtration and post-phenyl 
sepharose prolyl endopeptidase were each incubated with substrate at 37°C for 24hrs and were 
then centrifuged at 12,000 rpm for 5 min in a bench top centrifuge to remove any insolubles. 
40|iL of the resulting supernatant was spotted onto a 20x20 cm Silica gel G, type 60 (Merck 
No.5721) 2.5cm from the bottom of the plate. The following standards were also spotted onto 
the plates: 1.2mM Thyroliberin, 1  mM Thyroliberin-OH, 1 mM Cyclo(His-Pro), 1 mM D-L Histidine 
and 20mM D-L Proline. The plates were developed in vapour saturated tanks with the following 
solvent system: Chloroform/Methanol/33% Ammonia (60/30/5 v/v/v).
Histidine-containing peptides were visualised using Pauly’s reagent (Solution A: 1% sulphanilic 
Acid in 1 M HCI, Solution B: 5% aqueous Sodium Nitrite. Equal volumes of A and B were mixed 
together before spraying). Each plate was allowed to stand at room temperature for 5 minutes
83
before being sprayed with Solution C  (15% sodium carbonate wN  in H2 O).
Amino acids were visualised by spraying the plates with freshly prepared Ninhydrin reagent 
(0 .2 % w/v Ninhydrin, 0.5% w/v cadium acetate and 2 % v/v acetic acid in methanol) and by then 
heating the plate to 1 2 0 ’C  for 10 min.
2.17.2.2. Substrate specificity of the synaptosomal Prolyl Endopeptidase by HPLC
The second method for the investigation of the substrate specificity of the post-Phenyl 
Sepharose prolyl endopeptidase was using HPLC (as described for synaptosomal PAP) except 
that equal volumes of sample and of 1  mM of each potential substrate were incubated for 24 
hours at 37°C. Following incubation, the reaction was terminated by the addition of 400^L of
0.2% TFA, pH2 .0 .
The peaks were resolved by the same gradient system as described in Section 2.15.1.
2.18. Inhibitor studies
2.18.1. Inhibitor studies on the synaptosomal pyroglutamate aminopeptidase
The effects of various inhibitors on the membrane-bound, the Triton X-100 solubilised, the post 
ion-exchange and the post phenyl sepharose synaptosomal PAP were investigated. The 
inhibitors were prepared as follows:
50|j.L of each sample were pre-incubated with an equal volume of each potential inhibitor for 10 
min at 37°C. 400(j.L of 0.1 mM <Glu-His-ProMCA was added and the reaction was allowed to 
proceed for a further 60 min. The fractions were assayed as described in section 2.2.2.1. 
Appropriate controls were prepared for each enzyme assay.
2.18.2 Inhibitor studies on the synaptosomal prolyl endopeptidase
The effects of a variety of inhibitors on the membrane-bound, the Triton X-100 solubilised, the 
post-gel filtration and the post-phenyl sepharose prolyl endopeptidase were assessed as 
described for the synaptosomal PAP (Section 2.16.1) using 0.1 mM Z-Gly-ProMCA as a 
substrate.
2.18.3. Effect of DTT on the synaptosomal PAP activity
The effects of DTT on post phenyl sepharose synaptosomal PAP activity was assessed by 
dialysing a 2 mL aliquot of post phenyl sepharose synaptosomal PAP against 10OmM potassium 
phosphate , pH 7.4 for 4 hours. 250(xL of dialysed sample were then incubated with a range of 
concentrations of DTT for 10 min at 37°C. 100(iL were then assayed for synaptosomal PAP
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activity according to section 2.2.2.1.
2.18.4. Effect of DTT on the synaptosomal PE activity
The effects of DTT on post phenyl sepharose PE were assessed using the same method as 
descrided in section 2.16.3. PE activity was asayed as in section 2.2.3.
2.18.5. Effect of EDTA on the synaptosomal PAP activity
A 2mL aliquot of post phenyl sepharose synaptosomal PAP activity was dialysed against 
1 0 0 mM ptassium phosphate, pH 7.4 with 1mM DTT for 4 hours. 250|iL were incubated with a 
range of EDTA concentrations for 10 min at 37’C. 100|iL sample was taken from each 
concentration of EDTA and was assayed for synaptosomal PAP activity as described in section 
2.2.2.1.
2.18.6. Effect of EDTA on synaptosomal PE activity
The effects of EDTA on post phenyl sepharose PE activity were assessed in the same way as 
for synaptosomal PAP (section 2.16.5.). PE activity was measured as described in section
2.2.3.
2.19. Metal ion studies
The effects of various metal ions on the synaptosomal PAP and prolyl endopeptidase were 
investigated by pre-incubating 50^ .1. of enzyme sample with an equal volume of each metal ion 
solution (to give a final concentration of 1mM metal ion) for 1 0  min at 37‘C. 400p,L of each 
substrate was added and the reaction was allowed to proceed for a further 60 min. The reaction 
was terminated by the addition of 1 mL of 1 ,5M acetic acid. The release of MCA was measured 
for each enzyme as described in sections 2 .2 . 2  and 2.2.3. Appropriate controls were prepared 
for each enzyme assay.
85
3. Results
3.1. Development of Two New Fluorimetric Assays for the 
Measurement of Pyroglutamate Aminopeptidase Activity
3.1.1. Use of the fluorimetric substrate <Glu-His-ProMCA for the detection of 
PAP activity with a coupled enzyme assay
The use of a new fluorimetric substrate <Glu-His-ProMCA as a possible substrate for the 
measurement of PAP activity was assessed initially using cytosolic PAP purified from rat liver as a 
positive control (section 2.4). The method used was a modification of a coupled enzyme 
spectrophotometric assay developed by Friedman and Wilk (1986). The PAP activity was 
determined with <Glu-His-ProMCA in a coupled enzyme assay with excess DAP IV and in the 
presence of Z-Pro-prolinal, a specific PE inhibitor (Wilk and Orlowski, 1983). Z-Pro-prolinal 
blocks the cleavage of the Pro-MCA bond by prolyl endopeptidase. The assay is based on the 
following reaction sequence:
PAP
1. <Glu-His-ProMCA ------------------►  <Glu + His-ProMCA
DAP IV
2. His-ProMCA --------------- ►  His-Pro + MCA
I I
The free MCA can then be measured fluorimetrically using excitation and emission wavelengths 
of 370 and 440nm respectively.
Fig 3.1 shows the effect of varying the concentration of <Glu-His-ProMCA on the release of 
MCA by PAP. 40 nanomoles of substrate were found to be sufficient to ensure that the 
substrate was present in adequate quantities to be saturating without inhibiting the PAP activity.
Once it was established that the fluorimetric substrate <Glu-His-ProMCA was suitable for 
detecting PAP activity, the assay parameters were established using bovine brain PAP and rat 
liver cytosolic PAP as a positive control. The use of PAP from rat liver cytosol purified in our 
laboratory was preferable to the commercially available pyroglutamate aminopeptidase activity 
(Sigma Chemical Co., St. Louis), as this commercial enzyme was found to be inactive and 
unstable in several batches. This commercial enzyme preparation was also impure and required 
purification over a Sephadex G-100 column to separate the PAP and PE activities. For these 
reasons it was more convenient and reliable to use PAP activity purified from rat liver as a 
positive control.
In the design of this kinetic enzyme assay a number of criteria were examined:
1. The concentrations of substrate and the second enzyme (i.e. DAP IV) should all be in excess 
to ensure that they are not rate-limiting.
2. There should be no inhibitors of the enzyme in the reaction mixture.
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Fig. 3.1 MCA Release from Increasing <Glu-His-ProMCA Concentration by 
PAP
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3. All environmental factors such as pH, temperature and ionic strength should be controlled. 
The third criteria was established using the conditions as described by Friedman and Wilk 
(1986). All assay mixtures were prepared in 10OmM potassium phosphate, pH 7.4 unless 
otherwise stated, and all reactions were carried out at 37*C.
3.1.1.1. The effect of pyroglutamate aminopeptidase volume on MCA release
Fig. 3.2 shows the effect of varying PAP volume on M CA released. IOOjj.1 of PAP activity with 
400 1^ of 0.1 mM <Glu-His-ProMCA ensured that the quantity of PAP was not limiting the 
reaction.
3.1.1.2 . The effect of Z-Pro-prolinal on PAP and PE activities
Since prolyl endopeptidase can also cleave the substrate <Glu-His-ProMCA, a specific PE  
inhibitor, Z-Pro-prolinal was used to ensure that any M CA released from the substrate was due 
solely to PAP activity. A  bovine brain crude homogenate (section 2.5), containing both 
cytosolic and particulate PAP and PE  activities was assayed in the presence of a range of
concentrations of the specific PE inhibitor, Z-Pro-prolinal (Fig 3.3). It was found that 20jil of 1 0 ' 5  
M Z-Pro-prolinal was sufficient to completely inhibit any PE activity in the crude homogenate or 
in the rat liver cytosolic fraction following incubation with both 0.1 mM Z-Gly-ProMCA and 0.1 mM 
<Glu-His-ProMCA. To ensure that this inhibition was not time dependent, the efficacy of the
inhibitor at a concentration of 1 0 " 5  M was assessed over time (Fig. 3.4). It was also seen that 
this inhibitor has no effect on PAP activity.
3.1.1.3. The effect of DAP IV volume on MCA release
The coupled-enzyme assay system calls for DAP IV to be present in excess to cleave the Pro- 
MCA bond, following the primary cleavage by PAP of the <Glu-His bond. Without that primary 
cleavage by PAP, DAP IV has no activity on the substrate. A  range of volumes of DAP IV
(purified from bovine brain) were pre-incubated with 1 0Ojxl of PAP and 2 0 |il of 10' 5  M Z-Pro- 
prolinal (to inhibit any PE activity) for 10mins at 37°C. 400jxl of 0 . 1  mM <Glu-His-ProMCA was 
added and the reaction was allowed to proceed as described in section 2.2.2.1. A volume of 
40fjJ gave a sufficient excess of DAP IV (Fig. 3.5).
The purpose of the DAP IV addition to the reaction mixture is to speed up the conversion of His- 
ProMCA to His-Pro + MCA as the naturally-occurring cyclisation reaction is quite slow. As can be 
seen in Fig. 3.6 the quantity of MCA released in the absence of DAP IV is only 30% of that 
released in its presence.
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Fig. 3.3. Effect of Different Concentrations of Z-Pro-proiinai on PAP and PE 
Activities
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Fig. 3.5. Effect of Differing Volumes of Secondary Enzyme (DAP IV) on 
Release of MCA from His-ProMCA Following Primary Cleavage by PAP
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Fig. 3.6. Release of MCA from <Glu-His-ProMCA by DAP IV Over Time 
Following the Primary Cleavage by PAP
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It was thought that the addition of DAP IV to the assay mixture at the beginning of the assay 
might pose a problem in the measurement of kinetic constants. It was decided to assess the 
possibility of allowing the reaction to proceed in the absence of DAP IV and compare the release 
of MCA with the rate of MCA release in the presence of DAP IV from time 0 and after its addition 
following 60 mins incubation.
By incubating the enzyme with the substrate for 60 mins prior to the addition of DAP IV ( Fig.
3.6), it can be seen that after 120 mins the reaction has gone to completion and there is no 
further release of MCA. By allowing the reaction to proceed in the absence of DAP IV for the 
initial 60 mins, possible interference by DAP IV in the measurement of any kinetic parameters 
can be avoided.
However, this does not ensure that the reaction goes to completion. It is the possible that 
following the addition of DAP IV to the reaction, PAP can continue cleaving the <Glu-His- 
ProMCA, while the DAP IV will cleave the His-ProMCA produced. For the correct estimation of 
kinetic parameters, one must be certain that the latter reaction has gone to completion, i.e., that 
the DAP IV has cleaved all the His-ProMCA produced from the primary cleavage of the substrate 
by PAP. By adding a PAP inhibitor, 1 ,1 0 -phenanthroline (which has no effect on DAP IV 
activity) after 60 mins at the same time as the DAP IV addition, any further PAP activity is 
prevented and the DAP IV is free to cleave all the His-ProMCA which was formed by PAP (Fig.
3.7).
3.1.2. Design of the Spontaneous Cyclisation Assay
The spontaneous cyclisation of His-ProNH2 to Cyclo(His-Pro) is well documented (Bauer and
Nowak, 1979; Bauer and Kleinkauf, 1980) and was found to proceed at a rate of 1 .5% min'1 in 
1 0 0 mM potassium phosphate buffer, pH7.4. This corresponds to a half-life of 44 mins if first 
order kinetics is assumed (Moss and Bungaard, 1990). Using this feature of the His-ProMCA, it 
was our aim to design an assay based on spontaneous cyclisation. This assay would have the 
advantage over the coupled-enzyme assay of not requiring the second enzyme, DAP IV.
The reaction sequence is as follows for the spontaneous cyclisation assay:
PAP
1. <Glu-His-ProMCA--------------------►  <Glu + His-ProMCA
Spontaneous
2 . His-ProMCA-------------------------- ► His-Pro + MCA
Cyclisation
Fig. 3.8 shows the release of M CA in the presence and absence of DAP IV over time. MCA  
release by spontaneous cyclisation does occur, but it takes much longer to go to completion. In 
the presence of DAP IV, the reaction is complete in approximately 2 hours, whereas it takes over 
1 0  hours to reach completion by spontaneous cyclisation alone.
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Fig. 3.7. MCA Release from His-ProMCA Following the Addition of DAP IV 
(Primary Cleavage of <Glu-His-ProMCA by PAP)
(PAP II Inhibitor * Added after 60 mins)
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Fig. 3.9. Release of MCA from <Giu-His-ProMCA Following Incubation with 
PAP and Cyclisation at 80°C
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By varying the pH of the reaction, it was hoped to speed up the rate of cyclisation, but at alkaline 
pHs there is an interference with the emission of fluoresence. At acidic pHs, the fluoresence 
was not affected, but there was no increase in the cyclisation. Several reports have found that 
the rate of cyclisation was optimum at physiological pH (Peterkofsky et al.,1982; Bungaard and 
Moss, 1990), and so pH 7.4 was used for all the assays, with 1,5M acetic acid then used to stop 
the reaction.
The rate at which the cyclisation occurs was investigated by increasing the temperature of the 
reaction after the initial 60 mins incubation. The enzyme reaction was stopped as usual after 60 
mins at 37°C, and the samples were then placed in an 80’C  waterbath. The release of free MCA  
was monitored overtime (Fig. 3.9).
The rate of release of MCA was increased, with levels apparently higher than those of the 
coupled enzyme assay (0.7nmol/min/mL) being achieved after 30 mins at 80'C. However a 
major problem lies in the degradation of the substrate at such high temperatures. Once this 
degradation is accounted for in any estimations of enzyme activity, the levels of free MCA are 
comparable to those of the coupled enzyme assay. Under these conditions the assay may be 
used to measure PAP activity.
Fig. 3.10 shows that <Glu-His-ProMCA can also be used as a substrate for measuring prolyl 
endopeptidase activity, although throughout this work Z-Gly-ProMCA was used routinely for 
quantifying PE activity.
A  standard curve of fluorimeter units versus MCA concentration is shown in Fig. 3.11. It has a 
correlation coefficient of 0.99955. This curve was routinely used to calculate the enzyme 
activities.
3.2 Thyroliberin-Degrading Activities in Different Subcellular 
Locations
3.2.1. Demonstration of Two Thyroliberin-Degrading Pyroglutamate 
Ami nopeptidases in Different Subcellular Locations of Bovine Brain.
When bovine brain homogenates were resolved into a particulate and cytosolic fraction, both 
fractions were assayed for PAP activity using the new fluorimetric coupled assay. The samples 
were assayed both in the presence and absence of DTT and EDTA, as cytosolic PAP has been 
reported to require a sulphydryl reagent for activity (Browne and O ’Cuinn, 1983). A s can be 
seen in Table 3.1, very low levels of PAP activity are detected in the suppernatant. However, in 
the presence of DTT and EDTA, 65% of the total brain PAP activity is found in the soluble 
fraction. The low levels of PAP activity in the cytosolic fraction in the absence of DTT and EDTA 
are characteristic of this enzyme requiring a thiol reagent for activity (Browne and O ’Cuinn,
1983).
Increased PAP activity was also found in the particulate fraction with the addition of DTT and
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EDTA, and therefore all further assays were carried out In the presence of 1 mM D TT and 1 mM 
EDTA. Overall 38% of the total brain PAP activity was detected in this particulate fraction. The 
rise in particulate PAP activity in the presence of D TT  and EDTA is of particular note as 
previously identified particulate PAP activities have reported that the particulate PAP activity is 
inhibited by EDTA, even at 1mM concentrations (O’Connor and O’Cuinn, 1984).
Table 3.1 Demonstration of the Presence of Two PAP Activities In Different 
Subcellular Locations of Bovine Brain
Fraction Total PAP Activity 
(nmol/min)
(-1mM DTT/1mM EDTA)
Total PAP Activity 
(nmol/min)
(+1mM DTT/+1mM EDTA)
Crude Homogenate
68.97 (100%) 182.88 (100%)
Supernatant
2.12 (3.1%) 119.85 (65%)
Particulate Fraction
26.1 (37.8%) 66.26 (35.5%)
3.2.2. Demonstration of Two Thyroliberin-Degrading Prolyl Endopeptidase 
Activities in Different Subcellular Locations of Bovine Brain.
The supernatant and particulate fractions were also assayed for PE activity using the substrate 
Z-Gly-ProMCA. To date, PE activity had only been characterised from the cytosolic fraction of 
brain, although it has been suggested that a particulate PE activity may be present in small 
quantities (Dresdner et al., 1982; Camargo et al., 1984). There was a sizeable difference in the 
amount of PE activity detected, even in the crude homogenate compared to the levels of PAP 
activity in the crude homogenate (Table 3.2).
In the presence of D TT and EDTA, nearly 50% of the total PE activity was detected in the 
soluble fraction, with about 42% PE activity found in the particulate fraction. This was a higher 
amount of PE activity in the particulate fraction than had previously been reported from other 
sources. Camargo et al. (1984) suggested 10% PE was membrane-associated in rabbit brain, 
while Dresdner et al. (1982) suggested that 35% of the PE activity could be found in the crude 
mitochondrial fraction from the same source. However both of these studies comment on the 
very low levels of PE activity present in the particulate fraction, and of the activity probably being 
associated with a crude mitochondrial fraction.
9 6
The addition of D TT and EDTA to the homogenisation mixture caused little variation in the levels 
of PE activ'itiy, there was a slight increase in the total PE activity, but this increase was reflected 
by a similar increase in the soluble and particulate PE activities.
Table 3.2 Demonstration of the Presence of Tw o Prolyl Endopeptidase 
Activities in Different Subcellular Locations of Bovine Brain.
Fraction Total PE Activity 
(nmol/min)
(-1mM DTT/1mM EDTA)
Total PE Activity 
(nmol/min)
(+1mM DTT/+1mM EDTA)
Crude Homogenate
2506.7 (100%) 3003.1 (100%)
Supernatant
1267.12 (50.5%) 1467.12 (48.8%)
Particulate Fraction
1068.4 (42.6%) 1275.8 (42.4%)
3 . 3  D e t e c t i o n  o f  P o s s i b l e  O c c l u d e d  E n z y m e  A c t i v i t i e s
3.3.1. Effect of Osmotic Shock on the Release of PAP from the Particulate 
fraction
Following an initial 0.5M salt-washing step, the particulate fractions were subjected to an osmotic 
shock by resuspending the salt-washed pellets in distilled water with gentle rehomogenisation. 
This osmotic shock step was employed to determine whether the PAP activity was actually 
membrane-bound or was in fact occluded in vesicles as has been reported for many ‘membrane- 
bound’ enzymes (Van Amsterdam et al., 1983; Dalmaz et al., 1986). Half of the pellets were 
resuspended in potassium phosphate buffer as a control. After vigorous washing of the pellets 
with either the buffer or the distilled water the samples were centrifuged as described before 
(Section 2.8.2.). As can be seen from the results in Table 3.3, no extra PAP activity was 
released from the membrane fractions following washing with either buffer or distilled water. 
These results strongly suggest that the PAP activity is a membrane- bound enzyme and is not 
just a soluble activity that has become occluded in the vesicles that are formed by the 
homogenisation process.
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3.4.2. Effect of Osmotic Shock on the Release of PE from the Particulate 
Fraction
As described above, the membrane fraction was subjected to an osmotic shock in order to 
release any PE activity that may be occluded in vesicles formed by the membranes. The results 
are shown in Table 3.4. Following the osmotic shock step, another 3.46nmol/min/mL PE activity 
were released which only represents 0.4% of the total salt-washed particulate PE activity and is 
due to any occluded PE activity that was trapped in vesicles by the membranes. This figure is 
smaller than the 0.6% PE activity released by the buffer wash. Therefore the effect of the 
osmotic shock on the release of PE activity from the membranes is minimal. Any PE activity that 
remains in the particulate fraction following the initial salt-washing and an osmotic shock step 
should either be a membrane-associated or membrane-bound protein.
Table 3.3 Effect of Osmotic Shock on Particulate PAP Activity
Fraction
PAP Activity
(nmol/min/mL)
%  PAP Activity (as a %  of 
the salt-washed pellet)
0.5M Salt-Washed 
Membrane Fractions 16.40 100.00
Control (Buffer-Washed 
Pellet) 15.60 93.90
Control (Buffer-Wash 
Supernatant) 0.00 0.00
Osmotically-Shocked
Membranes 15.73 95.90
Osmotically-Released
Material 0.00 0.00
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T a b l e  3 . 4  E f f e c t  o f  O s m o t i c  S h o c k  o n  P a r t i c u l a t e  P E  A c t i v i t y
Fraction PE Activity 
(nmol/min/mL)
%  PE Activity
0.5M Salt-Washed 
Membrane Fractions 806.00 100
Control (Buffer-Washed 
Pellet) 600.64 74.4
Control (Buffer-Wash 
Supernatant) 5.31 0.6
Osmotically-Shocked
Membranes 599.80 74.4
Osmotically-Shocked
Material 3.46 0.4
3 . 4  S a l t - W a s h i n g  o f  t h e  P a r t i c u l a t e  F r a c t i o n s
3.4.1. Effect of Repeated Salt-Washing on the Particulate PAP Activity
Following the identification of a particulate PAP activity, a series of repeated salt-washing steps 
were performed on the particulate fraction to determine whether the enzymes were membrane- 
bound or just non-specifically associated with the membrane fraction. The pellet from the 
osmotic shock step was repeatedly resuspended in a 4M NaCI solution. Each time the 
supernatant and a sample of the pellet were assayed for PAP activity. Fig. 3.12 shows how the 
level of PAP activity in the washes drops very quickly following sequential salt-washing, while 
the PAP activity in the particulate fraction remains at a constant level (12.5nmol/min/mL), which 
represents 74% of the activity of the post-osmotic shock pellet, and is approximately 26% of the 
original crude particulate pellet.
3.3.2. Effect of Repeated Salt-Washing on the Particulate PE Activity
Fig. 3.13 shows how PE activity remains associated with the particulate fraction, even after 
vigorous salt-washing. The level of PE activity in the final wash is negligible, while that in the 
particulate fraction is at approximately 35% of that in the original post-osmotic shock pellet. The 
figure represents 19.6% of the original crude particulate pellet. Such activity remaining 
associated with the particulate fraction after a series of salt washes suggests that the PE is more 
than just loosely associated with the membrane, as repeated salt washing should dislodge any 
non-specific loosely-bound proteins.
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Fig. 3.12 The Effect of Repeated 4M Salt Washes on Synaptosomal PAP 
Activity
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□  Particulate PAP Activity (nmol/min/mL) 
S  Soluble PAP Activity (nmol/min/mL)
Fig. 3.13 The Effect of Repeated 4M Salt Washes on Synaptosomal PE 
Activity
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3 . 5  S u b c e l l u l a r  L o c a l i s a t i o n  o f  t h e  P a r t i c u l a t e  T h y r o l i b e r i n -  
D e g r a d i n g  A c t i v i t y
3.5.1. Subcellular Localisation of the Particulate PAP Activity
Using a combination of differential centrifugation and isopynic ultracentrafugation (with sucrose
gradients), the salt-washed particulate fractions of bovine brain were divided into three fractions. 
These fractions were subsequently identified as the myelin, synaptosomal membrane and 
mitochondrial fractions by use of specific enzyme marker assays as described in section 2.6. 
Following their identification, each fraction was assayed for PAP activity (Table 3.5). Following 
subfractionation of the salt-washed particulate fraction there was a three-fold enrichment of PAP 
specific activity in the synaptosomal fraction. This represented 75% of the total PAP activity. 
The PAP specific activity actually decreased in the myelin and mitochondrial fractions. The 
localisation of PAP activity with the synaptosomal membranes is in agreement with previous 
reports of PAP localisation (O’Connor and O'Cuinn, 1984).
Table 3.5 Subcellular Localisation of the Particulate PAP Activity
Fraction SDH
(nmol/min/
mg)
LDH
(nmol/min/
mg)
5'-Ribonucleo-
tidase
(nmol/min/
mg)
PAP Specific 
Activity 
(nmol/min/ 
mg)
PAP in each 
fraction as a % 
of that in Crude 
Homogenate
Crude
Homogenate
3.61 1.00e+5 0.57 18.50 100.00
Supernatant
2.43 3.07e+5 0.10 13.13 71.16
Salt-Washed
Particulate
Fraction 0.62 2.89e+4 0.76 4.92 26.70
Salt-Washed
Pellet
Fractionated
Into:
PAP as a %  of 
the Salt-Washed 
Particulate 
Fraction
Myelin
0.11 1.59e+4 0.32 3.41 18.45
Synaptosomal
membranes
0.33 6.15e+4 1.96 13.98 75.80
Mitochondria
1.36 8.88e+4 0.44 3.66 19.80
1 0 1
3 . 5 . 2 .  S u b c e l l u l a r  L o c a l i s a t i o n  o f  t h e  P a r t i c u l a t e  P E  A c t i v i t y
Using similar subcellular localisation methods as those employed for the localisation of PAP 
activity, PE activity was also found to be associated with the synaptosomal membranes (Table 
3.6). The apparent low level of PE activity was the result of soluble PE being removed during 
osmotic shock and loosely, non-specifically-bound activity being removed by repeated salt- 
washing. The remaining PE activity was all membrane-associated or membrane-bound. There 
was a 2-fold enrichment in PE specific activity from the salt-washed fraction to the synaptosomal 
membranes. There was only a slight increase in specific activity in the mitochondrial fraction and 
a decrease in specific activity in the myelin fraction. This high figure of synaptosomal membrane- 
associated PE activity is in contrast to previous reports of PE activity being primarily found in the 
cytosolic fraction of brain. All previous reports of a particulate PE refer to its low activities, its 
probable presence in the membranes solely as an occluded activity, and of its presence in the 
crude mitochondrial fraction (Dresdner et al., 1982; Dalmaz et al., 1986). No report to date has 
investigated the actual location of the PE activity within the crude particulate fraction which 
would contain mitochondrial, microsomal and synaptosomal membranes.
The ability of the PE activity to remain in the synaptosomal membrane fraction following 
repeated salt-washes and hypo-osmotic shock indicates that the activity is more than just 
membrane-associated enzyme.
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T a b l e  3 . 6  S u b c e l l u l a r  L o c a l i s a t i o n  o f  t h e  P a r t i c u l a t e  P E  A c t i v i t y
Fraction SDH
(nmol/min/
mg)
LDH
(nmol/min/
mg)
5-Ribonucleo-
tidase
(nmol/min/
mg)
Specific PE 
Activity 
(nmol/min/ 
mg)
PE in each 
fraction as a % 
of that in Crude 
Homogenate
Crude
Homogenate 3.61 1.00e+5 0.57 833.40 100.00
Supernatant
2.43 3.07e+5 0.10 573.70 48.80
Salt-Washed
Particulate
Fraction 6.18 2.89e+4 0.76 159.07 19.08
Salt-Washed
Pellet
Fractionated
Into:
PE as a % of the 
Salt-Washed 
Pellet
Myelin
0.11 1.59e+4 0.32 60.25 7.22
Synaptosomal
membranes 0.33 6.15e+4 1.96 252.90 30.30
Mitochondria
1.36 8.88e+4 0.44 156.60 18.80
3 . 6  P h a s e - P a r t i t i o n i n g  S t u d i e s  o n  t h e  P a r t i c u l a t e  T h y r o l i b e r i n -  
D e g r a d i n g  A c t i v i t i e s
3.6.1. Phase-Partitioning Study on the Particulate PAP Activity
The phase separation of membrane proteins was first described by Bordier (1981). This 
technique is used to differentiate between integral and peripheral membrane proteins. A 
solution of the nonionic detergent Triton X-114 is homogeneous at O'C but separates in to an 
aqueous phase and a detergent phase above 20°C. The Triton X-114 is used to solubilise the 
membrane’s enzymes and the solublised material is subjected to phase separation. Hydrophilic 
(peripheral) enzymes are found exclusively in the aqueous phase, and integral membrane
1 0 3
enzymes with an amphiphilic nature are recovered in the detergent phase.
Table 3.7 shows the results of the phase-partitioning of the PAP activity from the synaptosomal 
membranes. 60% of the PAP activity was found in the Triton X-114-enriched hydrophobic 
layer indicating that it exists for the most part as an integral membrane protein, with the majority 
of its surface embedded in the membrane leading to its hydrophobic nature.
Table 3.7 Phase-Partitioning Study on the Synaptosomal PAP Activity with 
Triton X-114
Fraction PAP activity 
(nmol/min/mL)
PAP Activity as a %  of 
that in Synaptosomal 
Membranes
Synaptosomal
Membrane 0.84 100.00
Triton X-114 
Depleted Layer 0.03 3.60
Triton X-114 
Enriched Layer 0.51 60.00
3.6.2. Phase-Partitioning Study on the Particulate PE Activity
Using the same procedure as described in section 3.6.1., the majority of the PE activity was 
found to be associated with the hydrophilic upper layer (Table 3.8). 87% of the PE activity was 
found in the Triton X-114 soluble layer, thereby indicating that the particulate PE is a peripheral 
membrane protein i.e. that the majority of the enzyme, containing its active sites, could be on 
the surface of the membrane and be exposed to the hydrophilic surroundings.
Table 3.8 Phase Partitioning Study on the Synaptosomal PE Activity using 
Triton X-114
Fraction PE Activity 
(nmol/min/mL)
PE Activity as a % 
of that in 
Synaptosomal 
membranes
Synaptosomal
Membranes 10.4 100
Triton X-114 
Soluble Layer 9.02 86.7
Triton X-114 
Insoluble Layer 0.84 8.7
1 0 4
3 . 7  R e l e a s e  o f  t h e  P a r t i c u l a t e  T h y r o l i b e r i n - D e g r a d i n g  A c t i v i t i e s  
f r o m  t h e  S y n a p t o s o m a l  M e m b r a n e s
3.7.1. Release of Particulate PAP Activity from the Synaptosomal Membranes.
Following localisation of the PAP activity on the synaptosomal membranes, the next step was to 
find an efficient method to release it from the membranes. Table 3.9 shows how a number of 
methods were used, including the detergent Triton X-100, the proteolytic enzymes trypsin and 
papain. Appropriate control washes were also included. Sonication was also tried as a method 
of releasing the enzyme from the membranes, but it was found to completely destroy the 
enzyme activity. It can be seen that while some of the procedures eg trypsin and papain, are 
very effective in removing protein from the sample, the amount of PAP activity released is quite 
small, and so the specific activity of the resulting sample is very low. The most efficient means of 
releasing PAP activity from the synaptosomal membranes was by solubilising the enzyme from 
the membrane with the detergent Triton X-100. This step gives a yield of 75% PAP activity from 
the initial salt-washed particulate fraction. Further optimisation with Triton X-100 showed that a 
concentration of 0.4% (v/v) was optimal (Fig. 3.14). Triton X-114, as was used for the phase- 
partitioning step, was not used for enzyme solubilisation as it was too severe on the enzyme 
activity.
3.7.2. Release of the Particulate PE Activity from the Synaptosomal 
Membranes.
In order to release the PE activity from the synaptosomal membranes, an approach similar to that 
used for PAP was employed. As with particulate PAP activity, Triton X-100 proved to be the 
most efficient means of releasing PE activity from the membranes (Table 3.10). Sonication was 
found to almost completely inactivate the enzyme activity, yielding only 5% recovery of PE 
activity. Even though papain reduced the protein concentration of the sample more than any 
other method (90% loss of protein), it caused a very low release of PE activity (22%), resulting in 
a low specific activity. Fig. 3.15 shows how a concentration of 0.3-0.4% Triton X-100 was 
required to solubilise the maximum amount of PE activity from the synaptosomal membranes.
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Control @ 4’C=particulate fraction incubated at 4*C for 60min 
Control @30’C=particulate fraction incubated at 30‘C for 60min 
Sonication= 2 5-second pulses on ice
Trypsin solubilised=particulate fraction incubated at 30‘C for 60 min 
Papain solubilised= particulate fraction incubated at 30‘C for 60 min 
Triton X-100 solubilised=particulate fraction incubated on ice for 60 min
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M e m b r a n e s
Fraction Total Activity 
(nmol/min)
Total
Protein
(mg)
Specific
Activity
(nmol/min/mg)
Purification
Factor
%
Recovery
Salt-Washed
Particulate
Fraction 18.200 2800.000 0.007 1.000 100.00
Control (@ 4 C) 2.090 171.730 0.012 1.910 11.50
Control (@ 30 C) 2.750 194.130 0.014 2.200 15.10
Sonication 0.010 399.200 0.000 0.000 0.00
Trypsin Solubilised 
(20,800 units of 
activity) 5.220 446.250 0.012 1.900 28.70
Papain Solubilised 
(30.4 units of 
activity) 5.770 268.800 0.021 3.230 31.70
Triton X-100 
Solubilised
13.600 329.760 0.040 6.150 74.90
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Control @ 4*C=particulate fraction incubated at 4‘C for 60min 
Control @30’C=particulate fraction incubated at 30'C for 60min 
Sonication= 2 5-second pulses on ice
Trypsin solubilised=particulate fraction incubated at 30"C for 60 min 
Papain solubilised= particulate fraction incubated at 30*C for 60 min 
Triton X-100 solubilised=particulate fraction incubated on ice for 60 min
T a b l e  3 . 1 0  R e l e a s e  o f  t h e  P a r t i c u l a t e  P E  f r o m  t h e  S a l t - W a s h e d  S y n a p t o s o m a l
M e m b r a n e s
Fraction Total Activity
(nmol/min)
Total
Protein
(mg)
Specific
Activity
(nmol/min/mg)
Purification
Factor
%
Recovery
Salt-Washed
Particulate
Fraction 820.10 2800.00 0.29 1.00 100.00
Control (@4 C) 168.10 297.07 0.57 1.97 20.50
Control (@30 C) 159.10 315.50 0.19 0.70 19.40
Sonication 46.20 400.50 0.11 0.39 5.50
Trypsin Solubilised 
(20,800 units of 
activity)
216.50 446.25 0.26 0.90 26.40
Papain Solubilised 
(30.4 units of 
activity)
181.20 268.80 0.22 0.76 22.10
Triton X-100 
Solubilised
676.60 329.76 2.05 7.10 82.50
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Fig. 3.14 Effects of a Range of Triton X-100 Concentrations on the Release of 
PAP Activity from the Synaptosomal Membranes
12
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Fig. 3.15 Effects of a Range of Triton X-100 Concentrations on the 
Release of PE from the Synaptosomal Membranes
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3.8.1. Gel Filtration Chromatography on Sephacryl S-200 HR
PAP activity was released from the synaptosomal membranes by treatment with Triton X-100, 
and separated from the particulate matter by centrifugation ( as outlined in section 2.10.2.1.). A 
5mL sample of Triton X-100-solubilised PAP was applied to a Sephacryl S-200 column. The 
elution profile is shown in Fig. 3.16. The enzyme activity eluted close to the void volume and 
was clear from the main protein peaks. The fractions with the highest activities were pooled and 
were stored at 4‘C.
3.8.2. Ion-Exchange Chromatography on DEAE-Sepharose
A 4mL sample of Triton X-100-solubilised PAP was applied to a DEAE- Sepharose anion 
exchange column. The column was equilibrated with a 50mM potassium phosphate buffer, pH
7.4. The sample was eluted using a linear salt gradient (0.2 - 0.5M NaCI). The PAP activity 
separated clearly from the bulk of the protein (Fig 3.17). The most active fractions were pooled 
and stored at 4°C.
Ion exchange chromatography gave a consistently higher yield of PAP activity than gel filtration 
and so it was regularly used as the first step in the purification scheme.
3.8.3. Concentration of the Post-Ion Exchange PAP Activity
Following ion-exchange the PAP activity was concentrated by reverse dialysis on a bed of PEG 
6000. This step was incorporated into the purification scheme as the volume of the pooled 
fractions following ion exchange was too large to apply to a 2mL phenyl sepharose column. A 
5mL post-ion exchange PAP sample was concentrated down to 2 mLs.
3.8.4. Hydrophobic Interaction Chromatography on Phenyl Sepharose
The concentrated synaptosomal PAP sample was applied to a phenyl sepharose column under 
high salt conditions (2M (NH4 )2 S 0 4 ). The PAP activity was eluted using a positive linear
glycerol gradient (0-25%) and a negative salt gradient (2M-0). The protein content of the 
samples was at a minimum following ion exchange and so there was very little protein to be 
separated (Fig 3.18). The most active synaptosomal PAP fractions were pooled and were 
stored at 4°C.
Table 3.11 summarises the purification scheme for synaptosomal PAP. There was a 20.7% 
yield of activity from the original synaptosomal fraction and the enzyme was purified 644-fold.
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T a b l e  3 .1 1  P u r i f i c a t i o n  T a b l e  f o r  P u r i f i e d  S y n a p t o s o m a l  P A P
Fraction Total Protein 
(mg)
Total Activity 
(nmol/min)
Specific
Activity
(nmol/min/mg)
% Recovery Purification
Factor
Crude
Homogenate
6857.500 190.00 0.02 * *
Synaptosomal
Fraction
2838.00 69.00 0.02 100.00 1.00
Sait-Washed
Synaptosomal
Fraction 2010.00 20.20 0.01 29.30 0.05
Triton X-100 
Solubilised
300.50 14.80 0.05 21.40 2.50
Post
Ion-Exchange
23.50 16.70 0.63 24.20 35.50
Post Phenyl 
Sepharose
1.11 14.30 12.88 20.70 644.00
3.8.5. Assessment of the Synaptosomal PAP Purification Scheme by 
Electrophoresis
3.8.5.1. Sodium Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SOS-PAGE was carried out on a sample from each of the purification stages in order to monitor 
the actual purification and to estimate the molecular weight of the purified enzyme. Fig. 3.19 
shows how the molecular weight of the purified synaptosomal PAP corresponds to a molecular 
weight of 230kDa.
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3.9.1. Gel Filtration Chromatography on Sephacryl S-200HR
A 5mL Triton X-1 OO-solubilised sample (as described in section 2.8.4.2.) was applied to a 
500mL Sephacryl S200HR column on the Pharmacia Biopilot FPLC system. As can be seen in 
Fig. 3.20, the PE activity eluted much later than the synaptosomal PAP activity and was well 
separated from any major protein peaks. The most active fractions were pooled and stored at 
-20’C.
3.9.2. Hydroxylapatite Chromatography
Following gel filtration, a 10mL PE sample was dialysed for 3 hours into 20mM potassium 
phosphate buffer, pH 7.4. This sample was then applied to a calcium-phosphate 
(hydroxylapatite) column and the prolyl endopeptidase activity was eluted with a linear 
phosphate gradient (20-500mM) (Fig. 3.21). The PE eluted away from most of the protein 
peaks, which were already quite low (less then 0.1mg/mL). The most active fractions were 
pooled and stored at -20'C.
3.9.3. Hydrophobic Interaction Chromatography
5mL of a post-hydroxylapatite sample were applied to a phenyl-sepharose column under high 
salt conditions (2M(NH4 )2 SC>4 ). The PE activity was eluted using a positive linear (0-50%) 
glycerol gradient and at this stage the protein levels were almost undetectable (0.04mg/mL). 
Under these conditions, the synaptosomal PE activity eluted at approximately 45% glycerol 
(Fig.3.22).
Table 3.12 summarises the purification scheme for the synaptosomal PE activity. There was a 
23% recovery of activity from the initial particulate fraction and the prolyl endopeptidase was 
purified 1407-fold.
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T a b l e  3 . 1 2  P u r i f i c a t i o n  T a b l e  f o r  P u r i f i e d  S y n a p t o s o m a l  P E
Fraction Total Protein 
(mg)
Total Activity 
(nmol/min)
Specific
Activity
(nmol/min/mg)
% Recovery Purification
Factor
Crude
Homogenate
6890.00 2907.50 0.36 * •
Synaptosomal
Fraction
2845.00 1300.00 0.46 100.00 1.00
Salt-Washed
Synaptosomal
Fraction 2000.00 850.90 0.43 65.50 0.93
Triton X-100 
Solubilised
305.90 680.70 2.23 52.40 4.90
Post Gel 
Filtration
32.25 444.86 13.80 34.20 30.00
Post
Hydroxyl-
apatite 5.50 391.05 71.10 30.00 154.60
Post Phenyl 
Sepharose
0.47 304.30 647.40 23.40 1407.50
3.9.4. Assessment of the Synaptosomal PE Purification Scheme by 
Electrophoresis
3.9.4.2. Sodium Dodecyl-Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE)
In Fig. 3.23 an SDS-Gel of the purified synaptosomal PE confirms the subunit molecular weight 
of the enzyme as being in the region of 87kDa.
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Fig. 3.23. A 10% SDS-PAGE of Bovine Synaptosomal PE
• * -  Myosin
ß-Galactosidase 
•<- Phosphoylase B
BSA
Ovalbumin
-Carbonic Anhydrase
7. 6. 5. 4. 3. 2. 1.
1. Crude Homogenate
2. Synaptosomal Fraction
3. Salt-Washed Synaptosomal Fraction
4. Triton X-100 Solubilised Fraction
5. Post Gel Filtration Fraction
6. Post Hydroxylapatite Fraction
7. Post Phenyl Sepharose Fraction
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3.10.1. Molecular Weight Determination of the Synaptosomal PAP Activity
The molecular weight of the synaptosomal PAP activity was determined by gel filtration on a 
sephacryl S-200 column ( as described in section 2.9.1.). A plot of Ve/Vo versus the logarithm 
of the molecular weight of a number of standard proteins was linear as shown in Fig. 3.24. The 
synaptosomal PAP solubilised by Triton X-100 was found to have a Ve/Vo value which 
corresponded to a molecular weight of approximately 230kDa.
3.10.2. Molecular Weight Determination of the Synaptosomal PE Activity
The molecular weight of the synapotosomal PE was estimated in the same way as described in 
section 3.10.1. The molecular weight was found to be 87k0a (Fig. 3.25).
3.10.3. pH-Rate Profile of the Synaptosomal PAP Activity
The activity of the synaptosomal PAP was assayed for activity over a range of pH units from 5 to 
8.5 using 100mM MES, pH 5-6.5, 100mM potassium phosphate, pH 6.5-7.5 and 100mm Tris- 
HCI, pH 7-8.5. The purified synaptosomal PAP had an optimum between pH 7.0 and 7.5 (Fig. 
3.26). This optimum was achieved in both potassium phosphate and Tris-HCI buffers. The 
enzyme activity dropped dramatically in the Tris-HCI buffer once its pH went over 7.5. The 
activity of the PAP in MES was much lower than in either of the other two buffers, but the MES 
pH range was quite acidic (pH5-6.5). From this data it can be seen that the choice of 
physiological pH 7.4 for all assays was a suitable one.
3.10.4. pH-Rate Profile of the Synaptosomal PE Activity
The activity of the PE purified from the synaptosomal membranes was stable over a broader 
range of pH units than the synaptosomal PAP activity (Fig. 3.27). The prolyl endopeptidase 
activity was high in all three buffers from pH 5.5 through to pH 8. There appeared to be a 
preference by the enzyme for potassium phosphate buffer at pH 7.0, but this increase in activity 
was only slight. Only at pH 8.5 did the PE activity begin to decrease.
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Fig. 3.24. Molecular Weight Calibration Curve for Synaptosomal PAP
log molecular weight 
PAP M.W. = 230kDa
Fig. 3.25. Molecular Weight Calibration Curve for Synaptosomal PE
log molecular weight 
PE M.W. = 87 kDa
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3.10.5. Effect of Different Buffers on Thyroliberin-Degrading Activities
3.10.5.1. The activity of the synaptosomal PAP in a range of buffers
The activity of the Triton X-100-solubilised PAP in a range of different buffers is shown in Fig. 
3.28.
The enzyme was most active in 100mM potassium phosphate buffer, but appeared to have an 
equal preference for both 100mM HEPES and Tris-HCI. Its activity was lowest in 100mM 
Imidazole buffer (20% of that in phosphate buffer).
Fig. 3.28 Synaptosomal PAP Activity In a Range of Buffers at 100mM 
Concentration, pH 7.4
0 .6  
0 .4  
0 .2  
0
Potassium Phosphate HEPES Imidazole Tris-HCI
®  Synaptosomal PAP Activity (nmol/min/mL)
3.10.5.2. The activity of the synaptosomal prolyl endopeptidase activity in a range of buffers
PE showed a marked preference for 10OmM potassium phosphate buffer, having at least 20% 
more activity in it than in any of the other buffers (Fig. 3.29). Its lowest activity was found in Tris- 
HCI, and it seemed to have an equal preference for both HEPES and Imidazole.
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Fig. 3.29 Synaptosomal PE Activity In a Range of Buffers at 100mM 
Concentration, pH 7.4
Potassium Phosphate HEPES Imidazole Tris-HCI
H  Synaptosomal PE Activity (nmol/min/mL)
3.10.6. Stability Studies on the Purified Synaptosomal Thyroliberin- 
Degrading Activities Under Different Conditions
3.10.6.1. Effect of temperature on the stability of the synaptosomal PAP activity
Both the Triton X-100-solubilised and purified synaptosomal PAP activities were quite unstable 
in contrast to the synaptosomal PAP purified from other sources (O’Connor and O’Cuinn, 1984; 
Wilk and Wilk, 1989). The Triton X-100-solubilised PAP in 100 mM potassium phosphate 
buffer, pH 7.4, was placed under different storage conditions in order to increase the stability of 
its activity. The activity of the sample was monitored over time. The first of the conditions 
investigated was temperature (Fig. 3.30). The activity of the sample at room temperature was 
most stable and the activity of the PAP increased slightly with time. At 4°C, the activity of the 
PAP initially decreased, but then the activity levelled out without any further decrease in 
activity. The synaptosomal activity PAP activity at -20'C was the most unstable, as it lost 75% of 
its activity in the first 24 hours which was not recovered over the time of monitoring.
The purified synaptosomal PAP was also assayed under the same conditions. Its activity was 
found to be the most stable at 4*C, when it only lost 15% of its activity over 100 hours (Fig. 
3.31). At room temperature, the condition preferred at the Triton X-100-solubilised stage, the 
PAP activity dropped by 25% over time. When stored at -20’C, the PAP activity decreased by 
50%.
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Fig. 3.30. Triton X-100-Solubilised PAP Activity Over Time
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Fig. 3.31. Purified PAP Activity Over Time
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3.10.6.2. Effect of glycerol on the stability of the purified synaptosomal PAP activity
The effect of glycerol as a stabilising agent was investigated with regard to purified 
synaptosomal PAP activity when stored at 4'C and -20’C. Fig. 3.32a shows the effect of 
glycerol on synaptosomal PAP activity when stored at 4*C. 20% (v/v) glycerol proved to have 
the most stabilising effect on the PAP activity, although 10% and 30% were also quite effective. 
The activity of the sample dropped by nearly 50% in the absence of glycerol, but only dropped 
by an average of 20% in the presence of glycerol. When samples were stored at -20°C (Fig. 
3.32b), glycerol again provided a stabilising influence on the PAP activity, but it was unable to 
prevent a huge drop in the enzyme activity. Even with 30% (v/v) glycerol, there was a 35% drop 
in the synaptosomal PAP activity. Without any glycerol, the activity dropped by 80%.
3.10.6.3. Effect of BSA on the stability of the purified synaptosomal PAP activity
BSA is commonly used as a stabilising agent for enzymes at low concentration. 1 and 2% (w/v) 
BSA and a combination of 1% (w/v) BSA and 10% (v/v) glycerol were used in an attempt to 
increase the stability of the synaptosomal PAP at 4*C and -20*C. At 4*C, the combination of 
BSA and glycerol proved quite effective with very little loss in activity (Fig. 3.33a). 1 and 2% 
BSA on their own resulted in 70% and 43% loss in activity respectively. At -20°C, the 
combination again provided the most protection against inactivation, but the activity still dropped 
by 57% of the original (Fig. 3.33b).
3.10.6.4. Effect of different buffers on the stability of the purified synaptosomal PAP activity
The possibility of providing increased stability to the purified PAP activity by storage in a 
different buffer was investigated. The enzyme was dialysed into the different buffers and was 
stored at 4’C and -20°C. The results from section 3.10.5. showed that the PAP activity was 
relatively unaffected by different buffers (Fig. 3.28).
Fig. 3.34a shows how the different buffers have little effect on the stability of the purified PAP 
activity when stored at 4°C. The different buffers provided even less protection against 
inactivation when the PAP was stored at -20‘C (Fig. 3.34b).
Following these experiments, the most effective method of storage of the purified enzyme was 
in 100mM potassium phosphate buffer,pH 7.4, with 10% (v/v) glycerol and 1% (w/v) BSA at 4°C. 
From the phenyl sepharose step, the enzyme is already in glycerol and so 1% BSA was added 
to the sample. Under these conditions, the purified PAP activity was stable for up to 1 week.
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Fig. 3.34a. Effect of Different Buffers at pH 7.4 on Purified PAP Activity 
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3.10.6.5. Effect of different storage conditions on the stability of the purified synaptosomal PE 
activity
Post-phenyl Sepharose PE activity proved to be quite stable under a range of different storage 
conditions, such as different temperatures, in the presence of glycerol and when stored in 
different buffers. The results of the various storage conditions on PE activity are shown.
Fig. 3.35 shows that PE activity was quite stable regardless of the temperature at which it was 
stored. The activity remained slightly higher when the sample was frozen, than at 4‘C. At room 
temperature the activity decreased by approximately 50% after 100 hours storage. In Fig. 3.36, 
the sample was stored at -20*C in the presence of 10% and 20% (v/v) glycerol and this resulted 
in only a 5% loss of activity even after 100 hours. Post-phenyl sepharose PE was already in 
glycerol and from the graph it can be seen that this inclusion of glycerol does not have any 
adverse effect on the purified prolyl endopeptidase activity.
Prolyl endopeptidase was also stored in a number of different buffers, in order to assess their 
effects on its activity. It was shown earlier (Fig. 3.29) that purified PE activity showed a 
preference for potassium phosphate, pH 7.4, and was least active in Tris-HCI. This same 
preference was displayed when the purified PE was dialysed into three different buffers- 
HEPES, Imidazole and Tris-HCI, and was then frozen at -20’C in these buffers (Fig. 3.37). The 
PE activity in HEPES and Imidazole was only 10% less than that in 100mM potassium 
phosphate, but the PE activity when frozen in Tris-HCI dropped by 25% of the original.
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3.10.7. The Substrate Specificity of the Thyroliberin-Degrading Activities from 
the Synaptosomal Membranes of Bovine Brain.
3.10.7.1. The substrate specificity of the synaptosomal PAP
The substrate specificity of the purified synaptosomal PAP was investigated by HPLC based on 
a method by Martini et al. (1985) and modified by Griffiths (1993). A chromatogram showing the 
cleavage of TRH by the purified synaptosomal PAP is shown in Fig. 3.38. The cleavage 
products retention times were compared to those of standards and were identified as cyclo(His- 
Pro) and pyroglutamic acid. The retention time of pyroglutamic acid was only 2.5 mins and so it 
was easy to detect its production. The production of <Glu indicated that cleavage of the 
substrate occurred by PAP, as it is the only enzyme capable of cleaving the <Glu-His bond. 
Table 3.13 shows the complete range of substrates which were assayed for cleavage by 
synaptosomal PAP. As can be seen, PAP purified from the synaptosomal membranes of 
bovine brain, displays the same narrow substrate specificity as the PAP type II from guinea-pig 
brain (O'Connor and 0 ’Cuinn,1985). Synaptosomal PAP will only cleave the tripeptide <Glu- 
His-ProNH2 or very closely related peptides such as <Glu-His-Trp (LHRH 1-3), <Glu-His-ProOH 
(acid thyroliberin ) or <Glu-(Me)His-ProNH2 (a thyroliberin analogue). Another thyroliberin 
analogue <Glu-ProNH2 was not cleaved, showing the absolute requirement for a <Glu-His in the
first and second position. Longer peptides such as neurotensin, bombesin and LHRH were not 
cleaved, despite the fact that PAP will cleave LHRH(1-3). Even the short dipeptide <Glu-His was 
not cleaved, showing how PAP has a specificity for tripeptides. <Glu-His-Gly (the anorexogenic 
peptide) was not cleaved either, even though it appears to fulfil the requirements for cleavage 
by PAP i.e. it is a tripeptide with <Glu-His in the first two positions. The glycine in the third 
position instead of the cyclic proline (or the cyclic tryptophan in LHRH 1-3) may be the reason 
for this lack of cleavage by the synaptosomal PAP.
3.10.7.2. The substrate specificity of the synaptosomal prolyl endopeptidase
Prolyl endopeptidase was shown to have a broad specificity when it was purified from the 
cytosolic fraction of rat (Andrews et al., 1982) and bovine (Yoshimoto et al., 1983) brains. Since 
a particulate PE has not previously been characterized, it was of interest to investigate whether 
the particulate PE from bovine brain would display a similar broad substrate specificity to its 
cytosolic counterpart. Fig. 3.39 shows how the cleavage products of thyroliberin incubated with 
prolyl endopeptidase are resolved by HPLC. The production of acid thyroliberin is clear and 
separates well from thyroliberin. The cleavage of a number of proline-containing peptides was 
also investigated by TLC and the cleavage products were visualised by Pauly’s reagent and 
Ninhydrin.
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+ indicates that cleavage of the peptide occurred 
-  Indicates that cleavage of the peptide did not occur
Substrate Number of Amino 
Acids
Cleavage of 
the Substrate
<Glu-His 2
-
Thyroliberin Analogue 
<Glu-ProNH2 2 -
Thyroliberin
<Glu-His-ProNH2 3 +
Acid Thyroliberin 
<Glu-His-ProOH 3 +
LHRH(1-3)
<Glu-His-Trp 3 +
Thyroliberin Analogue 
<Glu-(Me)His-ProNH2 3 +
Anorexogenic peptide 
<Glu-His-Gly 3 -
LHRH
<Glu-His-Trp-Ser- 10
-
Neurotensin (1-4) 
<Glu-Leu-Tyr-Glu- 13
-
Bombesin (1-4) 
<Glu-Gln-Arg-Leu- 14 -
Table 3.14 shows a range of substrates which were cleaved by the synaptosomal PE. The 
substrate specificity of the PE was examined before and after its release from the membrane, to 
ensure that the solubilisation of the enzyme did not affect its physiological activity. PE has a 
very broad specificity and cleaved all of the proline-containing peptides shown. Bombesin, a 
neuropeptide without a proline moiety was included to demonstrate the requirement for a
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proline for cleavage by PE. It is of interest to note the cleavage points of the substrates with 2 or 
more proline moieties. In the case of bradykinin, PE cleaves the Pro^-Gly^ and Pro^-Phe® 
bonds and not the Pro^-Pro® bond. For substance P, PE cleaves the Pro^-GIn^ bond and not
the Pro^-Lys® bond. This demonstrates a certain level of specificity which was previously 
reported by Camargo et al. (1979) for the cytosolic PE. They described the PE as an endo- 
oligopeptidase with a specificity toward small peptides. This specificity appears to be solely 
dependent on peptide size and there is no evidence to suggest that the bovine synaptosomal 
PE has a requirement for a basic amino acid prior to the proline moiety as described by Tate 
(1981) for bovine cytosolic PE. While some of the peptides do have a basic amino acid prior to 
the proline (eg thyroliberin, LHRH, neurotensin, angiotensin and substance P), others do not 
including bradykinin and the specific PE substrate Z-Gly-ProMCA. Vasopressin and oxytocin 
which have also been reported to be cleaved by the cytosolic PE (Welches et al., 1993) do not 
have a basic amino acid prior to the proline either.
Table 3.14 Substrate Specificity of the Purified Synaptosomal PE Activity
+ Indicates that cleavage of the peptide occurred 
-  Indicates that cleavage of the peptide did not occur
Peptide Position of 
Cleavage
Synaptosomal
Membrane-Bound
PE
Purified PE
Thyroliberin
<Glu-His-ProNH2
Pro3-NH2
+ +
LHRH
<Glu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2
Pro9-Gln10
+ +
Neurotensin
<Glu-Leu-Tyr-Glu-Asn-Lys-
Pro-Arg-Arg-Pro-Tyr-lle-LeuNH2
Pro7-Arg8 
Pro10-Tyr11
+ +
Angiotensin II 
Asp-Arg-Val-Tyr-lle-His-Pro-Phe
Pro7-Phe8
+ +
Bradykinin
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
Pro3-Gly4
Pro7-Phe8 + +
Bradykinin (1-7) 
Arg-Pro-Pro-Gly-Phe-Ser-Pro
Pro3-Gly4
+ +
Substance P 
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-
Pro4-Gln5
+ +
Bombesin
<Glu-Gln-Arg-Leu-Gly-Asn-
Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2
No Proline
m
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Fig. 3.39. HPLC Profile of Synaptosomal PE Activity on Thyroliberin
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3.10.8. Preliminary Kinetic Studies on the Synaptosomal Thyroliberin- 
Degrading Activities
3.10.8.1. Preliminary kinetic studies on the purified synaptosomal PAP
The kinetics of hydrolysis of <Glu-His-ProMCA by the purified synaptosomal PAP were 
examined as outlined in section 2.14. As shown in Fig. 3.40a, the hydrolysis of the synthetic 
substrate, <Glu-His-ProMCA was found to obey normal Michaelis-Menten kinetics and Km and 
Vmax values of 100|iM and 0.85nmol/min/mg respectively were calculated. The Lineweaver- 
Burk plot had a correlation coefficient of 0.99. The effect of the presence of a variety of 
peptides containing N-terminal pyroglutamyl residues, on the hydrolysis of <Glu-His-ProMCA by 
the purified synaptosomal PAP were examined.
The data resulting from this study was fitted to three types of plots, the Lineweaver-Burk, the 
Eadie-Hofstee and the Hanes-Woolf plot to compare the results (Figs. 3.40a-c). The use of the 
Lineweaver-Burk, although the most common, has been widely criticised (Henderson, 1992) as 
it groups the data points close to the origin and ignores the weighting of points. Both the Eadie- 
Hofstee and the Hanes-Woolf plots are preferable as both involve only one recipricol value, and 
are used in this case to confirm the findings of the Lineweaver-Burk plots. Table 3.15a shows 
the results when the data was fitted to the Lineweaver-Burk plot. The most unusual feature was 
the presence of several non-competitive inhibitors, especially acid thyroliberin and the 
thyroliberin analogue, <Glu-(Me)His-ProNH2 . Due to their similarity in structure to thyroliberin, a
competitive inhibition may have been expected. Their high Ki values indicate that they are not 
as effective inhibitors as may have been anticipated either. When compared to the synthetic 
peptides <Glu-His-Gly and <Glu-His-Trp, whose Kis are 10 fold lower than those of acid 
thyroliberin and <Glu-(Me)His-ProNH2 , they appear to be quite ineffective. However, the Ki
value for acid thyroliberin is still in the nM range and so must be considered to be an effective 
inhibitor.
Previously characterised synaptosomal PAP activities (O'Connor and O’Cuinn, 1985) have 
demonstrated a very high affinity for LHRH and thyroliberin (20pM and A2\M respectively), but 
the Ki values obtained from the synaptosomal PAP activity in bovine brain are at least an order of 
magnitude lower for the same two peptides (6.6 and 0.72|iM respectively).
The dipeptide <Glu-His was the only non-competitive inhibitor found for the synaptosomal PAP 
from guinea-pig brain (O’Connor and O’Cuinn, 1985), and again for the bovine brain 
synaptosomal PAP it was found to be an effective non-competitive inhibitor with a Ki of 1.2yM. 
Looking at the results from the Eadie-Hofstee plots (Fig. 3.15b), the first notable difference was 
the reduced number of non-competitive inhibitors. Only LHRH and <Glu-His were found to be 
non-competitive inhibitors and this finding was later confirmed by the Hanes-Woolf plots (Fig. 
3.15c). The synthetic peptides <Glu-His-Gly and <Glu-His-Trp again were seen to be very 
effective competitive inhibitors with Kis of 0.38p.M and 0.53(iM respectively. These Kis were 
even lower than those obtained by the Lineweaver-Burk plots and seem to indicate that 
synaptosomal PAP has an even higher affinity for these peptides than originally thought.
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Fig. 3.40a. Lineweaver-Burk Plot for Synaptosomal PAP with <Glu-His 
ProM CA
(Error bars represent S.E.M. = 3/ V n, where 3 = standard deviation and n = number of samples)
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Fig. 3.40b. Eadie-Hofstee Plot for Synaptosomal PAP with <Glu-His-ProMCA
(Error bars represent S.E.M. = 3/ V n , where 3 = standard deviation and n = number of samples)
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Fig. 3.40c. Hanes-Woolf Plot for Synaptosomal PAP with <Glu-His-ProMCA
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Thyroliberin also was shown to be an effective competitive inhibitor of the synaptosomal PAP 
activity with a Ki of 0.45(iM, again lower than was estimated with the Lineweaver-Burk plot 
(0.72|iM). The acid thyroliberin and the thyroliberin analogue once more had higher Ki values 
than some of the other synthetic peptides (4.2 and 2.6fiM respectively), but these figures were 
also lower than those estimated with the Lineweaver-Burk plots. A final comparison was made 
by fitting the data to the Hanes-Woolf plot, believed by some to be the most accurate of the 
three (Endrenyi and Kwong, 1972). A similar order was found using this method as had been 
seen with the other two methods. This method confirmed the findings of the Eadie-Hofstee 
that only two of the peptides were in fact non-competitive inhibitors, LHRH and <Glu-His. The 
fact that the Lineweaver-Burk plot seemed to indicate that there were more non-competitive 
inhibitors than those two, can be explained by the errors involved in using that method of 
presenting data. The synthetic peptides, <Glu-His-Gly and <Glu-His-Trp were again found to be 
the most competitive inhibitors with Ki values of 0.99 and 1.126nM respectively. Also the 
thyroliberin analogue, <Glu-(Me)His-ProNH2 was found to be the least effective inhibitor, 
although it had a Ki value of 7.9|iM. In Figs 3.41, 3.42 and 3.43, there is an example of a 
competitive (thyroliberin) and a non-competitive (LHRH) inhibitor, as plotted by each of the three 
methods.
The overall result seems to indicate the presence of two non-competitive inhibitors, LHRH and 
<Glu-His for the synaptosomal PAP activity and all the others appear to be competitive inhibitors. 
One unusual feature of these preliminary studies is the fact that thyroliberin analogue, <Glu- 
(Me)His-ProNH2 does not compete as effectively as some of the synthetic peptides for the
synaptosomal PAP activity. The most remarkable feature of these results is the fact that the Ki 
values are so low, indicating a highly specific enzyme.
Table 3.15 Activity of Synaptosomal PAP Towards Thyroliberin and Other 
Peptides
C = Competitive NC = Non competitive
Table 3.15 (a) Inhibition constants using Lineweaver-Burk plots
Peptide Whether
Hydrolysed
Inhibition Ki (jiM)
<G lu-His-Gly - C 0.45
<G lu -H is -Trp + C 0.60
Thyroliberin + C 0.72
<Glu-His - NC 1.20
Bombesin - C 3.00
Neurotensin - C 5.93
LHRH - NC 6.60
<Glu-ProNH2 - NC 7.40
Acid Thyroliberin + NC 7.50
<G lu-(M e)His-ProNH 2 + NC 8.40
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T a b l e  3 . 1 5  ( b )  I n h i b i t i o n  c o n s t a n t s  u s i n g  E a d i e - H o f s t e e  p l o t s
Peptide Whether
Hydrolysed
Inhibition Ki (nM)
<Glu-His-Gly - C 0.38
Thyroliberin + C 0.45
<Glu-His - N C 0.45
<G lu-H is-Trp + C 0.53
LHRH - N C 1.01
<Glu-(M e)His-ProNH2 + C 2.60
Bombesin - C 3.50
Neurotensin - C 3.80
Acid Thyroliberin + C 4.20
<Glu-ProNH2 - C 4.75
Table 3.15 (c) Inhibition constants using Hanes-Woolf plots
Peptide Whether
Hydrolysed
Inhibition Ki (|J.M)
<Glu-His - NC 0.82
<Glu-His-Gly - C 1.00
<G lu -H is-Trp + C 1.13
Bombesin - C 1.95
Thyroliberin + C 1.98
LHRH - NC 4.03
Acid Thyroliberin + C 6.20
Neurotensin - C 6.73
<Glu-ProNH2 - C 6.76
<Glu-(M e)His-ProNH2 + C 7.90
1 4 2
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(Error bars represent S.E.M. = 8/ V n , where 5 = standard deviation and n = number of samples)
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O Lineweaver Burk Plo t  ■with ImM <Glu—His—ProMCA 
•  Lineweaver Burk Plot  with  ImM Thyroliberin
Fig. 3.41b. Non-Competitive Inhibition of Synaptosomal PAP by LHRH 
(Lineweaver-Burk Plot)
1 / [ S u b s t r a t e ]  (1 / /xM)
O Lineweaver Burk Plot  with ImM <Glu—His—ProMCA 
•  Lineweaver Burk Plot  with ImM LHRH
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(Error bars represent S.E.M. = 3/ V n , where d = standard deviation and n = number of samples)
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Fig. 3.42b. Non-Competitive Inhibition of Synaptosomal PAP by LHRH (Eadie- 
Hofstee Plot)
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•  H a n es—Woolf Plot  with <Glu—His-ProMCA 
V H a n es—Woolf Plot  with ImM Thyroliberin
Fig. 3.43b. Non-Competitive Inhibition of Synaptosomal PAP by LHRH 
(Hanes-Woolf Plot)
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3.10.8.2. Preliminary kinetic studies on the purified synaptosomal PE
As with the synaptosomal PAP, the data resulting from these preliminary kinetic studies on the 
purified synaptosomal PE was fitted to the three different plots, the Lineweaver-Burk, the 
Eadie-Hofstee and the Hanes-Woolf plot (Fig. 3.44a-c) Synaptosomal PE had a Km of 60jiM for 
the substrate Z-Gly-ProMCA and a Vmax of 747.3nmol/min/mg. The Ki values resulting from the 
three plots correlated very well (Tables 3.16a-c). The non-competitive inhibitors, bradykinin, 
angiotensin II and substance P had the lowest Kis in all cases. The most effective competitive 
inhibitor was LHRH which had Ki values between 0.51 and 0.74jiM depending on the plot. 
Thyroliberin and acid thyroliberin were the two substrates with the highest Ki values regardless 
of the plot used to present the data. The values obtained with the Eadie-Hofstee and 
Lineweaver-Burk plots are quite close to the Km values which can be seen from Tables 3.16a-c, 
when the two plots became almost indistinguishable (Fig. 3.46a). Even though a synaptosomal 
PE activity has never been characterised to date, the cytosolic PE has been studied in detail 
from several sources. It appears to have a high affinity for Angiotensin II, Bradykinin, Substance 
P and Neurotensin, with less affinity for TRH and LHRH (Welches et al., 1993). The actual Ki 
values for the natural peptides with the cytosolic PE are all approximately 10-fold higher than 
those estimated for the synaptosomal PE (Table 3.16a), thus making the synaptosomal 
membrane-bound PE a far more specific enzyme, which may be as a result of its association with 
the membrane. A comparison of the three types of plots, each showing a competitive and a 
non-competitive inhibitor are shown in Fig. 3.45-3.47.
Fig. 3.48 shows the Lineweaver-Burk plot for PE with the thyroliberin substrate, <Glu-His- 
ProMCA. For <Glu-His-ProMCA, PE had a Km of 72.6pM and a Vmax of 418.4nmol/min/mL.
Table 3.16 Activity of Synaptosomal PE Towards Thyroliberin and Other 
Peptides
Table 3.16 (a) Inhibition constants using Lineweaver-Burk plots
Peptide Whether
Hydrolysed
Inhibition Ki (nM)
Bradykinin + NC 0.15
Angiotensin II + NC 0.18
Neurotensin + NC 0.25
Substance P + NC 0.64
LHRH + C 0.74
Acid Thyroliberin - C 22.85
Thyroliberin + C 44.93
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Flg. 3.16 (b) Inhibition constants using Eadie-Hofstee plots
Peptide Whether
Hydrolysed
Inhibition Ki (^M)
Bradykinin + NC 0.10
Angiotensin II + N C 0.11
Neurotensin + N C 0.14
LHRH + C 0.60
Substance P + NC 0.79
Acid Thyroliberin - C 9.80
Thyroliberin + C 53.07
Fig. 3.16 (c) Inhibition constants using Hanes-Woolf plots
Peptide Whether
Hydrolysed
Inhibition Ki (fiM)
Bradykinin + NC 0.17
Angiotensin II + NC 0.18
Neurotensin + NC 0.33
LHRH + C 0.51
Substance P + NC 0.52
Acid Thyroliberin - C 7.40
Thyroliberin + C 11.70
1 4 7
Fig. 3.44a. Lineweaver-Burk Plot for Synaptosomal PE with Z-Gly-ProMCA
(Error bars represent S.E.M. = 3/ V n , where 8 = standard deviation and n = number of samples)
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Fig. 3.44b. Eadie-Hofstee Plot for Synaptosomal PE with Z-Gly-ProMCA
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Fig. 3.44c. Hanes-Woolf Plot for Synaptosomal PE with Z-Gly-ProMCA
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Fig. 3.45b. Non-Competitive Inhibition of Synaptosomal PE by Bradykinin 
(Lineweaver-Burk Plot)
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Fig. 3.46b. Non-Competitive Inhibition of Synaptosomal PE by Bradykinin 
(Eadie-Hofstee Plot)
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Fig. 3.47b. Non-Competitive Inhibition of Synaptosomal PE by Bradykinin 
(Hanes-Woolf Plot)
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Fig. 3.48. Lineweaver-Burk Plot for Synaptosomal PE with <Glu-His-ProMCA
(Error bars represent S.E.M. = 3/ V n , where 3 = standard deviation and n = number of samples)
a)
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3.10.9. Effect of Functional Reagents on the Thyroliberin-Degrading Activities 
of the Synaptosomal Membranes of Bovine Brain
3.10.9.1. Effect of inhibitors on the synaptosomal PAP activity
The synaptosomal membrane-bound, Triton X-100-solubilised and the purified synaptosomal 
PAP activities were Incubated with a range of functional reagents as described in section 2.16. 
The effects of these reagents on PAP activity are shown in Table 3.17. There was no significant 
difference in the effect of the functional reagents on the profile between the synaptosomal 
membrane-bound PAP and the solubilised activity.
1. The Sulphydtyl Reagents: 2- lodoacetamide, iodoacetate, N-ethylmaleimide and PCMB were 
all found to be inhibitors to some extent of the synaptosomal PAP activity. At both 1 and 10mM 
concentrations, iodoacetamide and iodoacetate inhibited the PAP activity by over 90% for the 
purified enzyme. N-ethylmaleimide was the least inhibitory of the sulphydryl reagents, yet even 
at 1 mM it inhibited 50% of the PAP activity. PCMB at 1 mM concentration, completely inhibited 
the enzyme whether membrane-bound or purified. It was less effective at 0.1 mM 
concentration,causing only 30% inhibition of the purified enzyme. The inhibitory effects of 
these sulphydryl reagents on the synaptosomal PAP activity indicates that this PAP contains a 
thiol group essential for Its activity.
2. The Metal Chelators: 1,10-phenanthroline proved to be an effective PAP inhibitor. At 1 mM it 
inhibited the PAP activity (whether membrane-bound, Triton X-100-solubilised or purified) by 
over 90%. At 0.1 mM , it was not quite as effective. The other two metal chelators-8- 
hydroxyquinoline and EDTA, were not found to be inhibitors of the enzyme activity. They both 
inhibited up to 35% of the PAP activity, but were not as potent as 1,10-phenanthroline at either 
of the two concentrations examined.
3. The Serine Protease Inhibitors: Benzamidine and PMSF were not particularly potent 
inhibitors of the synaptosomal PAP. At best 10mM benzamidine inhibited only 35% of the 
Triton X-100-solubilised PAP activity. Because these inhibitors have little or no effect on the 
PAP activity, it can be concluded that PAP must not have an essential serine group in its 
structure.
N-acetylimidazole is a functional reagent with a preference for phenolic groups, but it will also 
react with His, Tyr and Cys residues. It is not a strong inhibtior of the synaptosomal PAP and 
only inhibits the purified enzyme by 30% even at 10mM concentration.
4. Puromycin and Bacitracin: Two protease inhibitors of microbial origin, puromycin and 
bacitracin, were also incubated with the synaptosomal PAP to assess their effects on the 
enzyme’s activity. At 1 and 0.1 mM concentration the puromycin inhibited the Triton X-100- 
solubilised PAP by up to 25%. However the membrane-bound PAP was inhibited by over 50% 
by 1 mM puromycin. The reason for this inhibition is not clear, but the solubilizing action of the 
Triton X-100 of the PAP from the membrane affords it some protection against the inhibitory 
actions of puromycin.
The specific prolyl endopeptidase inhibitor, Z-Pro-prolinal, had no effect on the synaptosomal 
PAP activity.
1 5 4
T a b l e  3.17 In h ib ito r  Profile of Part iculate  P y r o g l u ta m a te  
Am inopeptldase Activity
* Concentration of Bacitracin was 500 units of activity 
** S.D. Calculated for triplicates using V (x2) - (x  )2 where X = reading
Inhibitor Cone (mM) Purified Particulate PAP 
(as a % of that in 
control)
“ (+/-S.D.)
lodoacetamide 1 0 4.91 (+/- 0.25)
1 7.85 (+/-0.31)
lodoacetate 1 0 4.00 (+/-0.15)
1 5.10 (+/-0.20)
N-Ethylmaleimide 1 0 14.26 (+/-3.60)
1 52.71 (+/-9.40)
PCMB 1 0. 000
0.1 68.50 (+/-4.80)
Benzamidine 1 0 77.75 (+/-13.1)
1 75.35 (+/-7.90)
PMSF 1 72.95 (+/-1.05)
0.1 71.9 (+/-6.80)
N-Acetylimidazole 1 0 70.3 (+/-5.13)
1 81.35 (+/-2.3S)
1,10-Phenanthroline 1 0 7.22 (+/-6.10)
1 71.9 (+/-0.87)
8-Hydroxyquinoline 1 65.0 (+/-3.05)
EDTA 10 78.0 (+/-9.00)
1 88.0 (+/-2.20)
Puromycin 1 81.3 (+/-4.20)
0.1 83.9 (+/-2.50)
Bacitracin
*
27.5 (+/-2.50)
Z-Pro-prolinal 0.1 100.000
1 5 5
3.10.9.2. Effect of inhibitors on the synaptosomal PE activity
As for the synaptosomal PAP, the synaptosomal PE was assayed in the presence of a range of 
functional reagents at three different stages, membrane-bound, Triton X-100-solubilised and 
purified PE. The results of these tests on the purified enzyme are shown in Table 3.18.
1. The Thiol Protease Inhibitors: 2-lodoacetamide, iodoacetate, PCMB and N-ethylmaleimide 
were the first group to be investigated for their effects on PE. Neither 2-iodoacetamide or 
iodoacetate were strong inhibitors of the PE activity. 2-lodoacetamide inhibited the purified 
enzyme up to 40% at a concentration of 10mM, while at 1 mM it had no effect. Iodoacetate was 
less effectve- at 10mM it only inhibited 30% of the purified PE activity and caused no inhibition 
of the membrane-bound or Triton X-100-solubilised enzyme's activity at 10mM or 1mM 
concentrations (results not shown). PCMB and N-ethylmaleimide were very effective inhibitors 
of PE both at the membrane-bound and solubilised stages. PCMB completely inactivated the 
PE activity, with only 5and 10% activity remaining for the purified enzyme at 10 and 1mM 
concentrations respectively. N-ethylmaleimide was less effective at the lower concentration 
(1mM), but still inhibited 35% of the purified PE’s activity.
2. The Metal Chelators: 1,10-phenanthroline completely inactivated the purified enzyme at 
10mM concentration and only 12% activity remained after 1mM 1,10-phenanthroline. At the 
higher concentration, it inhibited 65% of the membrane-bound and Triton X-100-solubilised PE 
activities, but was less effective at 0.1 mM for these two stages (results not shown). EDTA did 
not cause any significant inhibition of the PE at any concentration. 8-hydroxyquinoline however 
proved to be quite a strong inhibitor of the purified enzyme at the 10mM concentration, 
inhibiting its activity by over 60%. It was far less effective at lower concentrations or when the 
enzyme was still membrane-bound.
3. The Serine Protease Inhibitors: Benzamidine and PMSF did not cause any significant 
inhibition of the PE activity at any concentration.
4. The Microbial Protease Inhibitors: Puromycin and bacitracin, were also assessed for their 
efficacy as PE inhibitors. At 1 mM concentration puromycin inhibited the purified PE activity by 
43%, but was quite ineffective at 0.1 mM. Bacitracin, at 500 units of enzyme activity, was quite 
an effective inhibitor as it inhibited both the membrane-bound and the Triton X-100-solubilised 
PE activities by 60%. N-acetylimidazole was not a strong inhibitor, as it only inhibited the purified 
enzyme by 24% even at 10mM concentration. Z-Pro-prolinal, the specific prolyl endopeptidase 
inhibitor, completely inactivated the PE activity, whether membrane-bound or solubilised at
10'4M.
While the thiol protease inhibitors proved to be the most effective inhibitors of the synaptosomal 
PE activity, suggesting that the PE has an essential thiol group at its active site, the metal 
chelator 1,10-phenanthroline, when present in even low concentrations is very effective in 
inactivating the PE activity. This inactivation by a metal chelator may suggest the requirement for 
a metal for PE activity. This idea is strengthened by the 60% inactivation of the purified PE’s 
activity by 10mM 8-hydroxyquinoline.
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Table 3.18 Inhibitor Profile of Particulate Prolyl Endopeptidase Activity
* The concentration of Bacitracin used was 500 units of activity 
** S.D. Calculated for triplicates using V (x2) - ( x )2 where X = reading
Inhibitor Cone (mM) Purified Synaptosomal PE 
(Activity as a % of that in 
Control)
**(+/-S. D.)
2-lodoacetamide 1 0 59.70 (+/-4.93)
1 101.4 (+/-13.77)
lodoacetate 1 0 70.44 (+/-1.03)
1 79.60 (+/-3.50)
PCMB
1 0 5.40 (+/-0.60)
1 10.8 (+/-0.90)
N-Ethylmaleimide 1 0 0.79 (+/-0.03)
1 65.5 (+/-0.80)
Benzamidine 1 0 81.8 (+/-S.57)
1 87.7 (+/-11.3)
PMSF 1 94.17 (+/-0.90)
0.1 87.17 (+/-7.90)
1,10-Phenanthroline
1 0 0.00
1 12.25 (+/-1.46)
EDTA 1 0 86.40 (+/-2.83)
1 101.5 (+/-0.10)
8-Hydroxyquinoline 10 39.02 (+/-3.42)
1 95.12 (+/-8.50)
Puromycin 1 57.34 (+/-2.02)
0.1 100.5 (+/-1.90)
Bacitracin * 37.9 (+/-2.00)
N-Acetylimidazole 1 0 76.72 (+/-10.5)
1 98.32 (+/-8.90)
Z-Pro-prolinal 0.1 0.00
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3.10.10. Effect of ED T A  and D TT  on the Thyroliberin-Degrading 
Synaptosomal Activities
3.10.10.1. Effect of EDTA and DTT on the synaptosomal PAP activity
Due to the previously reported synaptosomal PAP activities being strongly inhibited by EDTA 
and DTT, even at 1mM concentrations (O’Connor and O'Cuinn, 1984; Friedman and Wilk, 1986; 
Wilk and Wilk, 1989), the bovine synaptosomal PAP was assayed in the presence of a range of 
concentrations of EDTA and DTT to see if the enzyme's activity was effected at any 
concentration. Fig. 3.49 shows how the synaptosomal PAP activity remains constant regardless 
of EDTA concentration. The inclusion of DTT however had a dramatic effect on PAP activity. 
The addition of 1 mM DTT increased PAP activity by 40%. This rise in activity did not continue 
with increasing DTT concentration, the maximum enzyme activity was achieved in the presence 
of 1 mM DTT.
3.10.10.2. Effect of EDTA and DTT on synaptosomal PE activity
Prolyl endopeptidase from the synaptosomal membranes of bovine brain was incubated with a 
range of EDTA and DTT concentrations. The enzyme's activity was hardly effected across the 
range of EDTA, it maintained its activity between 1.6 and 1.65nmol/min/mL regardless of EDTA 
concentration (Fig. 3.50). There is only a slight increase in PE activity following the inclusion of 
DTT - the PE increases from 1.5 to 1.6nmol/min/mL with 1mM DTT, but does not increase with 
increasing DTT concentration.
3.10.11. Effect of Metal Ions on the Synaptosomal Thyroliberin-Degrading 
Activities
3.10.11.1. Effect of metal ions on synaptosomal PAP activity
Even though the synaptosomal PAP from bovine brain was not behaving as a classical 
metalloenzyme (see Table 3.18), it was previously reported that the synaptosomal PAP from 
other sources did have an essential metal in its active site (Czekay and Bauer, 1993). For this 
reason, the effect of a series of 1mM concentration metal ions was investigated (Fig.3.51).
Zn2+, Co2+, Fe2+ and Ag2+ were very inhibitory of the PAP activity, but none of the other 
metals tested had strong inhibitory action. In fact, Li+, Fe^+, Ca2+ and K+ all sightly increased 
the PAP's activity.
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Fig. 3.49. Effect of EDTA and DTT on Purified Synaptosomal PAP Activity
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Fig. 3.51 Effect of 1mM Metal Ions on Purified Synaptosomal PAP Activity
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3.10.11.2. Effect of metal ions on synaptosomal PE
Purified synaptosomal PE was found to be inhibited by 2 metal chelators, 1,10-phenanthroline 
and 8-hydroxyquinoline at high concentrations, suggesting that it had a requirement for a metal
in its active site (Fig. 3.52). Zn2+, Co2+, Cu2+ and Cd2+ were all strong inhibitors of the PE 
activity at 1mM concentration, while none of the metals tested increased the PE activity. The 
metal ions had a far greater effect on the prolyl endopeptidase activity than they had on the 
synaptosomal PAP.
K+ Na+Fe3+ Zn2+ Co2+ Fe2+ Ag2+ Li+ Ca2+Cu2+Mn2+Mg2+Cd2+
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Fig. 3.52 Effect of 1mM Metal Ions on Purified Synaptosomal PE Activity
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4. Discussion
4. Discussion
Since its discovery in 1968 (Doolittle and Armentrout, 1968), cytosolic pyroglutamate 
aminopeptidase (E.C. 3.4.19.3) has been known for its cleavage of the N-terminal pyroglutamyl 
from a wide range of peptides. For this reason the substrate routinely used for the detection of 
soluble PAP activity has been <Glu-MCA (Fujiwara and Tsuru, 1978). In 1984, when the first 
particulate pyroglutamate aminopeptidase activity (E.C. 3.4.9.-) was discovered in guinea pig 
brain (O’Connor and O’Cuinn, 1984), it was only detectable with thyroliberin as a substrate, as it 
did not cleave <Glu-MCA. In the early 1980’s Bauer and Kleinkauf (1980) had developed an 
assay capable of detecting PAP activity, which was based on its ability to degrade thyroliberin. 
Using radiolabelled thyroliberin as a substrate, they developed an assay that was sensitive and 
accurate for the quantitation of particulate PAP activity. However it was also time-consuming, 
complex and expensive. It was not until 1986 when Friedman and Wilk began using a 
chromogenic substrate for particulate PAP activity that the investigation began into new assay 
systems. They used the substrate <Glu-His-Pro-2naphthyl amide (NA) to detect particulate PAP 
activity. Unfortunately the cleavage of the <Glu-His bond solely will not allow the release of the 
chromophore, the Pro-2NA bond also needs to be cleaved. Friedman and Wilk counteracted 
this problem by the introduction of DAP IV into the reaction sequence, thereby developing the 
assay as a coupled-enzyme assay. However the Pro-2NA bond is susceptible to cleavage by a 
prolyl endopeptidase, and therefore a specific PE inhibitor, Z-Pro-prolinal also had to be 
included in the reaction mixture. While this assay system held distinct advantages over the 
radiolabelled thyroliberin assay, in that it was faster, more economical and did not involve the use 
of radioactivity, it also had some disadvantages. The use of the second enzyme, DAP IV was a 
problem as this enzyme was not available commercially and so had to be purified to 
homogeneity in the laboratory prior to its use in the assay system. In addition, the use of 
naphthylamides has been restricted due to their identification as carcinogens. For these 
reasons, the development of a new fluorimetric substrate by Bachem in 1989 opened the 
pathway for new assay systems specifically designed for the detection of particulate PAP 
activity. This new substrate was <Glu-His-ProMCA which had a 7-amino-4-methyl coumarin label 
attached. The MCA is highly fluorescent, leading to a far more sensitive reading than any 
chromophore could yield. It is also more economical to use as only picomolar quantities are 
required for detection. However this substrate also requires the use of DAP IV for the cleavage 
of the Pro-MCA. DAP IV was purified in the laboratory from rat liver (section 2.4) and Z-Pro- 
prolinal, the specific PE inhibitor was kindly donated by Sherwin Wilk.
The initial experiments involved the establishment of the assay parameters. By varying the 
concentrations of substrate, PAP and DAP IV, the optimum conditions for the detection of PAP 
activity were established. PAP activity from rat liver cytosol (purified in the laboratory) was used 
as a positive control for all the initial assays as the commercially available PAP activity was found 
to be inconsistent and unreliable in its activity levels and stability. In order to yield valid results a
4.1. Development of a new fluorimetric assay for the detection of
particulate PAP activity
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number of criteria had to be ensured:
1. The substrate and coupling-enzyme (DAP IV) concentration should never become rate- 
limiting.
2. There should never be inhibitors of the enzyme (PAP) present in the reaction mixture.
3. All the environmental factors such as pH, temperature and ionic strength should be 
controlled.
4.1.1. The fluorimetric coupled enzyme assay
The assay used 100nL of sample with 400^L of 0.1 mM <Glu-His-ProMCA. These quantities 
ensured that neither the substrate nor the enzyme were limiting the reaction. 20(j.L of 10'5 M Z- 
Pro-prolinal was included in the reaction to ensure that any PE activity present would be 
inhibited. This inhibition was shown to be comprehensive (Fig. 3.3) and not time dependent 
(Fig. 3.4).
The coupling enzyme, DAP IV, was the final ingredient in the reaction mixture to be 
investigated. If assays of this type are to yield valid results it is essential that the coupling 
enzyme never becomes rate-limiting so that the measured rate is always determined by the 
activity of the enzyme under investigation. Fig. 3.5 shows how the amount of DAP IV was varied 
to assess its effects on MCA release. 40(iL of DAP IV was found to be sufficient to ensure that it 
was present in excess and that it would not limit the rate of reaction.
The spontaneous and non-enzymatic cyclisation of His-ProNH2 to yield His-Pro and a free 
amide group has been well documented (Prasad and Peterofsky, 1976; Prasad et al.,1987). 
Bungaard and Moss (1990) studied the kinetics of this cyclisation and found that the cyclisation 
proceeded at maximum rate in phosphate buffer between pH 6.9 and 7.4 at 37°C. The 
cyclisation of His-ProMCA was investigated in Fig. 3.6. In the absence of DAP IV, MCA was also 
released but the actual release of MCA was far lower, yielding only 30% of the MCA released 
when DAP IV is present in the reaction mixture. In order to encourage the spontaneous 
cyclisation mechanism and to ensure that the presence of DAP IV was not interfering with the 
measurement of any kinetic constants, the reaction was allowed to proceed for 60 mins, prior to 
the addition of the coupling enzyme DAP IV. Fig. 3.6 shows that after a further 60 mins the 
reaction has gone to completion, and the possibility of DAP IV interfering with the measurement 
of any kinetic parameters was eliminated.
The metal chelator, 1,10-phenanthroline, was found to be an effective synaptosomal PAP 
inhibitor, withot having any effect on the DAP IV activity. It was added to the reaction mixture at 
the same time as the DAP IV to ensure that there was no further PAP activity, and to allow the 
DAP IV to cleave the His-ProMCA which had been produced by the first enzymic reaction. The 
inclusion of the 1,10-phenanthroline guaranteed that the reaction went to completion. By 
taking all these parameters into account, it was ensured that neither the substrate nor the 
coupling enzyme were ever limiting the reaction, there could be no interference in the 
measurement of kinetic parameters by the coupling enzyme and the entire reaction went to 
completion within the assay time.
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The coupled-enzyme fluorimetric assay was found to be an improvement on the coupled- 
enzyme spectrophotometric assay developed by Friedman and Wilk (1986), as it is more 
sensitive, more economical and does not involve the use of any known toxic or carcinogenic 
substances. Its major disadvantage is the requirement for DAP IV, the coupling enzyme , as this 
enzyme is not available commercially and has to be purified in the lab prior to performing the 
assay.
4.1.2 Spontaneous cyclisation assay
If His-ProNH2 non-enzymatically cyclises to yield His-Pro + NH2 in vivo, was it not possible to
utilise this mechanism in an assay? This would eliminate the use of a coupling enzyme and the 
need for purifying DAP IV for the reaction. Bungaard and Moss (1990) showed that phosphate 
buffer pH 6-7.4 catalysed the cyclisation (t-|/2 of 140min at pH 6-7 at 37*C). By omitting DAP IV 
from the reaction mixture, it was shown that MCA was indeed released over time, however the 
quantities were quite low (Fig. 3.8). The possibility of stopping the reaction with a basic species 
to encourage the cyclisation reaction instead of an acid was considered, but at high pH 
fluoresence is quenched. The temperature after the reaction was stopped was varied in order 
to encourage the cyclisation of His-ProMCA to His-Pro and free MCA. Fig. 3.9 showed that 
although the levels of MCA released following 30 mins at 80°C increased greatly, there was also 
a considerable amount of MCA released due to degradation of the substrate at such a high 
temperature. In order for the spontaneous cyclisation reaction assay to yield valid results, it is 
important to monitor the degradation of the substrate in the 80°C waterbath. Taking this 
disadvantage into account, the spontaneous cyclisation assay is an efficient, sensitive and 
economical assay, and has the advantage over the coupled-enzyme assay of not requiring a 
second enzyme, DAP IV.
4.2. Pvroalutamate aminopeptidase activity in bovine brain
4.2.1. Demonstration of two PAP activities in bovine brain
Cytosolic and particulate PAP activity has been studied in several species including guinea-pig 
(O’Connor and O’Cuinn, 1984), rabbit (Wilk et al., 1988) and rat (Garat et al., 1985). In this study 
bovine brain was chosen as a source of the PAP enzymes due to its large size and its ready 
availability. It proved to be a source rich in enzyme activity, activity higher than in any other 
species previously studied. Initially the cytosolic and particulate fractions were examined for 
PAP activity using the <Glu-His-ProMCA substrate (in order to detect both types of PAP activity) 
in the absence and in the presence of DTT and EDTA. Cytosolic PAP characteristically was 
found to have a requirement for DTT for activity (Browne and O’Cuinn, 1983), and previously 
studied particulate PAP from rat, rabbit and guinea-pig showed that the particulate PAP activity 
was strongly inhibited in the presence of EDTA and showed no requirement for DTT (Garat et
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al., 1985; Wilk and Wilk, 1989; O'Connor and O'Cuinn, 1984). These differing requirements for 
the sulphydryl reagent and the metal chelator were typically used as a means of distinguishing 
between cytosolic and particulate PAP activity. It was interesting therefore to note that the first 
indication of the bovine PAP displaying a species difference lay in the fact that while the soluble 
PAP behaved characteristically by increasing its activity in the presence of DTT, the particulate 
PAP activity behaved totally out of character by actually increasing the level of its total activity 
from 26.1|imol/min to 66.26fimol/min in the presence of DTT and EDTA. This figure 
represented 35% of the total PAP activity in the crude homogenate. While these results were 
unusual it was too soon to comment, without first ensuring that all the increased activity was due 
to the particulate fraction, and was not due to some soluble PAP activity entrapped by the 
membranes. This possibility was examined in section 2.8.
4.2.2. Effect of osmotic shock
In order to release any soluble enzyme activity which may have become entrapped in vesicles 
formed by the membranes during the homogenisation procedure, an osmotic shock step was 
performed on the membranes to release any such activity following the initial salt wash. Van 
Amsterdam et al., (1983) claimed that many loosely and non-specifically membrane-associated 
proteins were mistaken for membrane-bound activities, due to insufficient washing of the 
membranes. They also suggested the use of osmotic shock to release any entrapped vesicles 
formed by the membranes during homogenisation which may be harbouring occluded enzyme 
activity. The results of such a step are shown in Tables 3.3 and 3.4. The particulate fraction was 
subjected to an osmotic shock step, when the pellet was resuspended with hand 
homogenisation in distilled water. One pellet was washed in buffer as a control. As can be seen 
in Table 3.3, there was no extra PAP activity released following washing with distilled H2O or 
with buffer, 95% of the activity remained in the particulate fraction. At this stage, following the 
initial salt-wash and the osmotic shock step, 23.7% of the original crude particulate PAP activity 
is still remaining in the particulate fraction, indicating that the activity is at least membrane- 
associated and not just loosely and non-specifically attached to the membranes.
4.2.3 Salt-washing of the membranes
Following osmotic shock, the membranes were subjected to a series of vigorous salt-washing 
steps with 4M NaCI. The purpose of the salt was to remove any loosely-bound proteins from the 
surface of the membranes, which were now fully exposed following the osmotic shock step, and 
to ensure that any remaining activity was definitely membrane-associated if not membrane- 
bound. Following the four salt washes 74% of the PAP activty remained in the particulate 
fraction. This figure represents 19% of the original crude particulate PAP activity which is still 
associated with the membranes.
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4.2.4. Subcellular localisation of the particulate P A P  activity of bovine brain
PAP activity had previously been localised in the synaptosomal membranes of guinea-pig 
(O’Connor and O’Cuinn, 1984), rabbit (Wilk and Wilk, 1989) and rat (Torres et al., 1986)brains. 
In order to investigate whether the bovine particulate PAP activity shared the same location or 
not, a combination of differential centrifugation and isopynic ultracentrifugation steps were 
employed. The salt-washed particulate fraction was divided into three fractions which were 
identified as the myelin, synaptosomal membranes and mitochondria by specific enzyme marker 
assays (section 3.5). The majority of the particulate PAP specific activity was enriched in the 
fraction identified as the synaptosomal membranes, with 75.8% of the salt-washed particulate 
PAP activity being associated with this fraction. Small levels of activity were also found in the 
myelin and mitochondria, which was probably due to the mixing of the three layers during their 
removal. Following salt-washing, osmotic shock and subcellular localisation, approximately 17% 
of the original crude particulate PAP activity is still remaining associated with the synaptosomal 
membranes.
4.2.5. Phase partitioning studies on the synaptosomal thyroliberin-degrading 
PA P  activity
The single-most important feature to ascertain about a membrane protein at the outset is its 
mode of association with the bilayer. Integral (or intrinsic) membrane proteins are integrated into 
the hydrophobic phase and require disruption of the phospholipid bilayer or cleavage of the 
polypeptide from its membrane anchor for its release. Integral membrane proteins are classified 
into four groups depending on the proportion of their structure that it is in contact with the 
hydrophobic phase of the bilayers (Fig.4.1) (Findlay, 1990).
Peripheral (or extrinsic) membrane proteins on the other hand, are associated with the 
membrane surface through interactions either with other proteins or with the exposed regions 
of phospholipid. An assay developed by Bordier (1981) was used to determine the exact 
nature of the synaptosomal PAP and PE activities. A non-ionic detergent, Triton X-114, was 
used to solubilise the membrane enzymes. During solubilisation the non-ionic detergent 
displaces most lipid molecules in contact with the hydrophobic domain of the integral membrane 
protein and leads to the formation of a soluble protein-detergent mixed miscelle. Above certain 
temperatures, referred to as cloud points, phase separation occurs until two clear phases are 
formed,detergent-depleted and detergent-enriched respectively . The hydrophobic integral 
membrane proteins are located primarily in the detergent-enriched phase and the peripheral 
membrane proteins are in the detergent-depleted phase. Using this method 60% of the 
synaptosomal PAP activity was located in the detergent-enriched phase, identifying it as an 
integral membrane-protein.
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Class I Class II Class III ClasslV
Fig. 4.1. Structural Types of Integral Membrane Proteins
f i
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Class I: Proteins in which a substantial proportion of their mass is embedded in the bilayer 
Class II: Proteins bound to the bilayer via a phosphotidyl inositol-carbohydrate moiety attached 
to the C-terminus of the polypeptide chain
Class III: Proteins anchored in the bilayer by a single transmembrane segment
Class IV: Proteins associated with the bilayers via fatty acid acyl and/or diacylglycerol moieties
covalently attached to the N-terminus of the polypeptide chain .
The latter categories of membrane proteins contain most or all of their mass in the aqueous 
phase.
4.2.6. Release of the particulate thyroliberin-degrading PA P  activity from the 
synaptosomal membranes
When the exact location of the thyroliberin-degrading PAP activity was established, it was 
necessary to find an efficient method to effect the release of the activity from the membranes. 
The most commonly used methods- detergents, proteolytic enzymes and sonication were all 
tried for their efficacy in causing the release of the membrane-bound activity. It was found that 
for the synaptosomal PAP activity, the detergent Triton X-100 at a concentration of 0.4% (v/v) 
was the most efficient, releasing nearly 75% of the PAP activity from the salt-washed
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synaptosomal fraction. The requirement for such a high concentration of Triton X-100 (0.4% 
v/v) in order to release the PAP activity from the membranes lent further evidence to the fact that 
the enzyme activity is membrane-bound. A requirement for such high detergent 
concentrations for effecting the release of the enzyme from the synaptosomal membranes, 
added to the repeated salt-washing and the osmotic shock step, further confirms its status as a 
membrane-bound activity. The bovine synaptosomal PAP activity may therefore be classed as 
an integral synaptosomal membrane-bound enzyme. This specific location is in agreement with 
previously characterised particulate PAP activities from rat (Charli et al., 1988) and rabbit brain 
(Wilk and Wilk, 1989).
4.2.7. Purification of the synaptosomal PAP by column chromatography
A series of column chromatography steps was used to finalise the purification scheme for the 
synaptosomal PAP activity. These steps, including gel filtration, ion exchange and hydrophobic 
interaction chromatography, resulted in a 20.7% yield of synaptosomal PAP activity from the 
particulate fraction with a purification factor of 644. This apparent low level of enzyme activity is 
due primarily to its instability (Section 4.2.8.), as it was found to be veiy difficult to maintain its 
activity after 24 hours. This instability is in marked contrast to the extremely stable particulate 
PAP activity isolated from guinea-pig brain (O’Connor and O’Cuinn, 1984) and rabbit brain (Wilk 
et al., 1988).
The gel shown in Fig 3.19 show that the enzyme was purified to homogeniety. The SDS gel 
shows that the purified enzyme corresponds closely to the molecular weight marker catalase 
(230kDa). This size for the synaptosomal PAP was confirmed by running another set of 
molecular weight markers over the Sephacryl S-200 column, and is the same as the MW for the 
guinea-pig and rabbit particulate PAP II.
4.2.8. Characterisation of the synaptosomal PAP  activity from bovine brain
4.2.8.1. Stability Studies on the Synaptosomal PAP Activity from Bovine Brain
The characterisation of the bovine brain synaptosomal PAP involved a series of experiments 
designed to yield a fuller understanding of the behaviour of this enzyme, which already 
appeared to be different in many ways to its guinea-pig and rabbit brain counterparts. The first of 
these experiments was a series of stability studies on the synaptosomal PAP activity.
The bovine synaptosomal PAP displayed a narrow pH optimum in the neutral range (pH 7.0-7.5) 
in contrast to the broad pH range of the guinea-pig enzyme (O’Connor and O’Cuinn, 1984) and 
the rat enzyme (Charli et al., 1984). Its activity in different buffers was examined at both the 
Triton X-100-solubilised stage and for the purified enzyme for two reasons. The first was to see 
if the enzyme displayed a marked preference for any particular buffer and secondly to see if any 
of the buffers could increase the stability of the enzyme. At the Triton X-100-solubilised stage 
(Fig. 3.28), the enzyme did not appear to show any great preference for any of the buffers, 
although its activity was highest in potassium phosphate buffer. This slight preference was also
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displayed once the enzyme was purified. However, regardless of the buffer system, the activity 
of the purified enzyme was unstable when stored at 4”C or at -20°C (Figs. 3.36 a and b). Its 
stability was also examined by trying a range of commonly used stabilisation techniques. The 
addition of glycerol and BSA to the purified enzyme was examined when stored at both 4*C and 
-20'C. The most effective stabilisation technique was found to be the inclusion of 10% (v/v) 
glycerol and 1% BSA (w/v). As the synaptosomal PAP is eluted from the phenyl sepharose 
column with a glycerol gradient, it was not necessary to add any extra glycerol, and 1% (w/v) BSA 
was added routinely to the purified enzyme for added stability at 4'C. The activity continued to 
decrease at -20“C regardless of the amount of BSA, and was found to be the most stable with 
the addition of 10% glycerol. However this still resulted in a 30% loss of activity. This instability 
is in marked contrast to the reported long-term stability of the guinea-pig and rat brain 
synaptosomal PAP enzymes (O’Connor and O'Cuinn, 1984; Garat et al., 1985).
4.2.8.2. Substrate Specificity of the Synaptosomal PAP Activity
The narrow substrate specificity of the synaptosomal PAP from guinea-pig brain and other 
sources has been well documented (O'Connor and O’Cuinn, 1985: Elmore et al., 1990), where 
the enzyme has been shown to only cleave the N-terminal pyroglutamate from thyroliberin or 
very closely related peptides. It was also found that any substitution of pyroglutamyl at the N- 
terminus completely abolished the enzyme’s ability to hydrolyse the peptide. There has been 
some tolerance shown to substitutions of the ProNH2 residue resulting in cleavage of acid 
thyroliberin, LHRH (1-3) (<Glu-His-Trp), and the anorexogenic peptide, <Glu-His-Gly. This 
narrow substrate specificity was examined for the bovine brain synaptosomal PAP by HPLC. 
Like its guinea-pig counterpart, the bovine synaptosomal PAP displayed a narrow substrate 
specificity, cleaving only thyroliberin or its most closely related peptides i.e. acid thyroliberin, 
LHRH (1-3) and <Glu-(Me)His-ProNH2, a thyroliberin analogue (Table 3.15). The anorexogenic
peptide <Glu-His-Gly, which was cleaved by the guinea-pig synaptosomal PAP was not 
hydrolysed by the bovine enzyme. Longer or shorter peptides were not cleaved nor were 
peptides without <Glu-His at the N-terminus of the sequence.
4.2.8.3. Preliminary Kinetic Studies on the Synaptosomal PAP Activity
The synaptosomal PAP was found to obey Michealis-Menten kinetics with a Km of 100(xM and a 
Vmax of 0.85nmol/min/mL for the substrate <Glu-His-ProMCA. This Km is only slightly higher 
than that shown for the synaptosomal guinea-pig PAP II (40^ M) using the radiolabelled 
thyroliberin as substrate, and the Vmax is also quite similar (1.1nmol/min/mL) (O’Connor and 
O’Cuinn, 1985). This Km value suggests a similarly high affinity for the substrate as has been 
reported for other synaptosomal PAP activities. The difference in Km values may be due to the 
fact that <Glu-His-ProMCA is a new synthetic substrate, as opposed to the natural substrate 
previously used (radiolabelled thyroliberin). Wilk and Wilk (1989), the only other reported users 
of a synthetic substrate for the estimation of kinetic values, estimated a Km of 44pM for the 
rabbit brain synaptosomal PAP using the substrate <Glu-His-ProNA.
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The most interesting feature of the studies previously performed on the guinea-pig 
synaptosomal PAP, was that LHRH, although not hydrolysed by particulate PAP , showed a 
greater affinity for the enzyme (Ki=20jiM), than thyroliberin itself (Ki=40jiM) (O’Connor and 
O'Cuinn, 1985). It was of special interest then in this study to see if this phenomenon held true 
for the synaptosomal PAP activity from bovine brain.
As outlined in section 3.10.8, the data resulting from the kinetic studies was fitted to three 
plots, the Lineweaver-Burk, the Eadie-Hofstee and the Hanes-Woolf plots. The reasons for 
using three different types of plots are many. Firstly, each in their own way has some inherent 
inaccuracies, and so to reduce the errors involved in calculating the kinetic constants, all three 
were used. Secondly, the results from the first plot (Lineweaver-Burk) with the synaptosomal 
PAP yielded such unusual results, that the other two plots were used to confirm these findings. 
While competitive inhibition is a regular occurrance, many researchers claim that non­
competitive inhibition is a phenomenon that rarely occurs in practice, and in reality should be 
termed ‘mixed inhibition’ (Cornish-Bowden, 1979). However this study found that there existed 
two non-competitive inhibitors for the synaptosomal PAP from bovine brain, LHRH and <Glu- 
His, and these findings were confirmed by all three plots. The other peptides which were seen 
to be non-competitive initially when plotted on Lineweaver-Burk plots, were found to actually be 
competitive when plotted using both of the other two methods. This apparent reversal of 
results by different plots must be due to the errors incurred by the use of the double recipricol 
plot and explains why it is the least popular of the plots for estimation of the kinetic constants, 
even though it remains the most popular for displaying data (Henderson, 1992). Regardless of 
the method used to represent the data, the Ki values obtained were all quite similar. They were 
all in the jxM range indicating that the bovine synaptosomal PAP has a high affinity for all the 
peptides examined.
The high affinity of the guinea-pig particulate PAP for LHRH was mentioned earlier, where the 
enzyme was shown to have a higher affinity for LHRH than for thyroliberin itself (O’Connor and 
O’Cuinn, 1985). This was not the case for the bovine synaptosomal PAP, all three plots showed 
that the enzyme had a higher affinity for thyroliberin than for LHRH. However, the enzyme 
consistently had higher affinities for <Glu-His-Gly (the anorexogenic peptide) and for <Glu-His- 
Trp (LHRH(1-3)). It may have been expected that the enzyme would display a similar affinity for 
peptides closest to thyroliberin in structure i.e. acid thyroliberin and the thyroliberin analogue, 
<Glu-(Me)His-ProNH2 which were both hydrolysed by the enzyme. However, they consistently 
had amongst the highest Ki values indicating a lower affinity for these peptides.
The high affinities and the narrow substrate specificities displayed by the guinea-pig 
synaptosomal PAP II (O’Connor and O’Cuinn, 1985) and the rabbit synaptosomal PAP II (Wilk 
and Wilk, 1989) appear to be characteristics common to the bovine synaptosomal PAP enzyme 
also.
4.2.8.4. Effects of Inhibitors on the Activity of Synaptosomal PAP
The effects of a range of inhibitors on the synaptosomal PAP activity from bovine brain are 
shown in Table 3.17. The most interesting features of this inhibitor profile is the almost
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complete inhibition of the purified PAP activity by 2-iodoacetamide, iodoacetate and PCMB, and 
to a lesser extent, N-ethylmaleimide, which at 10mM concentration also inhibited the enzyme. 
These sulphydryl reagents, having such an effect on the enzyme's activity, indicate that the 
bovine synaptosomal PAP must have an essential thiol group for its activity.
The metal chelator, 1,10-phenanthroline, also inactivated the enzyme at high concentrations, 
suggesting that the enzyme has a requirement for a metal at its active site. Why these results 
are of particular interest is that all previously characterised synaptosomal PAP activities were 
found to be 'classical' metalloenzymes • inhibited by all the metal chelators (O'Connor and 
O'Cuinn, 1985; Wilk and Wilk, 1989). EDTA and 8-hydroxyquinoline, known to completely 
inactivate the guinea-pig particulate PAP at even 1 mM concentration, did not inactivate the 
bovine synaptosomal PAP even at a concentration of 10mM. The particulate PAP from rat brain 
was identified as having a requirement for a metal for activity in its active site, most probably Zn2+ 
(Czekay and Bauer, 1993). Due to the bovine enzyme’s inactivation by the metal chelator, 1,10- 
phenanthroline, it is possible that this enzyme has a similar requirement for a metal ion in its 
active site.
The noninvolvement of serine at the active site is indicated by the failure of PMSF and
benzamidine to inactivate the enzyme activity. N-acetylimidazole, previously shown to react with 
tyrosine, histidine or cysteine residues, (Means and Feeney, 1971), had no effect on the 
enzyme's activity, suggesting that none of these residues play an important role in the bovine 
synaptosomal PAP’s active site. Tyrosine, arginine and histidine were all identified as essential 
residues in the active site of guinea-pig synaptosomal PAP (O'Connor and O’Cuinn, 1987). 
These findings were in agreement with the findings that the active sites of metalloproteases 
usually contain a tyrosine residue and basic amino acids which are essential for their 
activity(Czekay and Bauer, 1993). Due to the apparent requirement for a thiol in its active site, 
the effect of DTT on the synaptosomal PAP activity was examined. As can be seen in Fig. 3.46, 
the enzyme’s activity increases by 60% once even 1mM DTT is added. The combination of DTT 
and EDTA has a similar effect on the enzyme's activity, while EDTA on its own does not effect 
the enzyme’s activity, negatively or positively. After 2mM DTT, increasing the concentration of 
DTT does not result in a corresponding increase in enzyme activity however. The effect of a 
range of 1mM metal ions was examined following the findings of the inhibitor studies on
synaptosomal PAP activity. Zn 2+, Co2+, Fe2+, and Ag2+ were found to have the most 
dramatic effect on the enzyme’s activity, causing upto 100% loss in activity (Fig. 3.43). Czekay 
and Bauer (1993) found that the rat particulate PAP activity was a typical metallopeptidase as it
was inhibited by the transition metal ions Zn2+, Hg2+, Cd2+ and Cu2+. The particulate PAP
activity was inhibited by Zn2+ immediately whereas the others inhibited the activity in a time 
dependent manner. For the bovine synaptosomal PAP activity, while it was inhibited by 1 mM 
Zn2+, the other transition metals assayed, Cu2+ and Cd2+ did not cause any significant 
inhibition. The rat particulate PAP activity, as with many zinc metalloproteases, was increased by 
Co2+, while the bovine synaptosomal PAP activity was completely inhibited by the addition of 
Co2+. Since the bovine synaptosomal PAP activity is inhibited by thiol-modifying reagents, the
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inhibition by some of the metal ions, notably Zn2+, Co2+, Fe2+ and Ag2+ could be due to 
interactions of the metals with essential thiol groups. Some of the metals caused an increase in 
enzyme activity, notably Fe^, Li+, Ca2+ and K+. It Is possible that one of these metals may be 
present in the active site of the bovine synaptosomal PAP.
Taking all these parameters into account, the bovine synaptosomal PAP appears to be a thiol 
protease with an essential metal in its active site.
4.3. Prolyl Endopeptidase
4.3.1. Demonstration of two prolyl endopeptidase activities in different 
subcellular fractions of bovine brain
The unusual nature of the bovine brain thyroliberin-degrading activities was further 
demonstrated when both the cytosolic and particulate fractions were assayed for PE activity. 
While PE activity in the cytosol has been well documented (Tate, 1981; Yoshimoto et al., 1983), 
there have only been infrequent and scant references to the presence of a ‘particulate prolyl 
endopeptidase’ activity (Dalmaz et al., 1986; Dresdner et al, 1982). However, from the levels of 
PE activity seen in Table 3.2, it is dear that there are high levels of PE activity detected when the 
bovine brain homogenate is divided initially into its cytosolic and particulate fractions. After the 
inclusion of DTT and EDTA in the homogenisation buffer, the total cytosolic PE activity 
increased by 15%, while the level of PE activity in the particulate fraction remained the same. 
Cytosolic PE has been reported to have an essential thiol residue and its activity is increased by 
the inclusion of 13-mercaptoethanol or DTT (Kato et al., 1980; Kalwant et al., 1991) and so the 
increase in bovine cytosolic PE adivity is in keeping with those findings.
4.3.2. Effect of osmotic shock on the levels of PE  activity in the particulate 
fractions
In view of the fact that a particulate PE activity has not been previously purified or characterised 
from any source, it was important to ensure that the activity under investigation was indeed 
associated with the membranes, and was not a loosely-bound, non-specifically associated 
soluble enzyme activity. The criteria set out by many researchers for what adually constitutes a 
membrane enzyme were examined with reference to the particulate PE activity in bovine brain. 
Van Amsterdam et al., (1983) suggested that the lack of washing steps caused many reports of 
membrane-bound activities, when in fact the activity was merely non-specifically associated with, 
or entrapped within, the membranes. An initial salt-wash removed 36% of the PE activity from 
the original crude pellet, this activity was due mainly to residual soluble activity loosely attached 
to the membranes. By resuspending the pellet in distilled water with gentle hand 
homogenisation, the membranes are osmotically-shocked and release the contents of any
172
vesicles that may have been formed by the membranes during homogenisation. 0.6% of the 
PE activity was released from the vesicles by this step, leaving nearly 65% of the original crude 
particulate PE activity still in the pellet. Such a high percentage of activity remaining in the pellet 
suggests that the activity is more that just a non-specific soluble activity loosely attached to the 
membranes, and that it may in fact be a membrane-associated activity.
4.3.3. Effect of repeated salt-washing of the membranes
The membranes were then repeatedly washed by a 4M salt solution, in order to futher remove 
any soluble PE activity from the membranes. This step proved to be very effective as a means of 
removing excess loosely attached soluble PE activity, and ensuring that the resulting PE activity 
is Indeed a specific membrane-associated activity.
4.3.4. Subcellular localisation of the particulate P E  activity
Both previous references to a possible PE activity associated with the particulate fraction 
comment on its low activities, its probable presence in the membranes solely as an occluded 
activity, and of its location in the crude mitochondrial fraction (Dresdner et al., 1982; Dalmaz et 
al., 1986). Following a combination of differential centrifugation and isopynic ultracentrifugation, 
the PE specific activity was seen to increase nearly 2-fold in the synaptosomal membrane 
fraction, but there was no enrichment of PE activity in either the myelin or the mitochondrial 
fractions.
4.3.5. Phase-partitioning study on the particulate P E  activity
As discussed In section 4.2.5., the mode of association of a membrane protein with the bilayer is 
an important feature of that protein. The two types of membrane proteins are integral and 
peripheral, and these differ by their mode of attachment to the phospholipid bilayer. While 
integral membrane proteins are integrated into the hydrophobic phase and require disruption of 
the phospholipid bilayer for their release, peripheral membrane proteins are associated with the 
membranes surface through interactions with other proteins or exposed regions of 
phospholipids. The assay developed by Bordier (1981) exploits the hydrophobic nature of 
membrane proteins, to determine whether an enzyme is an integral or peripheral membrane 
protein. The assay can only be used as an effective means of determining the association of a 
membrane protein with the membrane once all non-specifically loosely-bound activities have 
been removed. The intensive salt-washing and osmotic shock steps which preceeded this step 
ensure that any remaining PE activity is membrane-associated. The phase-partitioning step 
showed that 87% of the PE activity was associated with the detergent-depleted phase, 
indicating that the PE is a peripheral membrane enzyme.
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4.3.6. Release of the synaptosomal PE  activity from the membranes
Van Amsterdam et al. (1983) queried the claims of many researchers when identifiying enzymes 
as being membrane-bound, while not examining the possibility of the membranes forming 
vesicles which entrap soluble enzyme activity. They urged the use of salt-washing, osmotic 
shock and higher concentrations of detergent, condemning low levels such as 0.05-0.1% (v/v) 
as being insufficient. They claimed that such low concentrations of detergent are not effective 
in detaching particle-bound enzymes, but are just capable of disorganising membraneous 
structures and causing the release of the soluble enzyme activities entrapped within the 
membranes. However, by assaying the synaptosomal membranes in the presence of a series of 
Triton X-100 concentrations (0-0.5% (v/v)), it was found that only with 0.3-0.4% Triton X-100 was 
the majority (82.5%) of the PE activity released. A requirement for such high detergent 
concentrations for effecting the release of the enzyme from the synaptosomal membranes, 
added to the repeated salt-washing and the osmotic shock step, further confirms its status as a 
membrane-associated activity.
4.3.7. Purification of the synaptosomal PE  activity by column chromatography
A series of column chromatography steps was used to complete the purification of the 
synaptosomal PE activity. In this case, gel filtration, hydroxylapatite and hydrophobic interaction 
chromatography were found to be the most efficient methods for its purification 1417-fold, 
which resulted in a 23% recovery of the PE activity. The use of the Pharmacia Biopilot system 
for the gel filtration step meant that larger than normal quantities of enzyme could be purified at a 
faster rate. The gels shown in Figs. 3.20 show how the enzyme was purified to homogeneity 
and from the SDS-gel, the molecular weight was estimated to be between 80 and 90kDa. This 
MW was confirmed to be 87kDa by running MW markers over the S-200 gel filtration column. 
This weight is slightly larger than the MW estimated for cytosolic bovine PE by Tate (1981) of 
65kDa and by Yoshimoto et al., (1983) of 76kDa. The larger size may be due to this enzyme 
being membrane-associated and could be due to some form of anchor or linkage to the 
membrane.
4.3.8. Characterisation of the synaptosomal PE  activity from bovine brain
4.3.8.1. Stability Studies on the Synaptosomal PE Activity
The purified synaptosomal PE activity proved to be quite stable under a variety of storage 
conditions. The enzyme lost only 5% of its activity when stored for 100 hours at -20°C in its 
purified state. It was slightly less stable at 4°C, loosing 15% activity over the same time period, 
and its activity dropped by 50% if the purified enzyme was allowed remain at room temperature. 
The addition of glycerol to the purified enzyme did not effect its stability at -20°C (Fig. 3.38) and 
it appeared to be relatively equally stable in either potassium phosphate, HEPES or imidazole 
buffers. The only buffer in which it was unstable wasTris-HCI, after 100 hours at -20°C its activity
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decreased by 21%. Overall it was an extremely stable enzyme regardless of its storage 
conditions.
4.3.8.2. Substrate Specificity Studies on the Synaptosomal PE Activity
The cytosolic PE has been reported to have a broad substrate specificity, cleaving proline- 
containing neuropeptides of length between 3 and 30 amino acids, including thyroliberin and 
LHRH, but it cannot hydrolyse longer peptides (O'Cuinn et al., 1990). However it will also cleave 
at alanine residues in oligoalanine peptides at low efficiency (Welches et al., 1993). PE was also 
shown to cleave at an Ala-Ser bond in which the serine was phosphorylated in an 
undecapeptide mimicking a phosphorylation site in proteins (Rosen et al., 1991). The failure of 
PEs to cleave at this same site of the unphosphorylated peptide was of interest because it 
suggests that PE's specificity and protein peptides phosphorylation could function as a method 
of control for peptide processing (Welches et al., 1993). The specificity of the synaptosomal 
PE was examined for both the membrane-associated and the purified enzyme to ensure that no 
physiological change occurred during the enzyme’s solubilisation from the membrane. Both the 
membrane-associated and the purified synaptosomal PE displayed a very broad substrate 
specificity and cleaved all of the proline-containing peptides. Bombesin, the only non-proline- 
containing peptide, was included as a control and was not cleaved.
However, the enzyme did display some specificity with regard to its position of cleavage in the 
case of peptides with more than one proline moiety. For both bradykinin and substance P, the 
enzyme cleaved at certain sites and ignored others (see Table 3.15). In bradykinin there are
three possible cleavage sites - Pro^Pro3, Pro3-Gly4 and Pro7-Phe8. The PE cleaves the latter
two bonds, but ignores the Pro2-Pro3 bond. Likewise in Substance P, it will cleave the Pro4-
Gln®, but not the Pro2-Lys3 bond. This demonstrates a certain level of specificity, which had 
previously been reported for the cytosolic PE, by Camargo et al. (1979).
Tate (1981) reported a bovine brain cytosolic PE which had a requirement for a basic amino acid 
residue prior to the proline, which would set that enzyme apart from all other PE activities 
previously characterised. He reported the cleavage of thyroliberin, LHRH, angiotensin II and 
neurotensin, but not of bradykinin, oxytocin or vasopressin, due to their lack of a basic amino 
acid prior to the proline moiety. However, this report has since been refuted by several 
researchers, including Yoshimoto et al. (1983). While also studying the cytosolic PE from 
bovine brain, Yoshimoto et al. claimed that the enzyme did not show any specificity for basic 
amino acids prior to the proline and showed the cleavage of bradykinin, oxytocin and 
vasopressin. In fact, Yoshimoto et al. (1983) were amongst the first researchers to use the 
synthetic specific PE substrate, Z-Gly-Pro2NNap, which incidently does not have a basic amino 
acid prior to the proline. In this study, a modified version of that same substrate was used, Z-Gly- 
ProMCA and detected both cytosolic and particulate bovine PE activity. This study also showed 
the cleavage of bradykinin by the membrane-associated PE, thereby suggesting that the 
bovine synaptosomal PE and the previously characterised cytosolic PE activities display a 
similarly broad substrate specificity.
175
4.3.8.3. Preliminary Kinetic Studies of the Synaptosomal PE Activity
As no particulate PE activity has been previously characterised, the only comparisons between 
kinetic constants can be made with the cytosolic enzyme. The synaptosomal PE was found to 
follow Michaelis-Menten kinetics using both the specific PE substrate, Z-Gly-ProMCA and <Glu- 
His-ProMCA as substrate. For Z-Gly-ProMCA, the enzyme had a Km of 60p.M and a Vmax of 
747.3nmol/min/mL. For the second substrate, <Glu-His-ProMCA, its Km was estimated at 
72.6^M and its Vmax was found to be 418.4nmol/min/mL. The results from these kinetic 
studies are shown in Table 3.14. The most notable feature is the number of non-competitive 
inhibitors, which were shown to be non-competitive regardless of the method used to plot the 
data. Considering that non-competitive inhibition is reported to occur only in rare cases 
(Cornish-Bowden, 1979), it is indeed remarkable that the majority of the naturally-occurring 
peptides (all hydrolysed by PE) were found to be non-competitive. Another interesting feature 
is the level of inhibition - all of the Ki values for the inhibitors are in the jiM range and most of 
them are less than 1pM. For non-competitive inhibitors to display such low Ki values, the 
synaptosomal PE enzyme must have a very high affinity for all of these neuropeptides. In each 
case, thyroliberin and acid thyroliberin have the highest Ki values - in the case of the 
Lineweaver-Burk and Eadie-Hofstee plots, the Ki is nearly equivalent to the Km for Z-Gly- 
ProMCA suggesting that it has a similar affinity for both the synthetic substrate and for 
thyroliberin and acid thyroliberin. It also shows a high Ki for the substrate <Glu-His-ProMCA 
(72.6(iM), in fact it has a higher affinity for this substrate than the synaptosomal PAP does.
The kinetic constants obtained with the bovine cytosolic PE by Tate (1981) are all in the (xM 
range also. The enzyme displays a high affinity for angiotensin II (1.2^ iM), LHRH (4jiM), 
neurotensin (1.8(xM) and bradykinin (7|iM). It has a very low affinity for acid thyroliberin (580jiM) 
and thyroliberin (480|iM). This low affinity for thyroliberin appears to be a feature of the cytosolic 
PE in all species. The Km for thyroliberin in rat brain was reported to be as high as 4100|xM 
(Andrews et al., 1980), but most values range from 540-690pM (Yoshimoto et al., 1983). The 
kinetic constants shown by the bovine synaptosomal PE for both the <Glu-His-ProMCA 
substrate (72.6^M) and thyroliberin (Ki= 44.93nM) and its very low Ki values for the other 
neuropeptides examined sets this enzyme apart from its cytosolic counterpart.
4.3.8.4. Effect of Inhibitors on PE Activity
The cytosolic PE has been well characterised from many sources including bovine, rat and rabbit 
brains. Due to this extensive charaterisation, it was of special interest to see if the inhibitor 
profile resulting from the investigation of the bovine synaptosomal PE activity was similar or very 
different to its cytosolic counterpart. There appears to be some conflict in the literature with 
regard to the exact nature of the cytosolic PE. It has been identified as a serine protease, with 
no metal requirement (Yoshimoto et al., 1977), it is reported to have an essential thiol group and 
its activity increased by DTT and 2-mercaptoethanol (Kato et al., 1980; Kalwant et al., 1991). Its 
inhibition by sulphydryl reagent also indicated the presence of a sulphydryl group necessary for 
expression of enzyme activity (Browne and O’Cuinn, 1983) and by benzyloxycarbonyl (CBZ)-
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Pro-prolinal in vitro and in vivo (Wilk and Orlowski, 1983; Friedman et al., 1984). The bovine 
synaptosomal PE was found to be completely inhibited by PCMB at all concentrations, and by 
N-ethylmaleimide at 10mM concentration. At the lower concentrations, N-ethylmaleimide only 
inactivated 34% of the purified enzyme. The two other sulphydryl reagents did not cause as 
much inactivation of the enzyme, whether membrane-bound or purified. The inactivation by 
PCMB and N-ethylmaleimide of the synaptosomal PE activity, whether membrane-bound, Triton 
X-1 OO-solubilised or purified, indicates that there is a thiol group present in the active site of the 
enzyme. The other major inhibitor was 1,10-phenanthroline, and to a lesser extent 8- 
hydroxyquinoline. EDTA, the third metal chelator, did not have any great effect on the 
enzyme's activity. This selective inhibition by both sulphydryl reagents and metal chelators is an 
unusual feature of the bovine synaptosomal PE’ s activity. However, Tisljar and Barrett (1990) 
reported the presence of endopeptidase 24.15 in both rat and rabbit which was a thiol- 
dependent metallopeptidase. The enzyme was inhibited by the metal chelators, EDTA and 
1,10-phenanthroline in a time-dependent manner, but this activity was restored with the 
addition of metal ions. The enzyme was activated by sulphydryl reagents such as 2- 
mercaptoethanol and DTT, and was inhibited by PCMB and other thiol blocking agents. Due to 
the apparent dual dependence of the enzyme on a thiol group and on an essential metal at its 
active site, the name ‘thimet protease’ was proposed for such an enzyme (Barrett and Brown, 
1990). It is possible that the bovine synaptosomal PE is such an enzyme, as it is inhibited by the 
sulphydryl reagents PCMB and N-ethylmaleimide (at high concentrations), yet it is also inhibited 
by the metal chelator 1,10-phenanthroline. The cytosolic PE was reported to be inhibited by 
bacitracin (Browne and O’Cuinn, 1983), and this bovine synaptosomal PE activity was also 
inhibited by 62% by 500 units of bacitracin .
The report by Barrett and Brown (1990) claimed that even though the endopeptidase 24.15 
was inhibited in a time-dependent manner in the presence by EDTA and 1,10-phenanthroline, 
that some metal ions were found to restore activity after such treatment. Zn2+, Mn2+, Ca2+,
Co2+ and Cd2+ were all seen to restore activity in a decreasing order of effectiveness. Other 
metal ions however were found to be inhibitory. Even though this type of assay was not 
performed on the bovine syanptosomal PE enzyme, the effects of a number of metal ions on
enzyme activity were examined. Zn2+, Co2+, Cu2+ and Cd2+ were all found to inactivate the 
enzyme by between 90 and 100%. The inhibition of metallopeptidases by transition metal ions 
such as Hg2+, Cd2+, Cu2+ and Zn2+ is a common occurrence. The inhibition of the enzyme’s 
activity by Hg2+, Cd2+ and Cu2+ usually proceeds in a time-dependent manner. An excess of 
Zn2+ can often result in immediate inhibition. This difference may be explained by the different 
inhibition mechanisms of Zn2+, which occupy an inhibitiory metal binding site in zinc- 
dependent proteases, whereas the inhibition by other transition metal ions is also due to the 
exchange of the catalytic Zn2+ ion. The enzyme’ s activity was not increased by Co2+, often an 
indicator of a zinc-metalloprotease, in fact it inhibited the enzyme’s activity by 90%.
Taking into account both the effects of the inhibitors and the metal ions, the bovine
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synaptosomal PE appears to have many of the features of a thimet protease as described by 
Barrett and Brown (1990).
The effect of EDTA and DTT on the purified synaptosomal PE activity was examined. EDTA 
showed no effect on the level of PE activity, and 1 mM DTT only increased the level of activity by 
5%. However, even this slight increase in enzyme activity is yet another indication of the 
presence of an essential thiol group in the prolyl endopeptidase’s active site.
4.4. Conclusion
The initial part of this work concentrated on the development of two new fluorimetric assays for 
the detection of particulate pyroglutamate aminopeptidase (PAP Type II). Prior to this, there 
existed two assays for the enzyme’s quantitation, the first, a complex assay based on 
radiolabelled thyroliberin being degraded by the particulate PAP (Bauer and Kleinkauf, 1980), 
and the second, a coupled-enzyme spectrophotometric assay using the synthetic substrate 
<Glu-His-ProNA (Friedman and Wilk, 1986). While both of these assays adequately detected 
particulate PAP activity, there were several drawbacks to their use. The radiolabelled 
thyroliberin assay was complex and tedious, and also very expensive, while the second assay 
involved the use of dipeptidyl aminopeptidase IV as the coupling enzyme. DAP IV is not 
available commercially, and so it had to be purified in the laboratory for use in the assay. The 
spectrophotometric substrate <Glu-His-ProNA had the added disadvantage of being sensitive 
only to the nanomolar range and also of using the known carcinogen, naphtylamide.
The development of a new fluorimetric substrate, <Glu-His-ProMCA, heralded a new opening 
for the development of an assay system for the detection of particulate PAP activity. The 
coupled enzyme fluorimetric assay developed using this substrate proved to be efficient, 
sensitive (up to the picomolar range), economical and easy to use. Its only disadvantage was its 
dependence on the coupling enzyme DAP IV for the cleavage of the Pro-MCA bond.
The spontaneous and non-enzymatic cyclisation of His-ProNH2 is a well recorded
phenomenon (Peterkofsky et al., 1982; Moss and Bungaard, 1990). The idea of exploiting this 
cyclisation mechanism led to the development of the second assay for the detection of 
particulate PAP activity. It was shown that by increasing the temperature of the sample after the 
reaction has been stopped by acid, the cyclisation of the His-ProMCA to cyclo(His-Pro) and free 
MCA is encouraged. This assay has many advantages over the coupled enzyme assay, the 
principal one being the assay does not require the coupling enzyme, DAP IV. It is as efficient, 
as economical and as easy to use as the coupled enzyme fluroimetric assay, but does not 
require DAP IV. Its only disadvantge is that the substrate tends to degrade at such high 
temperatures, but once this degradation is taken into account, the spontaneous cyclisation 
assay is fast, efficient and sensitive.
Particulate PAP activity has been studied from several different sources, guinea-pig (O’Connor 
and O’Cuinn, 1984), rat (Garat et al., 1985) and rabbit (Wilk et ai.,1988) being the most 
researched. This study used bovine brain as its source of PAP activity as it was readily available,
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large in size and proved to be rich in enzyme activity. The PAP activity, which was found to be 
localised on the synaptosomal membranes of the bovine brain, displayed many of the 
characteristics common to previously studied particulate PAP (PAP II) activities. Its location on 
the synaptosomal membranes, its large size, its narrow substrate specificity and its high affinity 
for its substrate thyroliberin, are all features common to the guinea-pig, rabbit and rat PAP II 
activities. However, the bovine brain particulate PAP also displayed some unusual features, 
such as an inhibition by thiol protease inhibitors, a requirement for DTT, no effect seen with 
EDTA and non-competitive inhibition by LHRH. These features are more in keeping with the 
cytosolic PAP activity, which is classed as a thiol protease, than with PAP II which is classed as a 
‘classical’ metalloprotease . As mentioned already, LHRH non-competitively inhibits the 
particulate PAP activity. Non-competitive inhibition is unusual in itself, but PAP II had been 
shown to have a higher affinity for LHRH than for thyroliberin, although it does not cleave LHRH 
(O’Connor and O'Cuinn, 1985). While the bovine particulate PAP still has a high affinity for 
LHRH, it consistently has a higher affinity for thyroliberin. The exact nature of the enzyme 
activity is still unknown. It appears to be a ‘hybrid’ form of pyroglutamate aminopeptidase, 
displaying many of the characteristics of both the cytosolic and the particulate type II PAP 
activity. A clearer understanding into the exact nature of the enzyme would be possible 
following investigation into the regulation of the enzyme, as the modes of cytosolic and 
particulate PAP regulation are very different (Bauer, 1987; Scharfmann et al., 1990). The 
reason as to why another form of pyroglutamate aminopeptidase would exist is also unclear, but 
with the ubiquitous nature of thyroliberin, it may act as an extra control mechanism for 
thyroliberin levels in vivo and for the production of cyclo(His-Pro), known to be a bioactive 
peptide byproduct of the actions of PAP on thyroliberin and on the thyroliberin precursor 
(Miyashita, et al., 1993).
Prolyl endopeptidase (PE) activity has been widely characterised from many sources 
(Yoshimoto et al., 1983; Camargo et al., 1984). However despite some references to the 
possibility of there existing a particulate form of the enzyme, such an activity was never 
investigated. Dresdner et al. (1982) localised the enzyme in the cytoplasm, they remarked on 
how a sizeable proportion of the PE activity appeared to be associated with the particulate 
fraction, but took this activity to be due to entrapped cytosolic activity, as they had not 
adequately washed the membranes. Camargo et al. (1984) and Dalmaz et al. (1986) likewise 
noticed PE activity in the particulate fraction, but took it to be non-specifically associated or to be 
associated with the crude mitochondrial fraction. Therefore, it was with extreme interest that the 
particulate PE activity in bovine brain was examined. As with all claims of a membrane-bound 
activity, many precautions had to be observed prior to giving the enzyme the title ‘membrane- 
bound’. Van Amsterdam et al. (1983) refuted many claims of membrane-bound activities by 
showing that following an osmotic shock step, and adequate washing of the membranes, much 
occluded enzyme activity is removed. This is soluble activity which has merely become 
entrapped within vesicles formed by the membranes during the homogenisation step. Van 
Amsterdam went on the say that most membrane-associated activities, even if they survived the 
washing and osmotic shock steps, would be removed from the membranes by a low
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concentration of detergent (upto 0.1% v/v Triton X-100). The bovine particulate PE was 
washed with repeated 4M salt solutions, was subjected to an osmotic shock step as suggested 
by Van Amsterdam, and was then localised to the synaptosomal membranes. Following such a 
vigorous series of steps the bovine PE activity was solubilised from the synaptosomal 
membranes with 0.4% v/v Triton X-100. This indicates that the enzyme is at least specifically 
membrane-associated, if not membrane-bound. Using the method of Bordier (1981), 
particulate PE was found to exist as a peripheral membrane activity. The enzyme was purified 
and characterised for the first time from a particulate fraction. It has a molecular weight of 87kDa, 
a broad substrate specificity and a high affinity for thyroliberin (higher in fact than the affinity 
displayed by the particulate PAP) and many other neuropeptides. Its chemical characterisation 
proved to be unusual as it was inhibited by some of the thiol protease inhibitors and also by 
some of the metal chelators. Such a dual dependency on a thiol group and an essential metal 
ion has been recorded before (Barrett and Brown, 1990; Tisljar and Barrett, 1990) and has been 
classed as a Ihimef protease. It is possible that the bovine synaptosomal PE activity is also a 
thimet protease.
The possible role of a particulate PE is of great interest. Its action on thyroliberin gives rise to 
acid thyroliberin which has been accredited with several effects of its own (Boschi et al., 1980; 
Webster et al., 1983). This biotransformation produces a relatively stable compound, His- 
ProOH, which is only slowly degraded into its constituent amino acids (Griffiths et al., 1983) and 
may have the ability to reamidate itself into thyroliberin (Webster et al., 1983). Based on the 
ubiquitous distribution of thyroliberin, acid thyroliberin and PE it is possible that a 
precursor/product relationship may exist between thyroliberin and acid thyroliberin similar to that 
for PAP (Prasad and Edwards, 1984). It is also possible that the particulate PE may act on the 
thyroliberin precursor and produce acid thyroliberin directly, in a manner similar to that shown for 
cyclo(His-Pro) production (Miyashita et al., 1993). Recent studies of angiotensin have shown 
that angiotensin (1-7) which can be produced by the action of prolyl endopeptidase on 
angiotensin, is also a bioactive fragment, activating vasopressin secretion (Schiavone et al., 
1988), stimulating the neuronal exicitability within the vagal-solitary complex (Barnes et al., 
1990), modulating the baroreflex (Campagnole-Santos et al., 1989) and releasing 
prostaglandins (Trachte et al., 1990). These biotransformations yielding such active by 
products, acid thyroliberin and angiotensin (1-7), strengthen the idea that these enzymes are 
multifunctional in degrading and producing neuropeptides and may be involved in many more 
as yet undiscovered biotransformations.
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Appendix
1. Derivation of Eadie-Hofstee Equations for Enzyme Inhibition (Segel, 1975)
Michaelis-Menten Equation: V = VmaxfS]
[S] + Km
V_ = Vmax - V_
[S] Km Km
By plotting V vs V/[S]:
Slope = -1/Km
Intercept on y-axis = Vmax /Km
1. Competitive Inhibition
J L  = ______ m _____
Vmax Ks(1+[l]/Ki) +[S]
VKs(1 +[I]/KQ + V[S] = [S] Vmax
V/IS] Ks(1 + [I] / Ki) + V = Vmax
V/[S] = Vmax - V
Ks(1 + [I] / Ki) Ks(1 + [I] / Ki)
By plotting V vs V/ [S]:
Slope = - 1
Ks(1+[iyKi)
Intercept on y-axis = Vmax
Ks(1 +[I]/Ki)
2. Non-Competitive Inhibition:
 V  =  [S]_________
Vmax Ks(1 + [l]/Ki) + [S] (1 + [l]/Ki)
VKs(1 = [I] / Ki) + V[S] (1 + [I] / KO = Vmax [S]
V / [S] = Vmax - Vmax
Ks(1 + [I] / Ki) Ks
By plotting V vs V/[S]:
Slope = -1/Ks
Intercept on y-axis = Vmax
Ks( 1 + [I] / Ki)
A1
2. Derivation of Hanes-Woolf Equations for Enzym e Inhibition:
Michaelis-Menten Equation: V= Vmax[S]
By plotting [S] vs [S]/V:
Slope = 1 / Vmax 
Intercept = Km / Vmax
[S] + Km
[S] = [S] + Km 
V Vmax Vmax
1. Competitive Inhibition:
V
Vmax
J§L
Ks(1+[l]/ Ki) + [S]
VKs(1 +[l]/K0 +V[S] = Vmax [S]
Ks( 1 + [I] / Ki) +[S] = Vmax [S] / V
V
[S] 
/max
Ks (1+[I]/Ki) 
Vmax
By plotting [S] vs [S] / V: 
Slope = 1/Vmax 
Intercept on y-axis Ks (1 + [I] / Ki) 
Vmax
2. Non-Competitive Inhibition:
V__
Vmax
J§L
Ks(1 + [I] / Ki) + [S] (1 +[I]/Ki) 
VKs(1 + [I] / Ki) + V[S] (1 + [l]/Ki) = [S] Vmax
VKs + V[S] = fSI Vmax
(1+ra/Ko
V (Ks + [S]) = [SI Vmax
(1 + [I] / Ki)
Ks + [S] = [S] (Vmax /( 1 + [I] / Ki)) 
~ T
By plotting [S] vs [S]/V:
Slope = (1 +[I]/Ki)
Vmax
Intercept on y-axis = Ks (1 + [I] / Ki) 
Vmax
A2
Michaelis-Menten Equation: V = Vmax [S]
[S] + Ks
By taking the reciprocal of both sides:
_L = Ks + [S]
V Vmax[S]
J_=  Ks + [S]
V Vmax [S] Vmax [S]
1 = 1 Ks + 1
3. Derivation of the Lineweaver-Burk Equation for Enzyme Inhibition:
V Vmax [S] Vmax
By plotting 1/[S] vs 1/V:
Slope = Ks/[S]
Intercept on y-axis = 1/ Vmax
1. Competitive Inhibition:
V = _____ [S]_______
Vmax Ks(1 + [I] / Ki) + [S]
1_ = Ks(1 +N1/KÌ) +[Sl
V [S] Vmax
1 = KsM + ill /Kfl + 1
V [S] Vmax Vmax
By plotting 1/ [S] vs 1/ V:
Slope = Ks/Vmax (1 + [I] / Ki)
Intercept on y-axis = 1 / Vmax
2. Non-Competitive Inhibition:
Y _  =  [SL
Vmax Ks (1 + [I] / Ki) + [S] (1+ [I] / Ki)
 V_____________ = fSl
Vmax/ (1 + [I] / Ki) Ks + [S]
By taking the reciprocal of both sides:
1_ = Ks (1+[I1/Ki) 1_+ J _  (1 + [1] /Ki)
V Vmax [S] Vmax
By plotting 1/ [S] vs 1/ V:
Slope = (Ks/Vmax) (1+[I]/Ki)
Intercept on y-axis = 1/ Vmax (1 + [I] / Ki)
A3
